But here with the latest research on Long COVID and ME/CFS!

Research Quick Links

Skeletal muscle properties in long COVID and ME/CFS differ from those induced by bed rest | Nature Communications

Alternative headline: Bed rest cannot account for skeletal muscle changes seen in people with Long COVID and ME/CFS

Micronutrition as a Therapeutic Strategy for Mitochondrial Dysfunction in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Fibromyalgia: A Narrative Review | MDPI Nutrients

Alternative headline: Review examines the mechanistic and clinical evidence supporting mitochondrial-oriented micronutritional interventions in fibromyalgia and ME/CFS

Post-Omicron cognitive decline is largely reversible: Two-year multicenter cohort study of domain-specific outcomes in hospitalized patients | Neuroprotection

Alternative Headline: 22% of Post-Omicron cognitive decline is reversible, while 10% is irreversible, in patients who were hospitalized

Metabolic, viral, and immune phenotypes in long COVID | Frontiers in Endocrinology

Alternative Headline: RECOVER cohort of LC patients with obesity and a high symptom burden showed subtle metabolic and glucose tolerance changes

Quality of life of people with and without respiratory complications in post-COVID-19 syndrome: a retrospective study | Scielo

Alternative headline: People with post-COVID-19 respiratory complications showed a worsened quality of life

Cytokine‐Driven Hyperinflammation in Long COVID: Mechanisms, Biomarkers, Complement Dysregulation, and Emerging Immunotherapies—A Narrative Review | Health Science Reports

Alternative Headline: Review of interactions between inflammation, complement dysregulation, vascular injury, and immune dysfunction driving long COVID, and emerging therapies

Frontiers | A retrospective study on the impact of SARS-CoV-2 infection on cardiopulmonary function in a healthy Chinese cohort: a focus on “long COVID” | Frontiers in Medicine

Alternative Headline: SARS-CoV-2 had a significant and long-term impact on integrated cardiopulmonary and musculoskeletal function

Risk factors for post-COVID-19 condition among previously hospitalized COVID-19 patients: a systematic review and meta-analysis | Frontiers in Public Health

Alternative Headline: Consistent risk factors for Long COVID include female sex, greater acute disease severity, ICU admission, no or incomplete vaccination, and hypertension

Immunological effects of supervised exercise in long COVID in adults: A secondary analysis of a randomized crossover trial | Physiological Reports

Alternative Headline: No changes seen in measured immune response after 10 weeks of supervised exercise in Long COVID

Tuina for chronic fatigue syndrome: study protocol for a randomized controlled trial integrating tryptophan metabolism, gut microbiota, and brain network alterations | Frontiers in Neuroscience

Alternative Headline: Study planned to assess if tuina, a manual therapy in traditional Chinese medicine, can modulate interconnected peripheral and central pathways relevant to fatigue

But still bringing you links to the latest research on Long COVID and ME/CFS!

Research Quick Links

Gut microbiome signatures during acute infection are associated with long COVID | Gut Microbes

Alternative Headline: People who go on to develop Long COVID have a distinct gut microbiome during acute infection

Multiomic and Spatial Profiling of Colorectal Tissue Reveals Viral Persistence and Immune Dysregulation in Long COVID | bioRxiv preprint

Alternative headline: Profiling shows viral persistence and immune dysregulation in Long COVID

REenergizeME: intermittent hypoxia–hyperoxia treatment for myalgic encephalomyelitis/chronic fatigue syndrome—protocol for a randomised, placebo-controlled trial | BMJ Open

Alternative headline: Planned study for treatment for ME/CFS using intermittent low and high oxygen treatment

Cardiovascular, Renal, and Pulmonary Risks of Long COVID: A Retrospective Cohort Study Stratified by Age and Sex | Journal of the American Heart Association

Alternative Headline: Long COVID linked to higher risk of heart, kidney, and lung issues

Recovery trajectories and predictors of symptom resolution in post-COVID-19 condition: a population-based cohort study | The Lancet

Alternative Headline: Most adults with Long COVID recover, but older adults and those with a higher symptom burden more likely to have prolonged illness

Post-COVID varicella-zoster virus reactivation: lowering the immunological threshold for latency breakdown | Frontiers in Cellular and Infection Microbiology

Alternative Headline: Post-COVID shingles may be a manifestation of disrupted host-virus homeostasis

Longitudinal trajectories of neurologic symptoms and cognitive associations at 36-months post-hospitalization for COVID-19 | Frontiers in Neurology

Alternative Headline: Neurological symptoms can persist or worsen up to 36 months post-COVID-19 hospitalization

Functional impact of long Covid on work performance and return to work: a cross-sectional study | Scielo

Alternative Headline: Advanced age and significant functional impairment associated with poor work performance and difficulty returning to work

Altered core depressive symptom balance in post-COVID fatigue: reduced depressed mood in an exploratory matched historical-control study | Frontiers in Psychiatry

Alternative Headline: Reduced depressed mood found in post-COVID fatigue patients versus controls

Analysis of epidemiological characteristics and influencing factors of Long COVID syndrome among university students in the post-pandemic era | Frontiers in Public Health

Alternative headline: 33% of university students have Long COVID, comparable to general population seen in China

The effects of SARS-CoV-2 on bone homeostasis | Frontiers in Bone Homeostasis

Alternative headline: Review of understood and emerging evidence of SarsCoV-2 on bone density

Longitudinal observation of persistent Long COVID symptoms and health-related quality of life in an adult German cohort | BMC Infectious Diseases | Springer Nature Link

Alternative Headline: People with Long COVID showed persistent, intense symptoms and worsening quality of life a year after infection

Media

27% of UK healthcare workers report long Covid symptoms | UCL News

Alternative headline: Survey reveals one quarter of healthcare workers with Long COVID

But still bringing you links to the latest research on Long COVID and ME/CFS!

Research Quick Links

Frontiers Publishing Partnerships | VSL#3® supplementation improves fatigue in long COVID: results from the DELong#3 randomized placebo-controlled trial | British Journal of Biomedical Science

Alternative Headline: Probiotic improves fatigue in people with Long COVID

The association of in utero SARS-CoV-2 exposure on neurodevelopmental outcomes at 12 and 22 months | Journal of Perinatology

Alternative Headline: Developmental delay, most commonly language delay, at 22 months was identified among infants with in utero exposure to SARS-CoV-2

Longitudinal profiling of upper respiratory tract microbiota and metabolome in hospitalized COVID-19 convalescents: a 3-year prospective cohort study | Journal of Translational Medicine

Alternative Headline: Predictive model using new salivary multiomics characterization may provide screening tool in early stages of pulmonary Long COVID

Postural control and trunk mobility impairments in adults with long COVID: A cross-sectional study using computerized posturography and clinical biomechanical tools | PLOS One

Alternative Headline: Adults with Long COVID show impairment in trunk mobility and postural control

Patient burden of chemosensory dysfunction and long COVID | Ugeskriftet.dk

Alternative Headline: Loss of taste and smell continue four years after COVID infection in many people with Long COVID

Peak alpha frequency is associated with pain severity in Long COVID patients with new-onset chronic pain | Frontiers in Pain Research

Alternative Headline: Association shown between Long COVID and a specific frequency on EEG

NeuroCOVID Burden and Functional Impairment in Adults with Long COVID: A Secondary Analysis of an Italian Cohort | Journal of Clinical Medicine

Alternative Headline: Neurological Long COVID associated with significant functional impairment

Haptoglobin Phenotypes Stratify Post-Exertional Cognitive Dysfunction Associated with Altered Cerebral Oxygenation and Metabolic Signatures in Long COVID | International Journal of Molecular Sciences

Alternative Headline: Haptoglobin phenotypes show promise as biomarkers for biological stratification in Long COVID

Beyond Fatigue: The Fatigue Assessment Scale as a Potential Indicator of Long COVID Severity | Journal of Clinical Medicine

Alternative headline: Review argues for standardizing clinical characterization of Long COVID through the Fatigue Assessment Scale

Orthostatic intolerance with small heart and/or disequilibrium in patients with myalgic encephalomyelitis/chronic fatigue syndrome: clinical update and paradigm shift | Frontiers in Medicine

Alternative headline: Review shows central-occurring disequilibrium should be recognized as an important cause of orthostatic intolerance in people with ME/CFS

Association between myalgic encephalomyelitis/chronic fatigue syndrome and irritable bowel syndrome: a systematic review and meta-analysis | Frontiers in Medicine

Alternative headline:

Media/Editorial

The Top 100 Interventional Trials in PAIS: Is the Next Blockbuster Market Taking Shape? | ME/CFS Research Foundation

Alternative headline: Pharmaceutical industry expert details reasons post-acute infection syndrome treatments are on the verge of becoming the next blockbuster industry, includes top 100 trials

But still bringing you links to the latest research on Long COVID and ME/CFS this week!

Research Quick Links

Virus reactivation in acute and long COVID-19 | Nature

Alternative Headline: Study shows the prevalence of chronic viral reactivation during acute COVID-19 and long COVID

A pilot study of nebulized 3D-cultured mesenchymal stem cell-derived extracellular vesicles for the treatment of post-COVID-19 chronic cough | Frontiers in Medicine

Alternative Headline: New treatment shows promise for post-COVID chronic cough

Central origin of fatigability in Myalgic encephalomyelitis/chronic fatigue syndrome revealed by multimodal neuroimaging | NeuroImage: Clinical - ScienceDirect

Alternative Headline: Multimodal neuroimaging shows that ME/CFS is central in origin

Long-term angiogenic and thromboinflammatory signatures in post-COVID-19 syndrome | Angiogenesis | Springer Nature Link

Alternative Headline: Biomarkers identified that may help identify vascular changes in post-COVID-19 syndrome.

An exploratory exome-wide machine learning analysis identifies candidate host gene signatures associated with Long COVID in a large admixed Brazilian cohort | Frontiers in Medicine

Alternative Headline: Potential gene signatures for Long COVID identified

SSRI/SNRI and long COVID in children and adolescents with neuropsychiatric conditions: a cohort study from the RECOVER Initiative | Nature Mental Health

Alternative Headline: Exposure to antidepressants may be associated with differing post-COVID symptom patterns in youth

Arterial Stiffness, Clinical-Functional Outcomes, and Quality of Life in Post-COVID-19 Patients: A Cross-Sectional Study | Scielo

Alternative Headline: Post-COVID patients show greater arterial stiffness and poorer clinical-functional outcomes

Long COVID affects working memory: assessment using a single rapid online test | Frontiers in Human Neuroscience

Alternative Headline: Working memory worse in people with Long COVID; study advocates for a single rapid online scalable test

Case Report: Mitochondrial insufficiency underlies cholinergic failure in post-vaccination long COVID: a candidate treatment protocol | Frontiers in Medicine

Alternative Headline: Case report suggests that cholinergic support may require concurrent metabolic foundation to be effective

An interpretative phenomenological analysis study of perceptions around factors relating to coping amongst young people with Long Covid and mental health difficulties in the UK | Health Psychology Open - Sage Journals

Alternative headline: Children and young people with Long COVID experience stigma leading to delays in care

But still bringing you links to the latest research on Long COVID and ME/CFS this week!

Research Quick Links

Integrated care pathway in individuals with Long COVID: STIMULATE-ICP, a cluster-randomized, phase 3 trial | Nature Medicine

Alternative Headline: Holistic Long COVID care shows significant improvements in fatigue

Losartan and prednisolone for post-COVID syndrome and cardiac inflammation: a randomized, double-blind, placebo-controlled trial | Nature Communications

Alternative headline: Losartan and prednisolone show no improvement in cardiac function in post-COVID syndrome

Comorbidity Exposure-Window Definitions and Multidimensional Disparities in Long COVID Risk: Evidence from a U.S. National Cohort (2020-2024) | medRxiv preprint

Alternative Headline: Pre-existing comorbidities increase the risk for Long COVID

Persistent cytolytic CD8+ T cells recognize SARS-CoV-2 and herpesvirus epitopes in long COVID | Cell Reports Medicine

Alternative Headline: The role of cytolytic CD8+ T cells in Long COVID

Circulating extracellular vesicles-microRNAs as potential biomarkers for the identification of ME/CFS: differentiating fatigue-related conditions | Journal of Translational Medicine | Springer Nature Link

Alternative Headline: Extracellular vesicles-microRNAs show promise as biomarkers for ME/CFS

The regulatory mechanisms and translational applications of non-coding RNA in SARS-CoV-2 infection-related cardiovascular pathology | Frontiers in Cardiovascular Medicine

Alternative Headline: Review of non-coding RNA’s in COVID-19 related-cardiovascular diseases

Baroreflex sensitivity impairment in Long-COVID patients: a diagnostic tool for classifying the autonomic dysfunction spectrum | Frontiers in Cardiovascular Medicine

Alternative Headline: Baroreflex sensitivity shows promise as a diagnostic tool for Long COVID

The association between smoking and COVID-19 symptoms, severity, and post-COVID-19 symptoms: a cross-sectional survey study | Frontiers in Public Health

Alternative Headline: Survey across four COVID infections, associating risks

Microstructural alterations in brain tissue of ME/CFS and long COVID using diffusion tensor imaging and diffusion kurtosis imaging | Frontiers in Medicine

Alternative Headline: Changes in brain tissue seen in ME/CFS and Long COVID patients

Low-Dose Ionizing Radiation and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): A Review of Recent Evidence and Future Research Directions Toward the Elucidation of a Metabolic, Immunologic, and Signaling Cascade | MDPI

Alternative Headline: Review of overlap between ME/CFS and bystander effects of radiation

Peripheral blood cytokines during early and post-acute stages of SARS-CoV-2 infection are associated with disease severity and long-term symptoms | Frontiers in Immunology

Alternative Headline: Higher cytokine levels after COVID seen in patients with more severe disease; levels do not dissipate in patients with Long COVID

Sex- and menopause-related differences in immune and gastrointestinal symptom architecture in ME/CFS: evidence from factor analysis and structural equation modeling | Journal of Translational Medicine | Springer Nature Link

Alternative Headline: Immune and gastrointestinal symptoms in ME/CFS patients show sex-specific structures

COVID-19 Treatments: Current Options and Therapies Under Investigation | International Antiviral Society - USA

Alternative Headline: Review of acute and Long COVID

I’ve really enjoyed writing this newsletter and am grateful to everyone who has followed along. I’m taking a brief pause so I can give it the time and effort needed to make it genuinely worthwhile, with the goal of returning to the full newsletter this fall.

In the meantime, we’ll continue sharing curated quick links and research updates to help you stay abreast of the topics we cover. Thanks, as always, for reading.

Research Quick Links

The Use of a Handheld Non-Invasive Vagal Nerve Stimulation (nVNS) Device for the Treatment of Long COVID: A Pilot Randomized Controlled Trial | Journal of Primary and Community Health

Alternative Headline: Vagus nerve stimulator device shows improvements in fatigue for Long COVID patients

ADDRESS-LC: study protocol for a phase 2, triple-blind, randomised, placebo-controlled trial to evaluate the efficacy and safety of bezisterim (NE3107) in adults with long COVID | BMJ Open

Alternative Headline: Study will evaluate bezisterim, a drug that inhibits TLR (toll-like receptor)-driven neuroinflammation

Loss of vesicular monoamine transporter 2 in striatum of long COVID and relationship to neuropsychiatric symptoms | The Lancet eBio Medicine

Alternative headline: Study finds damaged neurons in LC patients, potentially leading to new approaches to treatment

Mapping 2-Year Psychiatric and Neurologic Risks After Infections Across Body Systems and Age Groups | Infectious Diseases | JAMA Psychiatry

Alternative Headline: Study shows different types of infections increase the risk for neurologic and psychiatric issues

Neurologic Manifestations of Long COVID Affect Adult Females More Severely Than Males | Annals of Clnical and Translational Neurology

Alternative Headline: Females with Long COVID have higher symptom burden, worse quality of life, and poorer cognitive function than males

SARS-CoV-2 and Cancer Biology: Exploring the Mechanistic Links | Cancer Reports

Alternative Headline: Evidence shows mechanisms of SARS-CoV-2–induced inflammatory stress responses and pathways involved in cancer progression

A Research Classification for Long COVID: Symptom Frequency and Severity Improve Accuracy of Machine Learning Models | Chronic Diseases and Translational Medicine

Alternative Headline: Machine learning models using symptom frequency and severity more accurately distinguish Long COVID cases than models relying solely on binary symptom presence

Perioperative outcomes in patients with myalgic encephalomyelitis/chronic fatigue syndrome undergoing general anesthesia: a retrospective matched-pair study | BMC Anesthesiology | Springer Nature Link

Alternative Headline: Postoperative pain scores and requirements for opioids higher in an ME/CFS patient group following general anesthesia

COVID-19 vaccination timing, relative to acute COVID-19, and subsequent risk of long COVID | The Lancet eBioMedicine

Alternative Headline: COVID-19 vaccination appears protective against Long COVID

Item comprehension and content coverage of patient-reported outcome measures for long COVID: a qualitative study | Quality of Life Research | Springer Nature Link

Alternative Headline: Patient-reported outcome measures evaluated by Long COVID patients for use in clinical trial

Battling the Bots and Defending Against Fraudulent Responses in an International Community-Engaged Web-Based Survey With People Living With Long COVID: Methodological Study | Journal of Medical Internet Research

Alternative Headline: Fraudulent responses to online survey research and recommendations for web-based survey research

A Brief Pause

I’ve really enjoyed writing this newsletter and am grateful to everyone who has followed along. I’m taking a brief pause so I can give it the time and effort needed to make it genuinely worthwhile, with the goal of returning to the full newsletter this fall.

In the meantime, we’ll continue sharing curated quick links and research updates to help you stay abreast of the topics we cover. Thanks, as always, for reading.

Research Quick Links

Association of rapamycin treatment with the modulation of purine metabolism, reduced microglial inflammatory responses, improved mitochondrial energy metabolism, and alleviation of fatigue symptoms in ME/CFS subjects: pilot findings from phase-II observational study | Journal of Translational Medicine

Alternative headline: Rapamycin continues to show modest improvement in fatigue in ME/CFS patients, mechanistic pathway proposed

Effect of low-dose naltrexone for long COVID: a systematic review and meta-analysis | BMJ Open

Alternative Headline: Limited evidence suggests LDN may improve fatigue, cognition, sleep, pain and functioning in Long COVID

Efficacy and safety of rivaroxaban, colchicine, and famotidine–loratadine with specialist supportive clinical care for fatigue in patients with post-COVID-19 condition in the UK: a multisite, open-label, randomised controlled trial | The Lancet Infectious Diseases

Alternative Headline: Colchicine and antihistamines show modest improvement in fatigue for Long COVID patients

Metformin and Severe Post-COVID-19 Outcomes Among Individuals with Diabetes Mellitus | medRxiv preprint

Alternative Headline: Metformin is associated with lower mortality from acute COVID-19 and may protect against Long COVID in patients with Type 2 diabetes

Metabolomic Classification of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome via Explainable Ensemble Learning and Pareto-Guided Feature Selection | MDPI

Alternative Headline: Study findings support explainable boosting machine (EBM)-based metabolomic profiling as a validated approach for ME/CFS classification

Biomarkers of post-acute infection syndrome: a systematic literature review | Frontiers in Immunology

Alternative Headline: NF-κB pathway serves as a unifying hub in PAIS mechanistic pathways

Investigating respiratory infection as a post-COVID-19 condition using a large passive surveillance cohort from Track PCC | BMC Infectious Diseases | Springer Nature Link

Alternative Headline: Study finds higher odds of respiratory post-COVID conditions among Medicare/Medicaid users and current smokers

Enrolling and retaining a representative population in the NIH Researching COVID to Enhance Recovery (RECOVER)-Adult Cohort | Research Square Preprint

Alternative Headline: Study finds enrollment easier than retention of a sociodemographically-representative study population

Neurocognitive and psychological symptoms in post COVID-19 patients (PASC24): prospective cohort study protocol | BMJ Open

Alternative Headline: Study plans to chart neurocognitive effects and biomarkers of Long COVID over time

Cognitive Rehabilitation and Functional Outcomes in Long COVID–Related Cognitive Impairment: A Randomized Clinical Trial | Neurology | JAMA Network Open

Alternative Headline: Clinical trial shows that cognitive rehabilitation may effectively treat cognitive impairment in Long COVID

Long-term ocular symptoms following COVID-19 linked to immune dysregulation, dysautonomia and peripheral neuropathy | Nature Communications

Alternative Headline: Study offers biophysical explanation and diagnostic test for light sensitivity, eye pain, reading difficulty and gaze-focusing difficulty for patients with Long COVID

Sustained Reduction in Cardiopulmonary Fitness in Long COVID: A Report from the RECOVER-adult Cohort Study | JACC: Advances

Alternative Headline: Long COVID patients show sustained reductions in cardiopulmonary fitness 2 years after COVID-19

Research

Hyperbaric oxygen therapy improves clinical symptoms and functional capacity and modulates thalamic connectivity in ME/CFS: a prospective cohort study | Journal of Translational Medicine

Alternative Headline: Study Finds Promising Results for Hyperbaric Oxygen Therapy in Treating Chronic Fatigue Syndrome

Summary

• The study demonstrates that Hyperbaric Oxygen Therapy (HBOT) significantly improved clinical symptoms and functional capacity among 30 ME/CFS patients who received 40 sessions over 8 to 16 weeks.

• Notable improvements were measured in physical functioning, fatigue, pain, and cognitive performance using validated questionnaires and functional tests.

• The Short Form-36 Physical Functioning scores increased with an effect size of g = 0.71; Chalder Fatigue Scale scores reduced by −2.93 points post-treatment (P < 0.01); and mean handgrip strength increased by 1.14 kg.

• HBOT was also associated with a shift in thalamocortical connectivity towards patterns observed in healthy controls, pointing to potential neural mechanisms underlying treatment benefits. Of patients who completed the protocol, 76.67% reported subjective improvements.

Definitions

• Hyperbaric Oxygen Therapy (HBOT): A medical treatment that involves breathing 100% oxygen in a pressurized chamber to enhance oxygen delivery to tissues, aiding recovery.

Counterpoints

The study’s observational design and small sample size limit clinical applicability. The absence of a control group prevents clear causative conclusions regarding HBOT efficacy, and potential biases from self-reported outcomes could skew results.

Action Items

1. Advocate for larger, randomized controlled trials to validate HBOT’s efficacy for ME/CFS.

2. Monitor emerging research on neural mechanisms associated with ME/CFS treatments.

3. Consider individual patient experiences and responses when discussing treatment options.

Single-cell profiling of innate and adaptive immune dysregulation in Long COVID | bioRxiv preprint

Alternative Headline: Study Reveals Significant Immune Differences Between Long COVID Patients and Recovered Individuals

Summary

• The study used single-cell profiling to explore immune dysregulation in 20 Long COVID patients versus 18 recovered controls (156,478 PBMCs analyzed), revealing significant differences in immune cell composition and function.

• Elevated IL4R expression in naïve B cells indicates chronic antigen exposure and aberrant activation patterns. Monocytes showed heightened interferon signaling and enhanced migratory states, leading to poor myeloid differentiation.

• The T-cell compartment displayed a dichotomy, with central memory T cells remaining quiescent while effector memory populations exhibited signs of chronic exhaustion and dysfunction.

• Severe Long COVID was associated with a distinct immune signature marked by chronic AP-1-mediated inflammation, particularly in NK cells and CD14+ monocytes, while NK cells overall showed increased cytotoxic capabilities but compromised regulatory functions.

Definitions

• Single-Cell Profiling (SCP): A technique to analyze individual cells, providing insights into immune dysregulation.

• Chronic Exhaustion: A state where immune cells exhibit functional impairment due to prolonged activation, reducing their response to pathogens.

• AP-1: A protein family that regulates gene expression in response to stimuli, including inflammation.

Counterpoints

Despite valuable insights, limitations such as small sample size and single-center design may restrict the findings’ broader applicability. The study also did not fully account for confounding factors like recent infections or treatments, highlighting the need for further multi-center research.

My Take

These findings underscore the complex immune landscape in Long COVID, suggesting that understanding persistent immune dysregulation is key to addressing prolonged symptoms and cognitive dysfunction.

Action Items

1. Advocate for larger, multi-center studies to validate these findings across diverse populations.

2. Explore targeted therapeutic interventions aimed at restoring immune balance in Long COVID patients.

3. Monitor the development of potential biomarkers for better treatment guidance in Long COVID management.

Long-Term Follow-Up of Women with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): A 16-Year Longitudinal Study | Medicina

Alternative Headline: Long-Term Study Reveals High Fatigue and Cognitive Challenges Persist in Women with ME/CFS

Summary

• A study tracked 100 women diagnosed with ME/CFS (average age 47.3 ± 11.4 years) over 16 years, revealing persistent fatigue and cognitive challenges throughout.

• Quality of life assessments indicated significantly poorer emotional and physical well-being compared to age-matched controls (P < 0.005), with participants averaging a quality of life rating of 3.4 ± 1.5 on a scale of 0 to 10.

• Fatigue Severity Scale analysis showed an average score of 5.8 ± 1.2 — 65% of participants scored above the clinical threshold of 4.0. Only 18% demonstrated significant cognitive improvement over the study period.

• While some patients reported gradual improvement, a noteworthy subset remains severely affected, highlighting the need for ongoing support and intervention.

Definitions

• Fatigue Severity Scale (FSS): A tool used to measure fatigue severity and its impact on daily life, often used in clinical settings to assess treatment efficacy.

Counterpoints

The study’s single-center design and specific demographic may limit the applicability of findings across different populations. Variations in symptom reporting and the absence of objective biomarker assessment raise questions about the reliability of self-reported data, suggesting a need for multicenter trials and objective measures in future research.

Action Items

1. Advocate for ongoing research aimed at understanding the complexities of ME/CFS.

2. Encourage healthcare providers to adopt holistic approaches to improve patient well-being.

3. Support initiatives promoting awareness and education about ME/CFS in broader healthcare settings.

Elevated serum levels of interleukin-11 and matrix metalloproteinase-9 in myalgic encephalomyelitis/chronic fatigue syndrome | Frontiers in Immunology

Alternative Headline: Study Finds Elevated Inflammatory Markers in Female Patients with Chronic Fatigue Syndrome

Summary

• The study reports significantly elevated serum levels of interleukin-11 (IL-11) and matrix metalloproteinase-9 (MMP-9) in 40 female ME/CFS patients (mean age 51) compared to 38 age-matched healthy controls (mean age 43).

• Mean serum IL-11 levels were 127 pg/ml in ME/CFS patients versus 67 pg/ml in controls (P < 0.001), while MMP-9 levels rose from 17 ng/ml in controls to 126 ng/ml in ME/CFS patients (P < 0.0001).

• Mast cells stimulated with recombinant Epstein-Barr Virus protein released significantly higher levels of MMP-9, indicating a potential mechanism for neuroinflammation in ME/CFS.

• Despite elevated pro-inflammatory cytokines, no definitive biomarkers for ME/CFS have been established, reflecting the ongoing complexity of the disease.

Definitions

• Interleukin-11 (IL-11): A pro-inflammatory cytokine involved in immune responses and implicated in several inflammatory diseases.

• Matrix Metalloproteinase-9 (MMP-9): An enzyme that breaks down extracellular matrix components, playing a critical role in tissue remodeling.

• Mast Cells (MC): Immune cells involved in allergy, inflammation, and tissue repair, implicated in chronic conditions like ME/CFS.

Counterpoints

While the study provides crucial insights into inflammatory markers in ME/CFS, limitations include a modest sample size and lack of comprehensive characterization of individual patient backgrounds. The absence of significant biomarkers suggests the need for multi-center studies to validate and better understand these findings.

Action Items

1. Advocate for larger, multi-center studies to confirm the findings related to IL-11 and MMP-9 in ME/CFS.

2. Encourage focused research on the roles of mast cells and viral infections in ME/CFS.

3. Continue exploring potential biomarkers to improve diagnosis and treatment strategies for ME/CFS.

Exploring the mechanisms of acupuncture in improving cognitive function in post-COVID-19 myalgic encephalomyelitis/chronic fatigue syndrome: study protocol for a randomized controlled trial using multimodal MRI | Frontiers in Neurology

Alternative Headline: Study Investigates Acupuncture’s Potential to Alleviate Cognitive Issues in Long COVID Patients

Summary

• The study aims to provide insights into the effectiveness of acupuncture for cognitive dysfunction in post-COVID-19 ME/CFS.

• A randomized controlled trial will enroll 129 patients, comparing outcomes from verum acupuncture, sham acupuncture, and a waitlist control group (randomized 1:1:1).

• Participants will undergo three sessions a week over an 8-week intervention period (24 sessions total), alongside 30 healthy controls.

• The primary outcome will be change in scores on the Symbol Digit Modalities Test (SDMT) at baseline and week 8. By utilizing multimodal MRI, the study will also explore underlying neural mechanisms, including changes in hippocampal metabolites and resting-state functional connectivity.

Counterpoints

While the study design is robust, participant variability, the complex nature of ME/CFS, and reliance on subjective symptom reporting may pose challenges. Effects of concurrent treatments and lifestyle factors may also influence outcomes and necessitate long-term follow-up data for validation.

Action Items

1. Monitor the trial’s progress and participant feedback throughout the intervention.

2. Encourage collaboration with related research for comprehensive analysis of acupuncture’s effects.

3. Advocate for additional studies to explore the long-term benefits of acupuncture and its mechanisms in post-COVID-19 ME/CFS.

Retinal microvascular alterations consistent with endothelial dysregulation in pediatric post-COVID-19 syndrome: A prospective matched cohort study | Scientific Reports

Alternative Headline: Retinal Imaging is Proxy for System-wide Endothelial Changes in Pediatric Long COVID, Showing Ongoing Endothelial and Inflammatory Activity

Summary

• Retinal imaging enables non-invasive assessment of microvascular structure and function and may help to clarify whether endothelial dysregulation is present in children with post-COVID-19 syndrome (PCS). Retinal vessel analysis is a surrogate for microvascular function and regulation and is used as an indirect marker of function in cardiometabolic and inflammatory conditions.

• Findings in this study suggest a distinct microvascular pattern in children with PCS that is consistent with endothelial dysregulation months after infection.

• Longer follow-up intervals predicted decreasing venular diameter, and reductions in symptom burden correlated with increasing arteriolar-to-venular ratio (AVR) over time. Together, these results indicate heterogeneous, time-dependent changes in microvascular parameters.

• These findings are indicative of ongoing endothelial and inflammatory activity observed in post-COVID conditions. In light of the fundamental role of the microcirculation, including endothelial function, in regulating tissue perfusion, these findings offer important insights into the biological underpinnings of prolonged symptoms in paediatric PCS.

Stats/Trends

• Retinal vessel diameters and flicker-induced vasoreactivity were assessed at baseline and after a median of 14 weeks.

• Compared with matched healthy controls, multivariable analyses showed that PCS independently predicted wider central retinal arteriolar equivalent (CRAE + 28.1 μm, 95% CI 21.7–34.5, p < 0.001) and central retinal venular equivalent (CRVE + 21.7 μm, 95% CI 15.8–27.7, p < 0.001), with a higher arteriolar-to-venular ratio (AVR + 0.038 units, 95% CI 0.012–0.064, p = 0.005).

Inflammatory biomarkers in the assessment of kidney function decline in Long Covid syndrome | Kidney and Blood Pressure Research

Alternative Headline: Study Finds Inflammation May Link Long Covid to Decline in Kidney Function and Disease Risk

Summary

• The study identifies a biomarker signature in Long Covid patients that correlates with the decline in kidney function, emphasizing the role of inflammation in renal prognosis.

• Patients were categorized based on estimated Glomerular Filtration Rate (eGFR) into three groups: Group 1 (eGFR > 90 ml/min), Group 2 (eGFR 30–89 ml/min), and Group 3 (eGFR < 30 ml/min).

• Patients in Group 3 demonstrated significantly elevated levels of IL-17, IL-10, and VCAM-1, pointing to severe kidney impairment, while a notable increase in IL-6 was observed as eGFR decreased across groups.

• The findings provide a potential clinical framework for early identification of patients at risk for chronic kidney disease following COVID-19, particularly those with heightened inflammatory responses.

Definitions

• eGFR (Estimated Glomerular Filtration Rate): A key indicator used to assess kidney function.

• Inflammatory Biomarkers: Substances that indicate inflammation, often associated with health conditions including kidney disease.

Counterpoints

The findings provide valuable insights into the role of inflammation in chronic kidney disease post-COVID-19, but the single-center design limits applicability to broader populations. The study may not fully account for other contributing factors such as pre-existing kidney conditions or lifestyle variables that could influence outcomes.

Action Items

1. Clinicians should consider monitoring inflammatory biomarkers like IL-6 in Long Covid patients to assess kidney health.

2. Advocacy for larger, multi-center studies is essential to validate these findings and explore targeted therapies.

3. Develop early intervention strategies aimed at managing kidney health in Long Covid patients based on identified risk factors.

Rationale and Design of RECOVER-ENERGIZE: A Platform Clinical Trial of Interventions for Exercise Intolerance With and Without Post-exertional Malaise in Long COVID | medRxiv preprint

Alternative Headline: New Trial Investigates Exercise Interventions for Long COVID Patients Facing Exercise Intolerance and PEM

Summary

• The RECOVER-ENERGIZE trial is a multicenter, randomized controlled trial evaluating two interventions for exercise intolerance in Long COVID patients: cardiopulmonary rehabilitation for those without significant post-exertional malaise (PEM), and structured activity pacing for those with PEM.

• Exercise intolerance and PEM affect approximately 20% of individuals following SARS-CoV-2 infection, contributing to long-term physical, cognitive, and psychological challenges.

• The trial aims to enroll 360 patients for cardiopulmonary rehabilitation and 300 for pacing, with participants assessed at baseline, mid-intervention, post-intervention, and 12 weeks after — a total study duration of 6 months.

• A key feature is the integration of the modified DePaul Symptom Questionnaire to guide participant allocation, with continuous monitoring allowing for immediate reallocation to pacing if PEM emerges. The trial also emphasizes collaboration with patient representatives in developing protocols.

Definitions

• Post-Exertional Malaise (PEM): A worsening of symptoms following physical or mental exertion, often delayed and lasting days to weeks, significant in Long COVID.

• Cardiopulmonary Rehabilitation: An individualized program aimed at improving physical condition in patients with heart or lung diseases, adapted here for those with exercise intolerance due to Long COVID.

Counterpoints

The trial may face challenges such as participant adherence to interventions and varying responses based on individual symptomatology. The non-blinded nature of the interventions could introduce bias in self-reported outcomes, necessitating robust approaches to data collection and analysis.

Action Items

1. Monitor trial enrollment progress and participant adherence to interventions.

2. Evaluate the effectiveness of the modified DePaul Symptom Questionnaire in guiding participant allocation.

3. Engage with patient representatives throughout the trial to ensure the development of relevant protocols.

Persistent increased risk of renal replacement therapy following COVID-19: a 2-year follow-up study in Japan | BMJ Open

Alternative Headline: COVID-19 Increases Risk of Severe Kidney Disease, Highlighting Need for Ongoing Health Monitoring

Summary

• Analyzing data from over 6 million individuals (three million matched pairs of COVID-19 patients and controls), this study finds that COVID-19 is associated with a 2.8-fold increased risk of end-stage kidney disease (ESKD) requiring renal replacement therapy over up to 2 years (HR 2.79, 95% CI 2.56 to 3.04).

• The risk was pronounced for dialysis specifically — 2.77-fold for hemodialysis and 5.16-fold for peritoneal dialysis.

• This heightened risk spanned various demographic groups including age, sex, and comorbidities, and subgroup analyses confirmed the association across patients with varying levels of hypertension, diabetes, and COVID-19 severity.

• Among the matched cohort, there were 1,573.2 cumulative incidents of ESKD over a median follow-up of 9 months.

Definitions

• End-Stage Kidney Disease (ESKD): A condition requiring renal replacement therapy due to complete loss of kidney function.

Counterpoints

The study relies on retrospective claims data, which may introduce unmeasured confounders like lifestyle factors and comorbidities. The focus on a specific population in Japan may limit the generalizability of results to broader populations.

Action Items

1. Monitor renal health closely in individuals recovering from COVID-19, especially those with risk factors.

2. Develop targeted programs to assess and mitigate the risk of ESKD in former COVID-19 patients.

3. Encourage further research using prospective designs to validate and expand upon these findings.

Characteristics, all-cause healthcare resource utilisation, and costs among high-risk adults with long COVID during Omicron predominance, 2022–2023 | BMC Health Services Research

Alternative Headline: Study Reveals Significant Healthcare Burden of Long COVID Among High-Risk Adults During Omicron Surge

Summary

• The study examined healthcare resource utilization and costs associated with Long COVID in a cohort of 5,661 high-risk adults during the Omicron variant period (September 2022–May 2023), drawn from UK primary care electronic health records.

• Of eligible patients, 2,772 (49.0%) were identified as having Long COVID. Healthcare costs were higher in older adults and high-risk individuals eligible for COVID-19 vaccines, reflecting increased medical needs.

• There was an increased rate of primary care consultations and hospitalisations among Long COVID patients, emphasizing ongoing healthcare challenges. Notably, only 0.8% of Long COVID patients received formal referrals to Long COVID clinics, indicating a significant gap in the healthcare response.

Counterpoints

The study’s retrospective design and reliance on electronic health records may introduce biases in symptom reporting. The lack of longitudinal follow-up post-discharge limits comprehensive insights into Long COVID recovery patterns, warranting further exploration in multi-center studies.

Action Items

1. Encourage healthcare providers to improve identification and management of Long COVID symptoms.

2. Advocate for systematic referrals to Long COVID clinics to enhance patient care.

3. Support research initiatives that investigate Long COVID recovery patterns and long-term impacts.

Media

How long Covid research went so wrong | STAT

Alternative Headline: Long Covid Research Faces Setbacks Amid Political Shifts and Lack of Funding Support

Summary

• Long Covid research has faced significant setbacks due to its classification as a contested illness — one that lacks clear diagnostic markers and sits at the intersection of ongoing scientific and political debate.

• The termination of key funding like the RECOVER grant reflects a broader governmental retreat from the issue as priorities shifted. Despite over $1.8 billion in research investments, relevant studies declined sharply after 2022, with an estimated 80% reduction in new initiatives following the dismantling of institutional support.

• Long Covid’s multi-system symptom profile has complicated efforts to study and treat it through traditional biomedical methods, and the article argues that moving forward will require a patient-centered approach that goes beyond the standard biomarker-and-intervention paradigm. As of 2024, about 1 in 19 individuals are still affected.

🔗 Quick Links

• Characteristics, all-cause healthcare resource utilisation, and costs among high-risk adults with long COVID during Omicron predominance, 2022–2023: a retrospective cohort study using UK primary care data

• Two-timepoint multidomain follow-up of post-COVID condition and ME/CFS: overlapping autonomic, small-fiber, and cognitive changes

• Immune Dysregulation After COVID-19: Longitudinal Analysis up to 9 Months

• Retinal microvascular alterations consistent with endothelial dysregulation in paediatric post-COVID-19 syndrome: A prospective matched-cohort study

Article of the week

Our article of the week is “Unveiling the burden of long COVID in hospital and community settings,” from the PASCNET cohort study in Lombardy, Italy. The research tracks how long COVID manifests differently depending on whether patients were hospitalized or managed in primary care and the gap is striking. The one-year cumulative incidence was 39.9% in hospitalized patients versus 9.1% in those seen by general practitioners, and unresolved symptoms at the one-year mark were found in 30.2% of hospital patients compared to just 1.9% in the community group.

The study also sheds light on which early symptoms predict persistent illness. Respiratory symptoms appeared protective, while early headache, diffuse muscle pain, and neurological disturbances were associated with ongoing post-COVID condition possibly pointing to multi-system immune activation and a higher likelihood of persistent autoimmune activity. It’s a useful framework for thinking about who needs closer follow-up and why.

Research

Unveiling the burden of long COVID in hospital and community settings: findings from the Post-Acute Sequelae of SARS-CoV-2 Network (PASCNET) cohort study in Italy’s pandemic epicentre | BMJ Open

Alternative headline: Study Finds Significant Risk of Long-Term COVID Symptoms Varies Among Hospital and Home Patients

Summary

• The study revealed a one-year cumulative incidence of PASC of 9.1% among general practitioner patients and as high as 39.9% among hospital patients.

• Persistent symptoms were reported by 30.2% of previously hospitalized patients, compared to just 1.9% of those managed in primary care.

• Neurological and musculoskeletal symptoms were significant predictors of PASC, increasing the odds of long-term symptoms by up to 16-fold in the community cohort.

• The NIH RECOVER score proved instrumental in identifying probable PASC cases within the first year post-infection, enhancing early diagnosis and referral for care.

Stats/Trends

• A total of 1,162 participants were enrolled, including 616 general practitioner and 546 hospital patients.

• During the first year post-infection, 280 participants developed PASC, with 40.8% in hospitalized patients versus 9.3% in community patients.

• At one year post-infection, unresolved PASC prevalence was 30.2% among hospitalized patients versus 1.9% among community-managed individuals (P < 0.0001).

Counterpoints

• Potential biases include reliance on patient recall for symptom reporting and the necessity of in-person visits, which may skew the sample toward those with persistent symptoms.

• The lack of a comprehensive uninfected comparator group limits the generalizability of the findings across demographic categories.

Beyond recovery: long-term cardiovascular risks after severe COVID-19 requiring intensive care | Critical Care

Alternative headline: COVID-19 Survivors Face Increased Long-Term Heart Risks After Severe Illness, Study Finds

Definitions

• Atherosclerotic Cardiovascular Disease (ASCVD): A type of cardiovascular disease resulting from plaque buildup in arterial walls, narrowing arteries and restricting blood flow.

• Subdistribution Hazard Ratio (sHR): Used in competing risks analysis to account for the possibility of other events affecting the outcome of interest.

Summary

• A nationwide matched cohort study reveals that survivors of severe COVID-19 requiring ICU treatment face elevated long-term cardiovascular risks, particularly for atherosclerotic cardiovascular disease (ASCVD), heart failure, and atrial fibrillation within three years post-discharge.

• Patients discharged after severe COVID-19 showed a 42% increased risk for ASCVD compared to matched controls, with this risk being strongest in the first year of follow-up.

• The cumulative incidence of ASCVD was 10.9% among patients with severe COVID-19 versus 7.9% in the control group, reflecting a risk difference of 3 percentage points over three years (P < 0.05).

• Hospitalization rates for heart failure were significantly higher in COVID-19 survivors, with a subdistribution hazard ratio of 1.81 (95% CI 1.57–2.09).

Stats/Trends

• The study analyzed data from 16,530 individuals, including 3,350 cases of severe COVID-19 and 13,180 matched controls.

• Incidence rates for ASCVD were calculated at 42.3 per 1,000 person-years for severe COVID-19 patients compared to 29.0 per 1,000 person-years in controls, an absolute difference of 13.3 events per 1,000 person-years.

Counterpoints

• The reliance on matched cohorts may introduce residual confounding factors, as not all controls were strictly without prior COVID-19 exposure.

• The study did not account for the health status of patients prior to COVID-19 infection, which may affect cardiovascular outcomes.

Early-Phase Oral Antiviral Use and Post–COVID-19 Condition in Outpatients | JAMA Network Open

Alternative headline: Early Use of Antivirals in Acute COVID-19 is Associated with Decreased Risk of Long COVID

Summary

• This was a prospective, nationwide, multicenter, registry-based cohort study conducted at 51 acute-care hospitals across Japan in 2024 and 2025.

• The primary outcome was post-COVID condition (PCC), defined as persistence of 1 or more of 5 prespecified symptoms (cough, shortness of breath, malaise, smell disorder, or taste disorder), with the same symptoms reported on both days 28 and 84. Exploratory outcomes included failure to return to usual health by day 84.

• Early oral antiviral use was associated with a significantly lower risk of PCC in the primary adjusted analysis. Participants receiving antivirals were less likely to fail to return to usual health by day 84.

• These findings suggest that early antiviral treatment may help mitigate long-term consequences of SARS-CoV-2 infection.

Stats/Trends

• Among 7699 participants (2181 receiving antivirals: 51.9% male; median age, 58.0 [41-71] years; and 5518 without antivirals: 53.1% female; median age, 45.0 [29-57] years), most had mild COVID-19 (98.7%) and received 2 or more vaccine doses (89.6%).

• In adjusted analyses, the estimated PCC risk was 21.5% among participants receiving antivirals and 25.1% among those not receiving antivirals (aRR, 0.86).

• In addition, failure to return to usual health by day 84 occurred in 9.9% of participants receiving antivirals and 12.9% of those not receiving antivirals.

• After prespecified adjustment, antiviral use was associated with a lower risk of PCC (adjusted risk ratio [aRR], 0.86; 95% CI, 0.78-0.93). Results were consistent for ensitrelvir (aRR, 0.86; 95% CI, 0.79-0.95) and molnupiravir (aRR, 0.81; 95% CI, 0.67-0.98).

Counterpoints/Action Items

• The large nationwide prospective design of this study increases the validity of the study, although its observational nature makes the results an association rather than a causation.

• The cohort included outpatients across a wide age range and both with and without risk factors for severe disease, reflecting routine clinical practice.

• Further large studies on individual antivirals treating COVID-19 will elucidate whether all are effective in reducing risk of PCC.

• Patients and health care providers should consider being more diligent in diagnosing COVID-19 and advocate for more liberal use of antivirals when COVID-19 is diagnosed.

Long-term cognitive outcomes after mild COVID-19, critical COVID-19, and non-COVID critical illness: a prospective cohort comparison | Scientific Reports

Alternative headline: Study Reveals Recovery from Mild COVID-19 Linked to Cognitive Impairments and Increased Mental Health Issues

Definitions

• Post-COVID-19 Condition (PCC): A spectrum of persistent symptoms manifesting at least 12 weeks after a COVID-19 infection, unexplained by other diagnoses.

• Cognitive Fatigue: A subjective feeling of tiredness and impaired cognitive performance, frequently reported by patients recovering from illness.

Summary

• This study suggests cognitive impairments in COVID-19 patients recovering from mild and critical illness are comparable to those in non-COVID critical illness patients.

• At the four-month follow-up, mild COVID-19 patients reported poorer subjective cognitive outcomes despite similar objective scores to critical illness counterparts.

• Attention and executive functions were significantly impacted in the mild COVID-19 group, indicating a need for targeted rehabilitation efforts.

• Mental health assessments revealed higher anxiety and depression levels in mild COVID-19 patients compared to those who experienced critical illness, highlighting the psychological burden of PCC.

• The findings underscore the necessity for a multimodal rehabilitation approach combining cognitive training and mental health support for post-COVID recovery.

Stats/Trends

• The study included 51 patients: 17 from the mild COVID-19 group, 22 from the critical COVID-19 group, and 12 from the non-COVID critical illness group.

• While cognitive assessments showed no significant differences in composite scores, the mild COVID-19 group reported lower memory satisfaction and higher cognitive fatigue (P < 0.01).

• Patients in both the mild COVID-19 and COV-ICU groups showed significant attention deficits (P < 0.05).

Counterpoints

• Limitations such as small sample size and varied follow-up times may restrict the applicability of findings. Further research with larger cohorts and consistent follow-up is needed to validate results.

Association of long-COVID with major adverse cardiovascular events and mortality: a real-world data cohort study | BMC Cardiovascular Disorders

Alternative headline: Long COVID Patients Face Over Fourfold Increased Risk of Serious Cardiovascular Events, Study Finds

Definitions

• Major Adverse Cardiovascular Events (MACE): Significant cardiovascular complications such as heart attacks, strokes, or cardiac-related deaths.

• Hazard Ratio (HR): A measure comparing hazard rates between two groups; an HR greater than 1 indicates increased risk in the exposed group.

Summary

• Patients diagnosed with long COVID have a significantly higher risk of major adverse cardiovascular events (MACE) compared to those without it, with a hazard ratio of 4.48.

• Specific risks for conditions such as coronary artery disease and stroke were notably higher, with HRs of 6.48 and 3.46, respectively.

• Mortality rates were elevated among long COVID patients, with an HR of 1.53 compared to those without long COVID.

• The research utilized multicenter, real-world data from the TriNetX platform across patients aged 18 and older diagnosed with COVID-19 between 2020 and 2023.

Counterpoints

• The study relies on observational data, which may introduce biases. Variability in healthcare access and follow-up care could influence outcomes, necessitating further studies to validate these findings.

Underuse of Pharmacologic Therapies for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Before Specialist Evaluation | Annals of Family Medicine

Alternative headline: Study Finds Many ME/CFS Patients Lack Appropriate Pharmacologic Treatments Before Specialty Care

Definitions

• Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): A debilitating condition characterized by profound fatigue, post-exertional malaise, unrefreshing sleep, and cognitive difficulties lasting over six months.

Summary

• The study reveals a significant underuse of pharmacologic therapies for managing ME/CFS among patients before referral to specialty clinics.

• Approximately 31.7% of the patient cohort had not received any medications deemed appropriate for ME/CFS symptom management prior to evaluation by specialists.

• Common symptoms like pain and mood disorders were prioritized by general practitioners, while medications addressing fatigue and cognitive issues received less attention.

• A total of 571 patients diagnosed with ME/CFS were analyzed, underscoring the pressing need for clinician education regarding effective symptom management.

• Dietary supplements were commonly utilized, with 72.2% of the cohort reporting use, highlighting a potential gap in conventional treatment approaches.

Stats/Trends

• Of 571 patients, 390 (68.3%) had been prescribed at least one pharmacologic therapy at the time of their specialist consultation.

• The mean number of prescribed therapies per patient was 1.5.

• 412 patients reported use of dietary supplements, averaging 1.3 supplements per person.

Counterpoints

• The study’s retrospective nature limits causative conclusions and may overlook concurrent conditions affecting treatment. Reliance on patient self-reporting can introduce recall bias. Larger, multi-center studies are needed to validate these results.

Healthcare Pathways of Patients with Long COVID in Austria: A Qualitative Exploration of Experiences, Barriers, and Needs | International Journal for Equity in Health

Alternative headline: Austrian Patients With Long COVID Face Major Barriers to Care, Support, and Recovery Needs

Summary

• The qualitative study reveals that patients with long COVID in Austria face significant barriers in navigating healthcare pathways, impacting their recovery journey.

• Common barriers include limited access to specialized care, lack of awareness about long COVID among healthcare providers, and difficulties in obtaining timely medical services.

• Patients expressed a strong need for comprehensive follow-up care and interdisciplinary support to address the multifaceted symptoms of long COVID.

• Emotional and psychological challenges were frequently reported, highlighting the necessity for mental health support alongside physical rehabilitation.

Stats/Trends

• In-depth interviews were conducted with 30 long COVID patients in Austria.

• 70% of participants reported feeling unsupported by their healthcare providers throughout their recovery process.

• Approximately 60% of patients indicated they had to advocate for themselves to receive appropriate care for their symptoms.

Counterpoints

• The study’s small sample size may limit the generalizability of results. Self-reported data may be subject to biases, making it essential to corroborate these experiences through larger-scale, quantitative studies.

Cellular Metabolic Signatures of Long COVID-19 | Infectious Disease Reports

Alternative headline: Study Identifies Metabolic Changes in Long COVID-19 Patients, Highlighting Potential Diagnostic Pathways

Definitions

• Cellular Metabolic Signatures: Unique profiles of metabolites produced by cells that indicate cellular function or stress responses.

• Mass Spectrometry: An analytical technique determining the mass-to-charge ratio of ions for identifying and quantifying metabolites.

Summary

• The research uncovers distinct cellular metabolic signatures in long COVID patients, providing insights into post-viral syndromes.

• The study identified 125 significantly altered metabolites in long COVID patients compared to healthy controls using advanced mass spectrometry techniques.

• Specific pathways related to energy metabolism, oxidative stress, and inflammation were notably dysregulated.

• Data integration revealed mitochondrial dysfunction as a key factor in the chronic fatigue experienced by long COVID patients.

• The metabolic profiles suggest potential biomarkers for diagnosing and monitoring long COVID, as well as future therapeutic interventions targeting these pathways.

Stats/Trends

• The study analyzed plasma samples from 150 long COVID patients compared with 50 healthy controls.

• A total of 32 metabolic pathways displayed significant dysregulation (P < 0.005), especially related to the tricarboxylic acid cycle and cellular respiration.

• Lactate levels were elevated in 68% of long COVID patients, suggesting possible impaired oxidative metabolism.

Counterpoints

• The cross-sectional nature of the study may limit understanding of causal relationships. Reliance on plasma samples might not capture tissue-specific metabolic changes, indicating a need for longitudinal studies.

Action Items

• Advocate for further longitudinal research to understand the causal relationships in long COVID.

• Encourage exploration of tissue-specific metabolic changes to provide a more comprehensive view of long COVID pathology.

• Support the development of targeted therapeutic strategies based on identified metabolic pathways.

Association of Acute-Phase IL-6 and SAA with Cardiovascular Events and Mortality Six Years After COVID-19 Infection: An Observational Cohort Study | BMC Cardiovascular Disorders

Alternative headline: Elevated IL-6 and SAA Levels After COVID-19 Linked to Increased Long-Term Heart Risks

Definitions

• IL-6: Interleukin-6, a pro-inflammatory cytokine involved in inflammation and immune response.

• SAA: Serum amyloid A, a marker of inflammation often elevated in inflammatory conditions.

Summary

• This study establishes a significant association between acute-phase IL-6 and SAA levels following COVID-19 infection and the risk of cardiovascular events and mortality six years later.

• Patient outcomes reveal that those with elevated IL-6 and SAA had a notably increased risk of experiencing cardiovascular events compared to those with normal levels.

• Elevated IL-6 was correlated with a 50% increase in the risk of cardiovascular events (P < 0.01), while SAA levels showed a similar association (P = 0.03).

• The findings advocate for monitoring inflammatory markers such as IL-6 and SAA in the long-term assessment of COVID-19 survivors.

Stats/Trends

• The observational cohort study analyzed data from 320 individuals who had recovered from COVID-19.

• Among the cohort, 22.5% developed cardiovascular events within six years, with a mean follow-up period of 3.5 years post-infection.

• Individuals with elevated IL-6 (> 7 pg/mL) had a 1.5-fold increased risk of cardiovascular events (P < 0.01).

• SAA levels above 10 mg/L were linked to a 40% higher risk of mortality during the follow-up period (P = 0.05).

Counterpoints

• The observational design precludes definitive conclusions about causality. Potential confounding factors, such as pre-existing conditions and lifestyle factors, may influence the observed associations.

Action Items

• Healthcare providers should consider regular monitoring of IL-6 and SAA levels in COVID-19 survivors.

• Further research should aim to establish causal relationships between inflammatory markers and cardiovascular outcomes.

Exploring the perceived impact of physical activity on physical and mental health among individuals with long COVID: A qualitative interview inquiry | PLOS One

Alternative headline: Many Long COVID Sufferers Find Physical Activity Worsens Symptoms, Yet Some Report Mental Benefits

Definitions

• Post-Exertional Malaise (PEM): A worsening of symptoms following physical or mental exertion, commonly reported in individuals with long COVID.

Summary

• The study reveals that a significant proportion of individuals with long COVID (64.7%) report worsening symptoms with physical activity, while only 14.7% experience improvements.

• Participants indicated that physical activities could exacerbate symptoms such as fatigue, leading to post-exertional malaise and a loss of prior physical abilities.

• Some participants noted enhanced mental health outcomes linked to physical activity, including a sense of accomplishment and improved energy levels.

• Nearly all interviewees indicated lower levels of physical activity compared to their pre-COVID status.

• Participants’ self-reported health ratings were approximately one standard deviation lower than the general U.S. population, underscoring the significant health burden of long COVID.

Stats/Trends

• The study involved semi-structured interviews with 34 adults, averaging 52 years of age, of whom 62% were women.

• 73.5% of those reporting worsening symptoms noted fatigue or exhaustion post-activity.

• 32.4% recognized potential health benefits of physical activity, motivating them to engage despite their symptoms.

Counterpoints

• The reliance on self-reported data may limit the accuracy of findings. The sample’s homogeneity, mostly consisting of white women, raises questions about the generalizability of the results.

Leveraging Machine Learning to Assess Post-COVID-19 Glycemic Control in Diabetic Patients | International Journal of Environmental Research and Public Health

Alternative headline: Study Reveals Significant Glycemic Control Variations in Diabetic Patients After COVID-19 Recovery

Definitions

• HbA1c: A blood test that measures average blood sugar levels over the past two to three months, commonly used to assess diabetes control.

Summary

• The study highlights the application of machine learning algorithms to assess glycemic control in diabetic patients post-COVID-19, demonstrating significant variations in blood sugar management.

• Patients with a history of severe COVID-19 exhibited a marked increase in average HbA1c levels compared to those with mild cases, indicating possible longer-term metabolic impacts.

• The Random Forest algorithm was the most predictive model, achieving 85% accuracy in determining impaired glycemic control.

• Variables such as age, pre-existing diabetes duration, and hospital stay length significantly predicted glycemic outcomes.

Stats/Trends

• The study analyzed data from 300 diabetic patients, comparing HbA1c levels before and after infection.

• Average HbA1c levels rose from 7.2 ± 1.0% pre-COVID to 8.5 ± 1.5% post-COVID for patients with severe cases (P < 0.001).

• 60% of patients post-COVID were classified as having poor glycemic control (HbA1c > 7.5%), compared to 30% pre-COVID (P < 0.005).

Counterpoints

• The observational nature of the study may introduce biases related to patient selection. The reliance on retrospective data limits the ability to draw causal conclusions; future prospective studies with larger, diverse populations are essential.

Persistent Olfactory Dysfunction Three Years After COVID-19: A Multicenter Observational Study | Pathogens

Alternative headline: One in Three COVID-19 Survivors Face Lingering Smell Impairment Three Years After Infection

Definitions

• Persistent Olfactory Dysfunction: A long-term loss or alteration of smell following viral infections, particularly in COVID-19 survivors.

Summary

• The study identifies that persistent olfactory dysfunction affects a significant number of COVID-19 survivors, with 30% reporting olfactory impairment over three years post-infection.

• Among participants with persistent dysfunction, 45% exhibited a reduced olfactory threshold, indicating severe impairment in smell sensitivity.

• The study utilized both subjective assessments and objective olfactory testing to evaluate olfactory function among 500 participants across six centers.

• Quality of life measures indicated that individuals with lasting olfactory dysfunction experienced a marked decline in daily living satisfaction compared to those who fully recovered, with average scores of 60 ± 10 versus 80 ± 10 (P < 0.01).

Counterpoints

• Reliance on self-reported symptoms may introduce bias. Demographic variability across centers could introduce confounding variables, necessitating further studies in a more homogeneous population.

Action Items

• Advocate for long-term follow-up protocols for COVID-19 patients focusing on sensory impairments.

• Encourage further research into therapeutic options for persistent olfactory dysfunction.

Media

Virax Biolabs Reports Positive Early Clinical Data for ViraxImmune™ in Long COVID and Related Post-Acute Infection Syndromes | Virax Biolabs

Alternative headline: New Accurate Blood Test May Help Distinguish Long COVID and Similar Conditions from Healthy Cases

Summary

• Virax Biolabs has released early clinical data for ViraxImmune™, a diagnostic test designed to assess immune responses in long COVID and related post-acute infection syndromes.

• The pilot results are encouraging: the test achieved 88% specificity and a 92% positive predictive value in distinguishing patients from healthy controls.

• The ongoing UK clinical study includes over 120 subjects with long COVID, ME/CFS, and related conditions, with a larger validation analysis of 300 additional participants planned.

• If validated, ViraxImmune™ could offer the first objective immune profiling tool for these conditions — a significant step given that current diagnosis still relies heavily on symptom evaluation. With an estimated 21 million U.S. adults affected by long COVID and related syndromes, the potential clinical need is substantial.

BioVie completes enrollment in Long COVID trial as need for treatments grows | Proactive

Alternative headline: BioVie Completes Enrollment for Study on Bezisterim’s Impact on Long COVID Neurological Symptoms

Summary

• BioVie has completed patient enrollment for the ADDRESS-LC Phase 2 clinical study, evaluating bezisterim — a drug targeting inflammatory pathways — for treating neurological symptoms of long COVID, including brain fog, cognitive dysfunction, and sleep disturbances.

• The trial is fully funded through a U.S. Department of Defense grant. The need is real: approximately 15 million U.S. adults currently report long COVID, with 3.8 million experiencing significant interference with daily life, and no FDA-approved therapies specifically targeting the condition yet exist. Results from this trial could mark an important milestone in filling that gap.

UW Medicine Long COVID Clinic is expanding access and improving care - The Daily

Alternative headline: UW Medicine Clinic Addresses Long COVID Through Multidisciplinary Care and Mental Health Support Initiatives

Summary

• UW Medicine’s Long COVID Clinic is expanding its approach around a biopsychosocial model — one that addresses the biological, psychological, and social dimensions of a condition that rarely fits neatly into any single specialty.

• About one in four long COVID patients experiences anxiety or depression, and the clinic has responded by introducing a six-session group self-management program targeting cognitive difficulties, fatigue, and stress.

• A $1 million federal grant from the Agency for Healthcare Research and Quality is supporting the clinic’s work over five years, including efforts to train primary care providers and reduce disparities in care — particularly for underrepresented minority groups.

• Demand currently outpaces capacity, with a waiting list in place, but the clinic’s model may offer a template for how health systems can begin to meet the scale of this problem.

PolyBio’s Spring 2026 symposium: Advancing Long COVID biomarkers and treatments - The Sick Times

Alternative headline: Researchers at PolyBio Symposium Advocate for New Biomarkers to Improve Long COVID Diagnosis and Treatment

Summary

• At the PolyBio Spring 2026 Symposium, researchers made the case that long COVID is primarily a tissue-based disease — a framing that challenges conventional blood-based diagnostic approaches and has real implications for how biomarkers are developed and tested.

• PolyBio’s VIPER program will test multiple biomarker candidates across blood, saliva, stool, and tissue in a 150-participant study.

• One highlight from the symposium was a pilot study by Dominique Salmon combining maraviroc and pravastatin in 19 long COVID patients with severe gastrointestinal symptoms — 68% reported significant improvement, a promising early signal.

• PolyBio’s Long COVID Cure Initiative is working to move these findings toward clinical trials and eventually commercialization of new diagnostics and treatments.

This week’s research keeps circling back to the same handful of suspects — mitochondria that won’t recover, immune systems stuck in an old fight, gut microbes rearranged, blood vessels that don’t quite work right — but with sharper detail than before. There’s also a notable cardiovascular study quantifying real risks, a rehabilitation trial showing what actually helps, and a thoughtful piece on the ethics of running treatment trials when patients can’t afford to keep waiting. Plenty to dig into.

🗞️ Article of the Week

This week’s pick is “Multi-omics analysis of long COVID (post-COVID-19 condition) reveals persistent mitochondrial dysfunction, suppressed oxidative phosphorylation, and immune dysregulation,” published in Frontiers in Immunology. The study tracks how mitochondrial and immune system disruptions persist long after the acute infection has passed.

Key findings:

1. “Persistent mitochondrial and immune alterations are observed across multiple tissues in PCS-associated datasets,” underscoring how broadly long COVID affects the body.

2. “PCS skeletal muscle shows sustained OXPHOS suppression, consistent with fatigue-associated phenotypes,” pointing to a possible mechanism behind the debilitating fatigue many patients describe.

These findings give researchers something concrete to target — a real foothold for therapeutic development.

Research

Article: Frontiers | Multi-omics analysis of long COVID (post-COVID-19 condition) reveals persistent mitochondrial dysfunction, suppressed oxidative phosphorylation, and immune dysregulation

Alternative Headline: Study Links Long COVID to Ongoing Mitochondrial Dysfunction and Immune Response Lasting Up to a Year

🗞️ Definitions

• Mitochondrial Dysfunction: An impairment in the normal functioning of mitochondria, leading to decreased ATP production and increased oxidative stress.

• Immune Dysregulation: An imbalance or malfunction in the immune system’s response, leading to chronic inflammation or insufficient immune defense.

🗞️ Summary

1. The study reveals that long COVID, or Post-COVID Syndrome (PCS), is marked by persistent mitochondrial dysfunction and immune dysregulation that can last up to 12 months post-infection.

2. Key findings indicate that skeletal muscle shows significant and sustained suppression of oxidative phosphorylation, correlating with fatigue in PCS patients.

3. Multi-omics analysis demonstrated that inflammatory pathways remain activated in various tissues, suggesting a prolonged immune response following COVID-19.

4. Unique proteomic profiles in PCS patients indicate chronic upregulation of stress-response proteins and sustained mitochondrial dysfunction, contrasting with recovered individuals.

5. The study proposes a model where incomplete recovery of mitochondrial bioenergetic pathways may underpin prolonged symptoms in PCS, emphasizing the need for targeted therapeutic interventions.

🗞️ Stats/Trends

1. The multi-omics analysis involved data from multiple human cohorts and models spanning the acute infection to PCS stages, with follow-ups up to 12 months.

2. Sustained suppression of oxidative phosphorylation was observed in skeletal muscle biopsies from both hamsters and PCS patients, showing significant transcriptomic and proteomic overlaps.

3. Significant mitochondrial stress was evident at both 1 month and 6 months post-infection in longitudinal studies of serum from PCS patients compared to recovered controls.

🗞️ Counterpoints

1. The reliance on data from varied cohorts may present challenges in establishing causality.

2. Small sample sizes in some hamster studies and the observational nature of results may limit generalizations to the wider PCS patient population.

Article: Comparative Gut Microbiome Alterations in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome and Long COVID-19 Syndrome | MDPI Biomedicines

Alternative Headline: Distinct Gut Microbiota Profiles Found in ME/CFS and Long COVID-19 Patients, Study Reveals

🗞️ Definitions

• B/S Index: The ratio of beneficial bacteria to detrimental bacteria, useful for assessing gut health related to chronic diseases.

• Alpha Diversity: A measure of microbial diversity within a sample, indicating the complexity of the microbial community.

• LEfSe Analysis: A statistical method to identify biomarkers differentiating biological groups based on microbial composition.

🗞️ Summary

1. The comparison between patient cohorts revealed distinct gut microbiota profiles in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) patients and those recovering from Long COVID-19, indicating different microbial dysbiosis patterns.

2. ME/CFS patients exhibited higher relative abundances of pro-inflammatory bacteria compared to Long COVID-19 patients, correlating with clinical presentations of fatigue and cognitive dysfunction.

3. Alpha diversity was significantly lower in the ME/CFS cohort, suggesting a less resilient gut microbiome, with implications for therapeutic interventions.

4. The B/S index was significantly lower in ME/CFS patients at 1.8 ± 0.4, in contrast to 2.5 ± 0.5 in Long COVID-19 patients (P < 0.001), pointing to imbalances in gut microbiota linked to chronic fatigue symptoms.

5. Six months post-diagnosis, a subset from both groups showed only partial restoration of healthy gut microbiota, indicating long-term dysbiosis may contribute to sustained symptoms.

🗞️ Stats/Trends

1. The study assessed gut microbiome samples from 120 patients: 60 diagnosed with ME/CFS and 60 with Long COVID-19, including 30 healthy controls for comparison.

2. Elevated levels of pro-inflammatory bacteria were detected in 47% of ME/CFS patients, significantly higher than in Long COVID-19 patients (P < 0.005).

3. Shannon index values for microbial diversity were 3.1 ± 0.7 for Long COVID-19 patients versus 2.1 ± 0.6 for ME/CFS patients (P < 0.001).

🗞️ Counterpoints

1. The limited sample size and lack of longitudinal data may restrict the validity of the findings.

2. Dietary differences, medication history, and lifestyle variations were not meticulously controlled, indicating the need for larger, multi-site studies to validate these associations.

Article: Reframing ME/CFS: toward a unified mechanistic model of chronic post-infectious diseases | Journal of Translational Medicine | Springer Nature Link

Alternative Headline: Study Links ME/CFS to Biological Factors, Calling for New Approaches to Diagnosis and Treatment

🗞️ Summary

1. The article proposes a unified mechanistic model for ME/CFS as a disorder rooted in impaired adaptive capacity within post-infectious disease biology.

2. Advances in systems biology, influenced by Long-COVID research, reveal persistent immune dysregulation and mitochondrial dysfunction as key factors in ME/CFS.

3. The review emphasizes a shift from psychosocial explanations to biological frameworks in understanding ME/CFS, highlighting the complexity of its pathology under physiological stress.

4. Addressing the biological underpinnings can enhance diagnostic criteria and treatment strategies for individuals suffering from ME/CFS.

5. This reframing underscores the need for further research into the biological mechanisms driving post-infectious syndromes to improve patient outcomes.

🗞️ Stats/Trends

1. The review synthesizes findings from numerous studies on ME/CFS and related post-infectious conditions, though specific statistical analyses were not discussed.

2. Historical emphasis on psychosocial factors has limited the understanding of ME/CFS; emerging biological insights suggest significant underlying pathology related to immune and metabolic responses.

3. Insights from recent Long-COVID studies highlight correlations between viral infections and chronic fatigue syndromes.

🗞️ Counterpoints

1. While the proposed model offers a fresh perspective on ME/CFS, its reliance on emerging biological data requires validation through rigorous clinical studies.

2. The multifactorial nature of ME/CFS indicates psychosocial components may still play a role, suggesting a need for a comprehensive approach

Article: Association of long-COVID with major adverse cardiovascular events and mortality: a real-world data cohort study | BMC Cardiovascular Disorders | Springer Nature Link

Alternative Headline: Long COVID Linked to Increased Risk of Serious Heart Issues and Higher Mortality Rates

🗞️ Definitions

• MACE: Major Adverse Cardiovascular Events, including serious conditions such as heart attack and stroke.

• Hazard Ratio (HR): A measure comparing the probability of an event occurring in the treatment group vs. a control group.

• TriNetX: A research platform that aggregates electronic health records from multiple healthcare organizations for real-world data analysis.

🗞️ Summary

1. The study establishes a strong association between long COVID and major adverse cardiovascular events (MACE), highlighting a hazard ratio (HR) of 4.48 for those with long COVID compared to those without.

2. Specific cardiovascular conditions such as coronary artery disease and stroke exhibited HRs of 6.48 and 3.46, respectively, in the long COVID cohort.

3. Mortality rates were significantly elevated in the long COVID group, with an HR of 1.53, indicating a higher risk of death compared to patients not diagnosed with long COVID.

4. This research underscores the urgent need for ongoing monitoring and management of cardiovascular health in individuals recovering from COVID-19, particularly those with long COVID symptoms.

🗞️ Stats/Trends

1. The study utilized multicenter data from the TriNetX network, involving patients aged 18 and older diagnosed with COVID-19 from 2020 to 2023.

2. The overall hazard ratio for MACE among the long COVID cohort was 4.48 (95% CI: 3.95–5.07).

3. The mortality risk in the long COVID group was quantified with an HR of 1.53 (95% CI: 1.38–1.69).

🗞️ Counterpoints

1. While the study provides insights into cardiovascular risks associated with long COVID, its retrospective design may introduce biases related to data collection and the accuracy of health records.

2. Factors such as pre-existing conditions and variations in healthcare access can affect the generalizability of these findings, necessitating further prospective studies.

Article: Deficient TRPM3-linked mitochondrial Ca2+ influx in natural killer cells associated with myalgic encephalomyelitis/chronic fatigue syndrome | BMC Immunology | Springer Nature Link

Alternative Headline: Study Links Impaired Calcium Signaling in Natural Killer Cells to Chronic Fatigue Syndrome Challenges

🗞️ Definitions

• TRPM3: An ion channel involved in calcium signaling within cells, particularly in natural killer (NK) cells.

• Calcium Influx: The process by which calcium ions enter a cell, crucial for various cellular functions.

• Natural Killer Cells: A type of lymphocyte that targets and destroys infected or cancerous cells.

🗞️ Summary

1. The study reveals a significant deficiency in TRPM3-linked mitochondrial calcium influx in the natural killer (NK) cells of patients with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).

2. Impaired TRPM3 functionality corresponds with reduced cytotoxic activity of NK cells, potentially contributing to immune dysregulation in ME/CFS patients.

3. Findings suggest alterations in calcium signaling pathways may play a critical role in shaping ME/CFS symptomatology.

4. Live-cell imaging demonstrated defective cytosolic calcium signaling in NK cells from ME/CFS patients.

5. Understanding TRPM3-related deficiencies may lead to new therapeutic targets for enhancing immune function in ME/CFS.

🗞️ Stats/Trends

1. The study included NK cells from 30 ME/CFS patients alongside 15 healthy controls.

2. TRPM3 ion channel activity was significantly lower in NK cells from ME/CFS patients, with a 40% reduction in calcium influx compared to healthy controls (P < 0.001).

3. Cytotoxicity assays indicated NK cell function was compromised in ME/CFS patients, with a 50% decrease in lysis of target cells (P < 0.01).

🗞️ Counterpoints

1. The relatively small sample size and single-center nature of the study may limit broader applicability.

2. Unexamined variables such as comorbidities, treatment history, and environmental factors highlight the need for more diverse, multicentric studies to validate these findings.

Article: Analysis Of Salivary Herpesviruses Reveals Associations Between HHV-6 And Long COVID Severity | MedRxiv preprint

Alternative Headline: Study Links Higher Salivary HHV-6 Levels to Increased Severity of Long COVID Symptoms

🗞️ Definitions

• Herpesviruses: A family of DNA viruses associated with health conditions and capable of reactivation.

• Long COVID Propensity Score (LCPS): A composite score that quantifies the severity of symptoms associated with Long COVID.

🗞️ Summary

1. The study indicates a significant association between salivary HHV-6 shedding and the severity of Long COVID symptoms, suggesting a potential role of HHV-6 in LC pathophysiology.

2. Participants with Long COVID had higher mean salivary HHV-6 DNA copy numbers compared to controls, particularly in those reporting more severe symptoms.

3. No significant differences were observed in salivary EBV shedding between Long COVID patients and controls, indicating potential differences in the roles of these herpesviruses in post-acute sequelae.

4. Higher salivary HHV-6 levels correlated positively with elevated anxiety and depression scores among Long COVID participants.

5. The Long COVID Propensity Score effectively differentiated symptom severity between Long COVID participants and controls, providing a useful prognostic tool.

🗞️ Stats/Trends

1. The study enrolled 90 participants: 45 with Long COVID and 45 age-sex-matched controls.

2. Mean salivary HHV-6 DNA levels were significantly higher in the Long COVID group compared to controls (p = 0.018 for high severity, p = 0.047 for medium severity).

3. Anxiety and depression scores were positively correlated with HHV-6 DNA levels (GAD-7, p = 0.045; PHQ-2, p = 0.013).

🗞️ Counterpoints

1. The study is limited by a small sample size, which may affect the statistical power and generalizability of the findings.

2. The cross-sectional nature of the study prevents establishing causal relationships, necessitating further longitudinal research on herpesvirus reactivation in Long COVID.

🗞️ Action Items

1. Advocate for larger longitudinal studies to explore herpesvirus reactivation in Long COVID.

2. Consider the potential of salivary HHV-6 DNA as a biomarker for assessing Long COVID symptom severity.

3. Stay informed on emerging research regarding implications for targeted interventions and therapies.

Article: Association Between Post-COVID-19 Herpes Zoster Reactivation and Peripheral Nervous System Disorders: Multinational Real-World Evidence from TriNetX | International Journal of Medical Sciences

Alternative headline: Post-COVID-19 Herpes Zoster associated with increased risk for serious peripheral nerve disorders

🗞️ Definitions

• Propensity-matched cohort: An observational research design that uses statistical techniques rather than randomization to create treatment and control groups.

• Herpes zoster reactivation: The reactivation of latent Varicella-zoster virus (VZV) (chicken pox) is called herpes zoster, also known as shingles.

• Guillain-barre syndrome: A rare, serious disorder where the immune system mistakenly attacks the peripheral nerves, causing tingling, muscle weakness, and potentially paralysis.

• Myasthenia gravis: A chronic autoimmune neuromuscular disorder where autoantibodies block or destroy nerve-muscle communication, leading to extreme muscle fatigue and profound voluntary muscle weakness.

🗞️ Summary

1. Coronavirus disease 2019 (COVID-19) profoundly impacts the peripheral nervous system (PNS). A prominent complication is increased herpes zoster (HZ) reactivation.

2. Study authors theorized that post-COVID herpes zoster reactivation exacerbates latent immune dysfunction, which increases the risk for subsequent autoimmune/inflammatory PNS disorders.

3. This propensity score-matched (PSM) cohort study evaluated Bell’s palsy, guillain-barre syndrome (GBS), and myasthenia gravis (MG) incidence in COVID-19 survivors and found that HZ reactivation was associated with increased three-year risks of all outcomes.

4. Post-COVID-19 HZ is associated with an increased risk of peripheral nervous system disorders, highlighting the need for symptom-based neurological awareness during both early and delayed post-infectious periods.

🗞️ Stats/Trends

1. The risk of Bell’s palsy was elevated early and remained sustained (hazard ratio 3.625, 95% confidence interval 3.151-4.170).

2. In contrast, the risks of GBS (hazard ratio 1.858, 95% confidence interval 1.243-2.779) and MG (hazard ratio 1.640, 95% confidence interval 1.178-2.284) showed delayed increases emerging after the first year.

3. These associations remained consistent across sensitivity analyses and were more pronounced in individuals with metabolic comorbidities.

Article: Exploring Coagulation Abnormalities and Functional Impairment in Long COVID: Relevance to Primary Care Practice | Cureus

Alternative Headline: Study Links Coagulation Abnormalities to Severity of Long COVID Symptoms in Patients

🗞️ Definitions

• Coagulation Abnormalities: Disruptions in the blood clotting process, indicated by elevated biomarkers like D-dimer and fibrinogen, suggesting ongoing thrombo-inflammatory activity.

• Six-Minute Walk Test (6MWT): A test that measures the distance an individual can walk in six minutes, assessing exercise tolerance and functional capacity.

• C-reactive Protein (CRP): A marker of inflammation, with increased levels indicating inflammation or infection.

🗞️ Summary

1. The study evaluates the correlation between coagulation abnormalities and the severity of long COVID symptoms using accessible markers.

2. Reduced effort tolerance was the most prevalent symptom among participants, affecting 76.7% of those enrolled.

3. Significant elevations in D-dimer and fibrinogen levels were observed in patients with severe symptoms, correlating with relative risks of 3.0 for D-dimer and 2.34 for fibrinogen.

4. At three months post-initial assessment, persistent abnormal levels of D-dimer and fibrinogen were observed in over 50% of patients, indicating prolonged coagulation activation.

5. The integration of coagulation markers and the 6MWT into primary care could enhance early identification and management of long COVID patients.

🗞️ Stats/Trends

1. The study enrolled 197 adult participants with a mean age of 37.3 ± 11.97 years, predominantly experiencing symptoms of long COVID.

2. Elevated D-dimer was noted in 25.4% of participants, while fibrinogen was elevated in 21.8%, both significantly associated with severe symptoms (P < 0.001).

3. 55.8% of patients initially failed the 6MWT, reflecting significant functional impairment.

🗞️ Counterpoints

1. The modest sample size and lack of a control group may limit the generalizability of results.

2. The study’s reliance on patient-reported outcomes could introduce bias; further multi-center studies are needed to validate these findings comprehensively.

Article: Longitudinal assessment of myocardial involvement in PASC-CVS: a single-center study from China based on multiparametric CMR | Frontiers in Cardiovascular Medicine

Alternative Headline: Study Reveals Heart Improvement in Long COVID Patients, Yet Some Remain Affected After One Year

🗞️ Definitions

• PASC-CVS: Post-Acute Sequelae of SARS-CoV-2 Infection with Cardiovascular Involvement, characterized by persistent cardiovascular symptoms following COVID-19 recovery.

• Multiparametric CMR: A comprehensive cardiac magnetic resonance imaging technique that evaluates various cardiac parameters.

• Late Gadolinium Enhancement (LGE): A CMR technique to identify myocardial scarring or fibrosis following contrast injection.

🗞️ Summary

1. The study identifies significant myocardial involvement in PASC-CVS patients, observable through multiparametric CMR.

2. At one-year follow-up, patients showed a 12-point reduction in PASC scores from 14.1 to 5.4, indicating substantial clinical improvement.

3. Key CMR parameters, including Right Ventricular Ejection Fraction (RV EF) and Global T2 values, markedly improved after one year, underscoring potential recovery in PASC-CVS patients.

4. Logistic regression identified six independent predictors of PASC-CVS, with combined parameters yielding an area under the curve (AUC) of 0.94, demonstrating strong predictive power.

5. Despite overall improvements, 9.9% of patients exhibited no recovery, emphasizing the need for ongoing monitoring and potential interventions.

🗞️ Stats/Trends

1. The study analyzed data from 110 patients with PASC-CVS and 55 control subjects.

2. At one-year follow-up (n = 101), the PASC scores significantly decreased from 14.1 ± 4.4 to 5.4 ± 5.1 (P < 0.001).

3. Improvements in RV EF rose from 52.1% to 59.5% (P < 0.001); global T2 values decreased from 43.6 ms to 39.5 ms (P < 0.001).

4. Six independent predictors of PASC-CVS showed AUC values: Quantification of LGE (AUC = 0.89) and Global ECV (AUC = 0.75).

🗞️ Counterpoints

1. The study’s single-center design and limited sample size may hinder broader applicability.

2. The significant dropout rate for follow-up (only 20 out of 101 patients) raises concerns about the representativeness of improvement findings.

Article: Shared autonomous HERV loci transcription identifies a unique circulating CD14+-xCR1+ mononuclear cell phenotype in a patient group with post-acute sequelae of COVID-19 | PLOS One

Alternative Headline: Study Reveals Unique Immune Cell Traits Linked to Long-Term Effects of COVID-19 in Patients

🗞️ Definitions

• HERV: Human Endogenous Retrovirus, which can influence gene expression and immune responses.

• PASC: Post-Acute Sequelae of COVID-19, describing long-term effects following COVID-19 recovery.

• PBMC: Peripheral Blood Mononuclear Cells, crucial for the immune response.

• xCR1: A surface marker involved in linking innate and adaptive immunity.

🗞️ Summary

1. The study identifies a distinct circulating CD14+-xCR1+ mononuclear cell phenotype in patients experiencing post-acute sequelae of COVID-19, suggesting an atypical immune response.

2. Transcriptional patterns of autonomous HERV loci were predominantly found in CD14+ monocytes from Post-Acute Sequelae of COVID-19 (PASC) patients, indicating immune dysregulation.

3. The predominant HERV locus, Chr3:46,046,256–46,054,342, was detected in bronchial lavage cells from COVID-infected individuals, but not in healthy lung tissues, highlighting its potential relevance in COVID-19 pathology.

4. The presence of xCR1 in CD14+ PBMCs from PASC patients suggests a shared characteristic of immune cells that might reflect persistent immune dysfunction.

🗞️ Stats/Trends

1. The study analyzed blood samples from 12 PASC patients and 30 healthy controls.

2. HERV loci detection was significantly higher in PBMCs of PASC patients, with at least four unique loci identified exclusively in this group.

3. The specific HERV locus Chr3:46,046,256–46,054,342 was found in 11 out of 12 PASC patients, with significant differences from healthy controls (P < 0.001).

🗞️ Counterpoints

1. The small sample size and complex nature of long COVID symptoms limit the generalizability of these findings.

2. Longitudinal studies are needed to clarify the causative relationship between HERV activity and immune dysregulation.

Article: Population-based comparison of post-acute sequelae of COVID-19 and health-related quality of life across pandemic periods: Omicron era versus early pandemic | Scientific Reports

Alternative Headline: Post-COVID Syndrome Rates Decline During Omicron, Yet Quality of Life Remains Severely Affected

🗞️ Definitions

• Adjusted Relative Risk (RR): A statistical measure indicating the likelihood of experiencing PCS in different groups, adjusted for confounding variables.

• Health-related Quality of Life (hrQoL): Subjective evaluations of health, measured using standardized instruments.

• Symptom Clusters: Groups of symptoms frequently reported together, reflecting common health impacts.

🗞️ Summary

1. The study shows a decline in Post-COVID-19 Syndrome (PCS) prevalence from 29.6% during the early pandemic to 14.5% during the Omicron era.

2. Omicron patients had significantly lower rates of classic post-COVID symptoms, such as fatigue and cognitive impairment, compared to earlier cases.

3. Key risk factors for PCS remained consistent, with obesity, female sex, and chronic conditions as significant predictors.

4. Despite lower PCS prevalence, health-related quality of life was still severely impacted in affected individuals during both periods.

5. Acute symptoms during Omicron infections, like loss of taste and smell, were reported at significantly lower rates than in earlier infections.

🗞️ Stats/Trends

1. The study included 11,710 participants from the early pandemic cohort and 12,560 from the Omicron cohort, with response rates of 24% and 17% respectively.

2. The adjusted RR for PCS development was 0.50 for Omicron compared to earlier infections, indicating reduced risk.

3. Specific symptoms like fatigue and neurocognitive impairment were reported at lower rates in the Omicron era, with RRs of 0.54 and 0.53, respectively.

4. PCS participants had an average SF-12 score about 11-12 points lower than those without PCS, showing a substantial impact on quality of life.

🗞️ Counterpoints

1. The lower response rate in the Omicron cohort raises potential bias concerns in the data.

2. Variations in symptom reporting and treatment access during the Omicron phase may have influenced the results, warranting further investigation into the long-term effects of different variants on PCS.

Article: Symptom-based rehabilitation in people with post-COVID-19 condition (RELOAD study): a randomised controlled trial | BMJ Open Respiratory Research

Alternative Headline: New Study Shows Multimodal Rehabilitation Improves Quality of Life for Individuals with PCC

🗞️ Definitions

• Post-COVID Condition (PCC): A complex syndrome characterized by symptoms persisting for weeks or months after an initial COVID-19 infection.

• Multimodal Rehabilitation: An integrated approach combining various therapeutic interventions to address multiple symptoms in a systematic manner.

• Post-Exertional Malaise (PEM): A hallmark symptom of PCC characterized by severe fatigue and other symptoms following exertion, lasting over 24 hours.

🗞️ Summary

1. The RELOAD study demonstrates that a 3-week multimodal rehabilitation program significantly enhances physical and mental HRQoL in individuals with PCC compared to usual care.

2. Improvements in mental health metrics, including anxiety and depression, were notable in the REHAB group at both the 3-week and 3-month follow-ups.

3. The study population predominantly consisted of non-hospitalised individuals (90.4%), challenging previous research focused mainly on hospitalised patients.

4. Results indicate sustained benefits in HRQoL, with the REHAB group showing a significant mean difference of 2.9 points in physical HRQoL at 3 weeks post-baseline (P = 0.038).

5. Tailored interventions for fatigue and somatic symptoms proved more effective than those targeting cognitive problems, suggesting a need for specialized rehabilitation approaches for PCC patients.

🗞️ Stats/Trends

1. A total of 520 individuals were assessed for eligibility, with 104 ultimately included in the study after exclusions.

2. The REHAB group experienced a mean difference of 2.9 points in physical HRQoL (PCS) compared to the control group at the 3-week mark (95% CI 0.2 to 5.7, P = 0.038).

3. At the 3-month follow-up, the REHAB group’s change in PCS remained significantly greater, with a mean difference of 4.2 points compared to usual care (P = 0.003).

🗞️ Counterpoints

1. While the RELOAD study offers promising insights, its single-center design and focus on a specific population may limit broader applicability.

2. The reliance on self-reported measures could introduce subjectivity and variation in symptom reporting.

Article: Frontiers | De novo COVID-19-associated insulin resistance drives dysregulated neutrophil extracellular trap formation (NETosis) four months after infection

Alternative Headline: Study Links COVID-19 Infection to Increased Insulin Resistance and Inflammatory Responses in Patients

🗞️ Definitions

• Insulin Resistance (IR): A metabolic disorder where cells become less responsive to insulin, leading to elevated blood glucose levels.

• Neutrophil Extracellular Trap Formation (NETosis): A process where neutrophils expel DNA and protein structures to trap and kill pathogens.

• TLR7/8 Agonists: Compounds that stimulate Toll-like receptors 7 and 8, essential for detecting viral infections.

🗞️ Summary

1. The study revealed that 67% of COVID-19 patients who had no glucose metabolism disorders developed insulin resistance four months after infection.

2. Neutrophils from insulin-resistant patients showed increased basal NETosis but impaired responses to TLR7/8 agonists compared to healthy controls.

3. Plasma from insulin-resistant patients enhanced NETosis in healthy neutrophils, suggesting systemic factors play a role post-infection.

4. High levels of IL-6 and TNF-α correlated with insulin resistance and elevated NETosis, linking inflammatory markers with metabolic disturbances.

5. Insulin may enhance NETosis, highlighting new considerations for managing patients with post-COVID insulin resistance.

🗞️ Stats/Trends

1. The study included 60 COVID-19 patients, with assessments conducted four months post-infection regarding glucose metabolism and inflammatory parameters.

2. Among the cohort, 24 out of 36 patients without pre-existing glucose metabolism disorders developed insulin resistance.

3. Basal NETosis in neutrophils was significantly higher in insulin-resistant patients, with a p-value < 0.05 compared to healthy controls.

🗞️ Counterpoints

1. The study’s relatively small sample size and observational design may not fully account for all variables influencing insulin resistance and NETosis.

2. Longitudinal studies with larger cohorts are needed to establish causation and further understand the mechanisms involved.

Article: The role of genetic liability for psychiatric disorders and personality traits in post covid syndrome: data from three Nordic population cohorts - eClinicalMedicine

Alternative Headline: Genetic Factors Linked to Increased Risk of Post-COVID Syndrome in Individuals with High Neuroticism

🗞️ Definitions

• Polygenic Scores (PGS): A measure that estimates genetic liability for common diseases and traits based on the cumulative effect of many genetic variants.

🗞️ Summary

1. The study identifies a significant association between polygenic scores for neuroticism, major depressive disorder (MDD), and attention-deficit/hyperactivity disorder (ADHD) with increased odds of post-COVID syndrome across three Nordic cohorts.

2. In individuals with the highest quintile of neuroticism polygenic scores, odds ratios for developing PCS were observed at 1.44 in Norway, indicating a strong genetic predisposition.

3. The study encompassed a total of 80,726 participants with 6,103 cases of PCS, showcasing a robust sample across geographic and genetic backgrounds.

4. Adjustments for pre-pandemic psychiatric diagnoses and demographic factors did not alter the significant association between psychiatric PGS and PCS, reinforcing the standalone genetic influence observed.

5. While psychiatric polygenic scores moderately accounted for variance in PCS, the implications suggest genetic predisposition can inform future research and interventions targeting long-term post-viral outcomes.

🗞️ Stats/Trends

1. A total of 80,726 participants were analyzed from three cohorts, contributing to 6,103 documented cases of post-COVID syndrome.

2. Individuals in the top quintile for neuroticism polygenic scores exhibited odds ratios for PCS of 1.44 (95% CI: 1.32–1.55) in Norway, showing a clear genetic risk gradient.

3. No significant association was reported between polygenic scores for schizophrenia and bipolar disorder with PCS, contrasting stronger associations seen with neuroticism, ADHD, and MDD.

🗞️ Counterpoints

1. The study’s reliance on self-reported symptoms may introduce bias, and the inability to differentiate between post-viral effects and pre-existing liability highlights the need for further research.

2. Varying definitions of PCS across cohorts could affect the generalizability of the results.

Media

Article: Breaking the vicious cycle: How two German scientists seek to solve ME - The Sick Times

Alternative Headline: Researchers Identify Key Mechanisms of Myalgic Encephalomyelitis, Highlighting Potential New Treatment Targets

🗞️ Summary

• Klaus Wirth and Carmen Scheibenbogen have put forward a unifying hypothesis linking impaired blood flow and mitochondrial damage as central mechanisms of myalgic encephalomyelitis (ME), with disruptions in calcium-sodium metabolism in skeletal muscle cells positioned as pivotal in the development of ME symptoms — particularly post-exertional malaise.

• Their collaboration began in 2018 after Wirth read a regional report on the disease and began investigating the ME literature in earnest.

• Initial findings suggest a meaningful relationship between autoantibodies and energy metabolism disruptions, hinting at viable therapeutic targets.

• A candidate drug, MDC 002, is now in development to address the hypothesized central mechanism, with clinical trials planned to test its efficacy.

• Preliminary evidence from immunoadsorption procedures targeting autoantibodies has shown marked improvement in roughly 70% of treated cases, though effects were often temporary.

• ME symptoms also appear to persist long after initial infections like COVID-19, with consistent evidence of impaired capillary blood flow and mitochondrial dysfunction.

• Critics note the need for controlled studies to substantiate claims around calcium overload and autoantibodies, and greater international collaboration is needed to address gaps in understanding ME’s complex pathology. Patient advocacy groups continue lobbying for funding to support this research.

Article: The next phase in Long COVID research: addressing the ethical challenges in trials of disease-modifying treatments - eClinicalMedicine

Alternative Headline: Urgent Call for Clinical Trials to Address Long COVID and Ethical Research Challenges Ahead

🗞️ Summary

• The authors argue that disease-modifying treatment trials for Long COVID are urgently needed given the substantial patient burden and the absence of effective interventions — and that the ethical framework actively supports moving forward despite remaining uncertainties.

• An estimated 6-7% of adults and 2-20% of children report ongoing Long COVID symptoms after SARS-CoV-2 infection, with significant societal and economic consequences including healthcare system strain and declines in labor force participation.

• Current management focuses largely on symptomatic relief, with no adequate disease-modifying treatments available.

• The paper lays out specific ethical challenges including balancing the urgency of treatment development with rigorous trial design and fair participant selection.

• The authors argue that a favorable risk-benefit profile is achievable for participants, since several candidate treatments already have established safety records, and they call for active collaboration among researchers, industry, and policymakers to move the field forward.

• Critics counter that the considerable uncertainty around Long COVID can complicate informed consent, and that pushing for rapid trial initiation risks compromising scientific rigor or exploiting vulnerable patients desperate for treatment.

Long COVID keeps surfacing in unexpected places: in the gut, in blood vessels, in the way exhaustion lingers months after a workday. This week’s roundup pulls together studies tracing those threads: how the immune system stays unsettled, why fatigue hits some workers harder than others, and what’s behind the persistent vascular and metabolic changes researchers keep finding. There’s also real movement on the policy side, with Ontario now recognizing long COVID as a workplace injury and the Dutch Health Council pushing to bring long COVID care into the mainstream. Dig in.

🗞️ Article of the Week

This week we’re highlighting “Deterioration of neuroimmune homeostasis in Alzheimer’s Disease patients who survive a COVID-19 infection,” published in the Journal of Neuroinflammation. The study looks at how surviving COVID-19 may shape Alzheimer’s progression, with a focus on specific brain regions and cellular interactions.

Key findings:

1. “COVID-AD survivors show elevated Aβ plaque burden in select brain regions... Intriguingly, COVID patients showed higher Aβ coverage in the FG + ITG cortices and EC compared to Non-COVID and Pre-2020 patients.”

2. “With a majority of AD pathological changes occurring within these layers, the suggestion that COVID-associated neurological insults are also localized here lends to the idea of it being involved in disease progression.”

The article makes a strong case for sustained investigation into how COVID-19 may accelerate or interact with neurodegenerative disease.

Research

Article: Plasma Extracellular Vesicle Surface Marker Profiling Reveals Immune Cell–Associated Mitochondrial Membrane Potential Alterations in Long COVID and Myalgic Encephalomyelitis/Chronic Fatigue Syndrome | Open Forum Infectious Diseases | Oxford Academic

Alternative Headline: Study Finds Elevated Plasma Vesicles in Long COVID Patients Linked to Immune Dysfunction

🗞️ Definitions

• Plasma Extracellular Vesicles (EVs): Small membrane-bound particles released from cells, important for cell communication and potential biomarkers for various diseases.

• Mitochondrial Membrane Potential (MMP): A measure of the electrical potential across the mitochondrial membrane, reflecting mitochondrial function and health.

• False Discovery Rate (FDR): A statistical method used to correct for multiple comparisons, helping identify significant results while controlling for false positives.

🗞️ Summary

• The study reveals elevated plasma extracellular vesicle (EV) concentrations in long COVID (LC) patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) phenotype, suggesting shared immune signatures.

• Significant alterations in mitochondrial membrane potential were observed in EVs derived from immune cells, indicating potential immune-metabolic dysfunction.

• The study analyzed plasma EVs from 125 individuals across pandemic-era and prepandemic cohorts, revealing distinct plasma EV characteristics and concentrations.

• Both LC-ME/CFS and pan-ME/CFS groups showed increased EV concentrations compared to COVID-recovered controls, suggesting an inflammatory immune response.

🗞️ Stats/Trends

• The study involved 125 plasma samples across three cohorts: COVID-recovered individuals (n = 25), long COVID patients with ME/CFS phenotype (LC-ME/CFS, n = 21), and those with ME/CFS without prior COVID-19 (pan-ME/CFS, n = 29).

• Plasma EV concentrations were significantly elevated in both LC-ME/CFS (mean of 4.12 × 10^8 particles/mL) and pan-ME/CFS groups compared to COVID-recovered controls (P < 0.001 after FDR correction).

• The proportion of EVs positive for mitochondrial membrane potential was 43.0% in the pan-ME/CFS group, compared to 34.7% in LC-ME/CFS and 33.2% in COVID-recovered (P = 0.045).

Article: Endothelial dysfunction and metabolic biomarkers in post-COVID-19 syndrome | Scientific Reports

Alternative headline: Study finds fatty acid biomarkers for measuring fatigue severity in Long COVID

🗞️ Definitions

• Endothelial dysfunction: A condition characterized by impaired endothelial (the inner lining of the blood vessels) function, often resulting in inadequate regulation of vascular tone and blood flow.

🗞️ Summary

• Collectively, chronic inflammation, endothelial dysfunction (ED), and metabolic disturbances have emerged as key features of post-COVID-19 syndrome (PCS), and may also drive PCS-related fatigue severity.

• This prospective single-center cohort study showed that changes in specific biomarkers of nitric oxide (NO) metabolism persist following SARS-CoV-2 infection, potentially promoting endothelial dysfunction and vascular complications.

• Additionally, findings revealed that fatigue-related PCS severity is associated with persistent specific fatty acid elevations, suggesting their potential utility as biomarkers for establishing a diagnosis, assessing disease severity, and monitoring PCS.

🗞️ Stats/Trends

• At a median of 37.4 weeks after SARS-CoV-2 infection, participants with prior infection showed higher levels of soluble thrombomodulin (TM) and L-lactate dehydrogenase (LDH) than those without previous infection. Pathway analysis demonstrated decreases in arginine and taurine and hypotaurine metabolism - these are critical in NO metabolism, which is essential for endothelial function and vascular homeostasis. These findings were made in participants without and with symptoms of PCS.

• Analysis of serum levels of metabolites reflecting amino acid metabolism revealed that almost 40% of markers were altered in individuals post-acute infection, suggesting a persistent and substantial change of the amino acid metabolism.

• In participants with PCS-related high fatigue severity, concentrations of the polyunsaturated fatty acid (PUFA) linoleic acid (LA), and the monounsaturated fatty acids (MUFAs) oleic acid (OA) and palmitoleic acid (PA) were higher than in participants with low fatigue severity.

• The results demonstrate that changes in fatty acid metabolism, particularly the elevated levels of the PUFA LA and the MUFAs OA and PA, are associated with PCS-related fatigue severity and persist at a median of 37.4 weeks after SARS-CoV-2 infection.

Article: Fatigue after COVID-19 in occupationally exposed workers: prevalence, severity and associated risk factors in a cross-sectional analysis of a multicentre registry study | BMJ Open

Alternative Headline: Study Finds High Rates of Severe Fatigue Among Workers After COVID-19, Particularly in Education and Care Fields

🗞️ Definitions

• Fatigue Scale for Motor and Cognitive Functions (FSMC): A validated questionnaire for evaluating cognitive and physical fatigue.

• Modified Fatigue Impact Scale (MFIS): A validated tool assessing fatigue across cognitive, physical, and psychosocial dimensions.

• Logistic Regression: A statistical method for predicting outcomes based on independent variables.

🗞️ Summary

• The study reveals a high prevalence of clinically relevant fatigue among occupationally exposed workers post-COVID, with 78%-98% meeting fatigue severity thresholds.

• Cognitive and physical fatigue were significantly correlated, with older age and work incapacity identified as critical predictors of severe fatigue.

• A majority of participants reported multiple persistent symptoms, with 41.7% suffering from 6 to 10 symptoms, indicating a considerable burden after COVID-19.

• Educational and care professionals exhibited double the odds of experiencing severe physical fatigue compared to individuals in other professions.

• The study underscores the need for specialized fatigue assessments to tailor rehabilitation and interventions aimed at promoting worker recovery.

🗞️ Stats/Trends

• The analysis included 628 occupationally exposed workers, with fatigue assessed using validated questionnaires (FSMC, MFIS, WEIMuS).

• Clinically relevant cognitive fatigue was reported by 78%-93% of participants, while physical fatigue rates ranged from 87%-98%.

• The median age of participants was 54 years; 65.3% were categorized as overweight or obese, and 82.8% had at least one pre-existing condition.

Article: Gut microbiome shift in long COVID: impact of disease and montelukast treatment — JOGH

Alternative Headline: Long COVID Patients Show Gut Microbiome Changes, but Montelukast Treatment Remains Safe and Stabilizing

🗞️ Definitions

• Montelukast: A medication primarily used to manage allergies and asthma, which may influence gut microbiota.

• LEfSe Analysis: A statistical approach to identify features that differentiate between groups based on their microbial composition.

🗞️ Summary

• The study reveals significant alterations in the gut microbiome of long COVID patients compared to healthy controls, indicating a structural reorganization rather than depletion of core microbial communities.

• Long COVID patients exhibited an enrichment of Firmicutes genera, specifically Agathobacter and Faecalibacterium, while healthy controls showed higher relative abundances of Verrucomicrobiota and Actinobacteriota.

• Longitudinal analysis indicated that montelukast treatment resulted in an enrichment of the genus Dialister, despite overall microbial community stability.

• Species richness within the gut microbiota was largely preserved across both patient groups, suggesting no major loss of microbial species.

• The findings emphasize that montelukast treatment does not destabilize the gut microbiome, indicating its potential as a safe option for managing long COVID symptoms.

🗞️ Stats/Trends

• The study analyzed stool samples from 45 long COVID patients and 45 matched healthy controls using 16S rRNA sequencing.

• A significant enrichment of Firmicutes in long COVID patients was observed (P < 0.05), particularly in the genera Agathobacter and Faecalibacterium.

• Longitudinal assessment indicated montelukast treatment led to a significant increase in Dialister compared to placebo (P < 0.05).

Article: Impaired microvascular reactivity in post-COVID-19 syndrome is independent of cardiorespiratory fitness | American Journal of Physiology-Regulatory, Integrative and Comparative Physiology | American Physiological Society

Alternative Headline: Study Links Post-COVID-19 Syndrome to Microvascular Issues, Highlighting Need for Targeted Interventions

🗞️ Definitions

• Microvascular Function: The performance of small blood vessels that regulate blood flow and nutrient exchange; impairment can have various health consequences.

• Vascular Dysfunction: Disorders affecting blood vessels’ ability to regulate flow and pressure, often linked to chronic illnesses.

🗞️ Summary

• Impaired microvascular reactivity is a significant feature of post-COVID-19 syndrome, independent of cardiorespiratory fitness levels.

• Notable microvascular dysfunction was observed, suggesting even physically fit individuals can experience vascular repercussions from COVID-19.

• The results point to a potential mechanism through which SARS-CoV-2 may cause long-term symptoms, connecting vascular health with post-viral recovery

• Targeted interventions aimed at improving microvascular health in recovering COVID-19 patients are necessary.

🗞️ Stats/Trends

• The study included 62 participants, with 61.3% women and an average age of 50 years (±11.8).

• Participants had an average body mass index (BMI) of 27.6 ± 5.3 kg/m², reflecting diverse fitness levels.

• Significant impairments in microvascular reactivity were confirmed, though specific severity numbers were not disclosed.

Article: Symptoms, mechanisms, and management of long COVID: understanding its prevalence, characteristics, and healthcare challenges in Saudi Arabia | Frontiers in Cellular and Infection Microbiology

Alternative Headline: Long COVID in Saudi Arabia Affects Over 10% of Patients with Diverse and Persistent Symptoms

🗞️ Definitions

• Immune Dysregulation: A condition wherein the immune system’s response is abnormal, potentially contributing to persistent symptoms in long COVID patients.

• Biobank: A repository that collects and stores biological samples for research, aiding in understanding long COVID by linking symptoms to biological changes over time.

🗞️ Summary

• Long COVID has emerged as a significant public health challenge in Saudi Arabia, with over 10% of COVID-19 patients experiencing persistent symptoms.

• The predominant symptoms include fatigue (25–73%), cognitive dysfunction, respiratory distress (dyspnea: 6.9–47%), cardiovascular complications, and reproductive issues.

• Immunological mechanisms underlying long COVID involve viral persistence, immune dysregulation, and endothelial dysfunction, contributing to various multi-organ symptoms.

• Current studies in Saudi Arabia focus on symptom prevalence, highlighting the need for more rigorous longitudinal research to clarify biological underpinnings.

• A multidisciplinary approach is essential for effective management, integrating pulmonary, neurological, and psychological care to meet diverse patient needs.

🗞️ Stats/Trends

• Fatigue was reported by up to 73% of participants in various surveys conducted in Saudi Arabia.

• Approximately 61% of COVID-19 survivors recall experiencing lingering symptoms, with fatigue, breathlessness, and loss of smell among the most common.

• Studies indicate that up to 43.4% of patients experienced ongoing dyspnea two months post-infection.

• Rates of anxiety (13.2%) and depression (9.5%) reflect the mental health toll of long COVID.

• Persistent symptoms often last longer than six months in about 47.2% of survivors, with many reporting multi-organ involvement.

Article: Fatigue after COVID-19 in occupationally exposed workers: prevalence, severity and associated risk factors in a cross-sectional analysis of a multicentre registry study | BMJ Open

Alternative Headline: Study Finds High Levels of Fatigue Among Workers with Post-COVID Syndrome, Especially in Care Professions

🗞️ Definitions

• Clinically Relevant Fatigue: Persistent exhaustion exceeding expected levels of exertion.

• Occupational Health Assessment: Evaluation focused on the health of workers, especially in high-risk settings.

🗞️ Summary

• The study examined the prevalence and severity of cognitive and physical fatigue among occupationally exposed workers with Post-COVID Syndrome (PCS), revealing strikingly high rates across all participants.

• Between 78% and 98% reported clinically relevant levels of fatigue, indicating a pervasive issue among these workers.

• Older age and work incapacity were significant predictors of fatigue severity, suggesting that personal and occupational factors contribute significantly.

• Educational or care profession workers reported twice the odds of severe physical fatigue compared to administrative roles, indicating the impact of job demands.

• Correlations between fatigue dimensions and various health characteristics were found, but sex and pre-existing conditions showed no significant association with fatigue severity.

Article: Frontiers | Disrupted fluid homeostasis in patients with post-Covid-19 syndrome – a case series

Alternative Headline: Study Reveals Disrupted Fluid Balance as Common Yet Overlooked Issue in Post-COVID Syndrome Patients

🗞️ Definitions

• Osmolality: A measure of solute concentration in bodily fluids; normal serum osmolality typically ranges from 285 to 292 mOsm/kg.

🗞️ Summary

• This case-series identifies disrupted fluid homeostasis as an unrecognized clinical feature of post-COVID syndrome, with 70% of patients reporting symptoms of polydipsia and/or polyuria.

• Abnormal serum osmolality was detected in 9 out of 10 patients, with a mean value of 298 mOsm/kg, significantly higher than normal ranges.

• The combination of high serum and low urine osmolality correlated with poorer health status compared to patients with single abnormality presentations.

• Signs of connective tissue disorders were prevalent among participants, suggesting a link between physical traits and post-COVID complications.

🗞️ Stats/Trends

• The study included 10 consecutive patients with post-COVID syndrome, evenly split by gender (5 females, 5 males), with a mean age of 44 ± 14 years.

• 70% of participants reported symptoms of polydipsia or polyuria, with abnormal osmolality measures in all, and serum osmolality significantly above normal in 9 out of 10 patients.

• Patients with both abnormal high serum and low urine osmolality had a mean physical functioning score of 34, compared to 63 in those with only one abnormality.

Article: Towards biology-informed therapies for long COVID - eBioMedicine

Alternative Headline: Understanding Long COVID: New Insights Highlight Need for Tailored Therapies and Robust Biomarkers

🗞️ Definitions

• Biomarkers: Biological indicators that provide objective evidence of a condition, guide clinical decisions, and track treatment responses.

🗞️ Summary

• The review emphasizes the complexity of long COVID, highlighting the need for biology-informed therapies to address its heterogeneous nature.

• Evidence from multi-omics profiling studies suggests that immune dysregulation is common in long COVID patients, pointing toward new therapeutic avenues.

• The potential for persistent viral reservoirs in long COVID patients underscores the need for better diagnostic approaches and treatments.

• Developing reproducible, validated biomarkers is crucial to guide patient selection and measure meaningful clinical outcomes in long COVID research.

🗞️ Stats/Trends

• Longitudinal studies show that 10% to 30% of COVID-19 survivors experience lingering symptoms consistent with long COVID, affecting millions globally.

• A systematic review found immune dysregulation in 68% of individuals diagnosed with long COVID across varied studies and populations.

• Preliminary data suggests that nearly 25% of patients with persistent symptoms were previously hospitalized, highlighting a need for targeted follow-up care.

• Early biomarkers identified in research include elevated levels of inflammatory cytokines, present in 70% of studied long COVID patients.

Media

Article: New Research Funding From Solve M.E. Advances Innovative ME/CFS and Long Covid Studies Toward Treatments | Solve ME

🗞️ Summary

• Solve M.E. is advancing research into ME/CFS and Long Covid through two newly funded projects — “Mitochondrial stabilizer IVO-21 as therapy for ME/CFS” and “Sequence ME & Long Covid” — aimed at developing potential treatments and discovering biomarkers.

• The projects focus on mitochondrial stabilization therapies and comprehensive whole-genome sequencing to deepen understanding of these complex diseases.

• The Catalyst Awards bridge a critical funding gap, accelerating progress toward new clinical trials and significantly boosting recruitment for the DecodeME study.

• Emily Taylor, President and CEO of Solve M.E., emphasized the importance of patient-driven research shaped by lived experience.

• Millions worldwide suffer from ME/CFS and Long Covid, yet no FDA-approved treatments or definitive diagnostic tests exist, making sustained funding essential. Long-term challenges remain around funding sustainability, broader collaboration to validate findings, and accounting for individual variation in symptoms and socioeconomic context.

Article: Clear Health Centers Introduces Long-Haul COVID Care Pathway in Utah | The National Law Review

Alternative Headline: Salt Lake City Health Center Launches Comprehensive Care Pathway for Long-Haul COVID Patients

🗞️ Summary

• Clear Health Centers has launched a holistic long-haul COVID care pathway in Salt Lake City, taking an integrative approach to managing persistent post-COVID symptoms.

• The initiative, launched May 10, 2026, responds to rising patient demand and reflects how complex long COVID has proven to be — with over 45% of long COVID patients reporting symptoms across multiple systems and an estimated 10-30% of people who had COVID-19 affected overall.

• Dr. Alexander Haskell’s model moves away from symptom-specific treatment in favor of a system-wide evaluation addressing immune dysregulation, nervous system imbalance, and metabolic disruption concurrently.

• The pathway emphasizes gradual adjustments and continuous care, defining recovery as restored function across multiple systems rather than absence of infection. Critics note that holistic therapies remain largely anecdotal and need more clinical trial validation, and that the significant variation in long COVID symptoms makes any standardized treatment challenging.

Article: Dutch Health Council urges government action on long Covid - DutchNews.nl

Alternative Headline: Dutch Health Council Advocates for Long Covid Treatment Integration into Standard Healthcare System

🗞️ Summary

• The Dutch Health Council has called for Long Covid treatment to be incorporated into the regular healthcare system, acknowledging the significant impact of lingering symptoms — affecting neurological, cardiovascular, and muscular systems and producing chronic fatigue, cognitive dysfunction, and persistent pain — on patients’ lives.

• Marie-Charlotte Pezé shared her difficult six-year experience with Long Covid, illustrating how hard it has been for patients to be recognized and treated seriously.

• The recommendations mark a notable policy shift, recognizing the need for specialized care for the large population dealing with Long Covid and other post-acute infection syndromes.

• A patient survey found up to 70% expressed dissatisfaction with their care, struggling to gain recognition and appropriate treatment.

• While the new recommendations are a meaningful step, the lack of established treatment protocols may slow immediate implementation, and there are real concerns about whether a one-size-fits-all approach can address the nuances of individual experiences.

Article: Long COVID recognized as compensable workplace injury for Ontario PSW | HR Law Canada

Alternative Headline: Ontario Recognizes Long COVID as Compensable Injury for Personal Support Workers, Enhancing Worker Protections

🗞️ Summary

• Ontario has officially recognized long COVID as a compensable workplace injury for personal support workers (PSWs), enabling affected workers to claim benefits including medical treatment, rehabilitation, and income replacement.

• The ruling highlights the long-term effects of COVID-19 on frontline health workers exposed during the pandemic and sets a precedent for workplace policies, emphasizing comprehensive support systems for employees impacted by the virus.

• The Ontario Workplace Safety and Insurance Board (WSIB) has reported a rise in long COVID claims among health workers, indicating broader institutional recognition, with thousands of PSWs who provided critical care during the pandemic potentially affected.

• Roughly 10-30% of people who had COVID-19 experience prolonged symptoms.

• While this recognition represents real progress, awareness among employers and healthcare professionals remains limited, and the lack of standard diagnostic criteria for long COVID continues to complicate claims processing.

This week the research lands in a few places at once and they’re worth sitting with separately. The nervous system is taking center stage: orexin suppression in the brain, delayed smell recovery tied to a neurodegenerative protein, vagus nerve stimulation quietly improving autonomic function and PTSD scores in a small but striking pilot. Meanwhile, the cardiovascular data keeps getting harder to look away from — long COVID more than doubles the risk of a cardiac event in women, and a narrative review of 71 studies confirms the pattern holds across hospitalized and non-hospitalized patients alike. On the pediatric side, children are turning out to be more vulnerable than assumed, particularly with reinfection. And then there’s the fluvoxamine trial — a randomized study out of Brazil showing genuine fatigue reduction at both 60 and 90 days, while metformin flatlines. It’s not a cure, but it’s the kind of signal the field has been waiting for.

Article of the week

This week’s article is “The Effect of Fluvoxamine and Metformin for Fatigue in Patients With Long COVID: An Adaptive Randomized Trial,” published in the Annals of Internal Medicine. Run across 22 outpatient sites in Brazil with 399 participants, it’s one of the more methodologically rigorous treatment trials the long COVID field has produced. The proposed mechanism — fluvoxamine’s anti-inflammatory and immunomodulatory effects acting on neurocognitive pathways — is plausible but not yet confirmed; the trial wasn’t designed to trace causality through biological markers. The authors are clear that future work needs to bring in depression and anxiety baselines, inflammatory biomarkers, and broader symptom assessments. But for a condition with zero approved therapies, this is a meaningful step.

Research

Immune-metabolic trajectories delineate subgroups in paediatric long COVID | Nature Communications

Alternative headline: Study Reveals Distinct Subgroups in Pediatric Long COVID with No Overall Health Improvement in First Year.

Definitions

• Paediatric Long COVID (LC): A condition where children and adolescents experience persistent health issues following a SARS-CoV-2 infection, differing significantly from adult manifestations of long COVID.

• Biologically Driven Subgroups: Classifications of paediatric LC based on immune profiles and clinical symptoms, providing insights into varied disease trajectories.

• Th2 Cytokines: Cytokines associated with type 2 immune responses, often involved in allergic reactions and inflammation.

• Neurofilament Light Chain (NfL): A protein marker linked to neuroaxonal damage, used to assess neurological health.

Summary

1. The study identifies three distinct biological subgroups of paediatric long COVID, reflecting varying immune and metabolic dysregulation.

2. Patients analyzed within the first year of active long COVID showed no significant overall improvement in physical or mental health measures.

3. Elevated levels of Th2 cytokines and markers of systemic immune activation were noted within the first year of infection.

4. A significant association was found between Epstein-Barr Virus (EBV) exposure and a distinct inflammatory signature among paediatric LC patients.

5. Neurofilament light chain levels varied with symptom burden, highlighting differences in neuro-axonal stress across paediatric LC patients.

Stats/Trends

1. The cohort comprised 74 children with long COVID symptoms, alongside 27 control participants for comparative analysis.

2. Time since the last documented SARS-CoV-2 infection ranged up to 166 weeks, correlating with symptomatology.

3. Analysis revealed that 50% of participants had low or negative EBV serostatus, suggesting a potential correlation with milder disease severity (P < 0.05).

Transcutaneous auricular vagus nerve stimulation improves dysautonomia, post-traumatic stress disorder and cognitive impairment in long COVID patients: a pilot study | Scientific Reports

Alternative headline: New study finds transcutaneous auricular vagus nerve stimulation may improve symptoms in long COVID patients.

Definitions

• Transcutaneous Auricular Vagus Nerve Stimulation (taVNS): A non-invasive technique that stimulates the auricular branch of the vagus nerve through the ear to modulate autonomic function.

• COMPASS-31: The Composite Autonomic Symptom Score-31, a questionnaire used to assess the severity of autonomic symptoms.

• PTSD Checklist for DSM-5 (PCL-5): A standardized self-report measure for post-traumatic stress disorder symptoms.

• COGBAT: A cognitive assessment tool for measuring attention and executive function.

Summary

1. The pilot study demonstrates that transcutaneous auricular vagus nerve stimulation (taVNS) significantly improves autonomic symptoms and cognitive performance in long COVID patients.

2. After eight weeks of weekly taVNS sessions, the mean COMPASS-31 score decreased from 33.71 ± 16.81 to 13.78 ± 9.38, indicating a substantial reduction in autonomic dysfunction.

3. Psychological distress, as measured by the PTSD Checklist (PCL-5), showed notable improvement post-intervention, suggesting that taVNS may also alleviate PTSD symptoms in this population.

4. Cognitive function, assessed through the COGBAT, improved in participants following taVNS treatment.

5. This study highlights the potential of neuromodulation therapies like taVNS as promising interventions for treating complex post-viral syndromes such as long COVID.

Stats/Trends

1. Seventeen patients with long COVID participated in the open-label, single-arm pilot study.

2. COMPASS-31 scores decreased significantly, with a mean reduction of 19.93 points (P < 0.001), indicating a clinically meaningful improvement in autonomic symptoms.

3. Participants reported a decrease in PTSD symptoms, with PCL-5 scores showing a significant drop (P < 0.01) following the intervention.

4. Cognitive assessments via COGBAT demonstrated statistically significant improvements in attention and executive functioning after eight weeks of taVNS treatment.

One-year longitudinal cohort study of chemosensory recovery and plasma biomarker dynamics in SARS-CoV-2 survivors | Scientific Reports

Alternative headline: Study Reveals Delayed Recovery of Olfactory Function in SARS-CoV-2 Survivors, Highlights Need for Further Research.

Definitions

• Chemosensory Recovery: The process of regaining the ability to smell and taste following disruptions caused by viral infections like SARS-CoV-2.

• Plasma Biomarkers: Biological molecules in blood that indicate disease presence or severity, linked to physiological changes.

• α-Synuclein: A protein linked to neurodegenerative diseases, whose plasma levels may correlate with olfactory function.

Summary

1. This study presents a one-year longitudinal analysis of chemosensory recovery in SARS-CoV-2 survivors, focusing on both odor and taste function.

2. Gustatory function normalized across all participant groups at the initial visit, while significant improvements in olfactory function occurred within 3–6 months post-viral clearance.

3. The analysis identified a correlation between plasma levels of α-synuclein and olfactory performance, suggesting that neurodegenerative processes may underlie olfactory dysfunction.

4. Despite clinical symptom resolution, significant biomarkers’ plasma concentrations did not decline until approximately one year post-recovery, indicating a delayed response.

5. These findings emphasize the need for further research into the long-term effects of SARS-CoV-2 on chemosensory functions and their association with neurobiological changes.

Stats/Trends

1. The study recruited 120 participants assessed at 3, 6, and 12 months post-viral clearance.

2. Olfactory function showed significant improvement within 3–6 months post-clearance for the initial group, while other groups maintained stable function with no further improvement.

3. The correlation between α-synuclein levels and olfactory performance suggests a potential link, but significant declines in plasma levels were not observed until a year after recovery.

SARS-CoV-2 infection is associated with hypothalamic orexin suppression and persistent cortical NeuN attenuation | Journal of Neuroinflammation

Alternative headline: Study Reveals How SARS-CoV-2 May Cause Lasting Brain Injury and Neurological Symptoms in Long COVID.

Definitions

• Hypothalamic Orexin: A neuropeptide involved in regulating arousal, wakefulness, and appetite, which may be disrupted in various neurological conditions.

• NeuN: A protein used as a marker for identifying neuronal cells in the brain.

Summary

1. The study demonstrates that SARS-CoV-2 infection is associated with persistent cortical neuronal injury and suppression of hypothalamic orexin, potentially contributing to neurological symptoms in long COVID.

2. Investigations in K18-hACE2 and wild-type BALB/c mice reveal that viral RNA can persist in the brain beyond the acute phase of infection, coinciding with neuronal damage.

3. The downregulation of hypothalamic orexin was unique to SARS-CoV-2, indicating a distinct neuropathological signature not seen with influenza A virus.

4. Administration of exogenous orexin-A/B increased NeuN abundance in neuronal cultures, suggesting a potential therapeutic avenue for mitigating neuronal loss.

5. Findings highlight orexinergic dysfunction as a key factor underlying the neurological manifestations of long COVID.

Stats/Trends

1. The research utilized K18-hACE2 transgenic and wild-type BALB/c mice to investigate SARS-CoV-2’s effects on the nervous system.

2. Viral RNA persistence was documented in the brains of infected mice, showing ongoing neuronal loss beyond the acute infection timeline.

3. Significant suppression of orexin levels in infected mice compared to uninfected controls underscored the virus’s impact on orexinergic signaling.

Counterpoints

1. While the study provides compelling evidence of the neurological impacts of SARS-CoV-2, its reliance on animal models may limit direct applicability to humans.

2. The long-term implications of orexinergic dysfunction in long COVID patients necessitate further exploration, including variability related to age and pre-existing conditions.

Acute SARS-CoV-2 infection and self-reported post-acute cognitive dysfunctions from the Danish EFTER-COVID survey | Communications Medicine

Alternative headline: Study Finds Mild Increase in Cognitive Complaints Among COVID-19 Survivors Compared to Controls.

Definition

• COBRA Tool: A self-reported questionnaire that evaluates subjective cognitive deficits across attention, memory, and executive function.

• Score Ratio (SR): A statistical measure comparing mean cognitive scores between infected individuals and a control group to assess cognitive dysfunction.

• Longitudinal Study: Research design involving repeated observations over time to track changes in cognitive function.

Summary

1. The Danish EFTER-COVID survey indicates that self-reported cognitive dysfunction scores remain low in the general population of SARS-CoV-2 infected individuals, with only a slight elevation compared to test-negative controls.

2. Test-positive individuals exhibited an 11% increase in cognitive complaints as measured by the COBRA tool over 2–18 months compared to test-negative individuals.

3. Hospitalized individuals with SARS-CoV-2 had significantly higher mean COBRA scores, underscoring the correlation between the severity of infection and cognitive impairment outcomes.

4. The propensity for cognitive complaints (COBRA scores ≥15) was observed in 15–18% of infected individuals at 18 months post-infection, compared to 10–13% in controls, reaffirming the persistent cognitive challenges faced by COVID-19 survivors.

Stats/Trends

1. The study surveyed 25,485 SARS-CoV-2 test-positive individuals and 25,032 test-negative controls, primarily assessing cognitive scores across various follow-up periods.

2. The overall mean COBRA score for test-positive individuals was 11% higher than that of control participants across the entire 2–18 month period (Score Ratio = 1.11).

3. Among hospitalized SARS-CoV-2 patients, COBRA scores were significantly elevated, indicating more severe cognitive impairment tied to acute infection (P < 0.001).

Differences in the long-term course of post-COVID-19 symptoms in adults and children across epidemic periods: A retrospective cohort study in Japan, 2020–2024 | PLOS One

Alternative headline: Study Reveals Significant Disparities in Long-Term COVID Symptoms Between Adults and Children.

Definitions

• Adjusted Hazard Ratios (HRs): Statistical measures that compare the chances of symptom resolution between groups, adjusted for potential confounding factors such as age, gender, and severity of illness.

Summary

1. The study found that the prevalence of post-COVID-19 symptoms varied significantly between adults and children, with adults experiencing symptoms at higher rates across different epidemic periods.

2. At six months post-infection, the highest symptom prevalence in adults was recorded during the Delta period (47%), while only 20% were symptomatic during the Omicron-2024 period.

3. Children showed a markedly lower prevalence of persistent symptoms, with about 4.1% reporting symptoms two years after Delta infection, compared to 1.9% for those infected during the Omicron-2022 period.

4. By the end of the study, symptoms that persisted for more than two years showed little likelihood of further resolution, prompting calls for ongoing support and monitoring.

Stats/Trends

1. The study involved 2,689 participants diagnosed with COVID-19, comprising 1,524 adults and 1,165 children, between March 2020 and June 2024.

2. Six months after infection, 36.4% of adults reported post-COVID-19 symptoms during the wild-type period, declining to 20.6% during the Omicron-2024 period.

3. Two years following infection, around 20% of adults still reported persistent symptoms from pre-Omicron infections, contrasted with just 10% from the Omicron periods.

Counterpoints

1. The study’s reliance on self-reported data may introduce bias, potentially leading to overestimation of prevalence rates.

2. Variations in healthcare access and differences in healthcare systems may limit the generalizability of results to populations outside of Japan.

Long-term cardiovascular impact of COVID-19 among hospitalised and non-hospitalised populations: a narrative synthesis review | Frontiers in Cardiovascular Medicine

Alternative headline: Long COVID linked to serious cardiovascular complications, highlighting need for ongoing patient monitoring.

Definitions

• Cardiovascular Complications: Health issues related to the heart and blood vessels resulting from COVID-19, including myocardial injury and heart failure.

• Echocardiography: A non-invasive imaging technique used to assess cardiac function and structure, useful in evaluating post-COVID-19 cardiovascular complications.

• Cardiac Biomarkers: Substances in the blood, like troponin, that indicate heart stress or injury, often measured in long COVID studies to diagnose myocardial damage.

Summary

1. Both hospitalised and non-hospitalised patients can experience long-term cardiovascular complications, though hospitalised patients are at higher risk.

2. Common cardiovascular symptoms in long COVID include palpitations, chest pain, and dysautonomia, persisting long after the initial infection.

3. Hospitalised patients showed a higher prevalence of myocardial injury and arrhythmias, linking severe disease to lasting effects.

4. Vaccination reduces the likelihood of persistent cardiac injuries following COVID-19 infection.

5. Understanding the long-term cardiovascular impact of COVID-19 is crucial for follow-up care and monitoring in all individuals.

Stats/Trends

1. This narrative synthesis review includes evidence from 71 studies primarily conducted in Europe and Asia, examining cardiovascular outcomes in long COVID.

2. Up to 86% of individuals with long COVID reported persistent cardiovascular symptoms, with variations based on hospitalisation status.

3. Studies indicate hospitalised COVID-19 patients are significantly more likely to experience major cardiovascular events compared to controls.

4. Echocardiographic abnormalities were found in up to 70% of patients within three months post-COVID infection, with more severe cases showing greater risk.

The Effect of Fluvoxamine and Metformin for Fatigue in Patients With Long COVID: An Adaptive Randomized Trial | Annals of Internal Medicine

Alternative headline: Fluvoxamine shows improvement in fatigue in adults with long COVID.

Definitions

• FSS (Fatigue Severity Scale): A validated 7-point scale measuring severity of fatigue.

• CrI (Credible Interval): Describes and summarises the uncertainty related to the unknown parameters one is trying to estimate, using a probability distribution.

• Posterior Probability of Superiority: A Bayesian metric representing the probability that one treatment, group, or intervention (A) is better than another (B), given the observed data (P(A > B | data)). It is calculated by analyzing the proportion of samples from the posterior distribution where (A) outperforms (B), offering a direct probabilistic interpretation.

Summary

• Fluvoxamine showed a significant reduction in fatigue compared with placebo at day 60 and at day 90. Metformin showed no significant benefit.

• Fluvoxamine also improved quality-of-life scores.

• Recovery (FSS score <3) was more frequent with fluvoxamine than placebo, with standardized risk ratios of 1.48 at day 30, 1.36 at day 60, and 1.19 at day 90.

• Fluvoxamine’s central nervous system activity and anti-inflammatory/immunomodulatory effects may be a possible mechanism for improving neurocognitive and fatigue-related manifestations of long COVID.

Stats/Trends

• A total of 399 participants were randomly assigned to fluvoxamine (n = 150), metformin (n = 111), or placebo (n = 138) at 22 outpatient sites in Brazil.

• Fluvoxamine reduced fatigue compared with placebo, with a mean treatment effect of −0.43 points (95% CrI, −0.80 to −0.07 points) and a 99.0% posterior probability of superiority. This benefit was sustained at day 90, with a mean difference of −0.58 (CrI, −0.98 to −0.16) and a 99.7% probability of superiority.

• Metformin showed no evidence of benefit (day 60 treatment effect, −0.03 [CrI, −0.42 to 0.37; probability, 56.0%]; day 90 treatment effect, −0.04 [CrI, −0.47 to 0.38; probability, 57.8%]).

Counterpoints

• The evaluation of only one symptom of long COVID (fatigue) and one measure to assess this symptom are significant limitations of this study.

• The trial was not designed to evaluate whether effects were causally linked or mediated through specific biological pathways. According to study authors, the observed benefits may reflect improvements in overall well-being, symptom perception, or functional capacity, rather than modification of underlying long COVID pathophysiology.

• Future trials should incorporate assessments of depression and anxiety at baseline and follow-up, as well as inflammatory and metabolic biomarkers, to clarify mechanisms and identify subgroups most likely to benefit.

Long COVID and risk of incident cardiovascular disease: a prospective cohort study using the MIRACLE-S cohort | eClinicalMedicine

Alternative headline: Long COVID Increases Risk of Cardiovascular Disease, Particularly Among Women, Study Finds.

Definitions

• Cox Proportional Hazards Model: A statistical technique used to evaluate the effect of several variables on the time a specified event takes to occur.

• Cardiovascular Disease (CVD): Disorders affecting the heart and blood vessels, including coronary artery disease and stroke.

• Cardiac Arrhythmia: An irregular heartbeat that impacts blood flow and heart function.

Summary

1. The study reveals that individuals with long COVID experience a significantly elevated risk of developing cardiovascular disease compared to those without long COVID, suggesting it is a crucial cardiovascular risk factor.

2. Among participants with long COVID, the cumulative incidence of cardiovascular events was markedly higher: 18.2% in women and 20.6% in men, compared to 8.4% and 11.1% in the respective non-long COVID groups.

3. Long COVID was associated with an increase in the hazard ratio for cardiovascular outcomes, with women showing an HR of 2.06 and men an HR of 1.33, indicating notable sex differences.

4. The incidence of cardiac arrhythmias was prominent, with adjusted HRs of 3.11 in women and 1.61 in men, highlighting the urgency for targeted cardiovascular assessment.

5. The findings emphasize the need to integrate long COVID into cardiovascular health strategies, calling for structured follow-up care.

Stats/Trends

1. The study analyzed data from 8,999 individuals diagnosed with long COVID between October 2020 and January 2025, from a larger population of 1,217,693 individuals.

2. The incidence rates of cardiovascular events were 18.2% for women and 20.6% for men with long COVID, compared to 8.4% for women and 11.1% for men without long COVID.

3. Hazard ratios for major cardiovascular outcomes were 2.06 for women and 1.33 for men, based on the fully adjusted Cox model.

Counterpoints

1. The study’s reliance on physician-assigned diagnoses may vary and lead to potential misclassification.

2. The focus on individuals with healthcare contacts could inflate event rates and may not represent the less symptomatic long COVID population.

Action Items

1. Advocate for comprehensive cardiovascular assessments in post-COVID care for individuals with long COVID.

2. Support the development of structured follow-up programs aimed at monitoring long COVID patients’ cardiovascular health.

3. Encourage research on lifestyle factors and vaccination status to better understand their impact on long COVID outcomes.

Media

Reinfection Raises Long COVID Risk in Children and Adolescents | Northwestern Feinberg News

Alternative headline: Study finds children reinfected with COVID-19 face greater long COVID risks than single infection.

Summary

A Northwestern study analyzing over 465,000 patients under 21 found that a second SARS-CoV-2 infection more than doubles the risk of developing long COVID compared to a first infection — approximately 1,884 PASC cases per million after reinfection versus 904 per million after a single infection. The risks compound in serious ways: myocarditis was reported at more than three times the rate after reinfection, and thrombotic event risk more than doubled. The findings push back against the assumption that reinfection with milder Omicron-era variants is clinically insignificant for children. Causality can’t be firmly established from observational data, and vaccination rates and healthcare access varied across the cohort, but the signal is consistent enough to warrant caution in how reinfection is discussed and managed in pediatric settings.

Interdisciplinary Care Shows Promise for Children With Long COVID | Pharmacy Times

Alternative headline: Study Finds High Symptom Burden in Pediatric Long COVID, Highlighting Need for Specialized Care.

Summary

A review of 214 pediatric patients seen at a dedicated COVID recovery clinic between 2021 and 2023 found that children with long COVID carry a symptom burden comparable to those with chronic pain or cancer — with elevated rates of anxiety, sleep disturbances, and fatigue that often get misread as school avoidance or anxiety disorders. The clinic’s interdisciplinary model paired infectious disease specialists with integrative medicine practitioners over a 12 to 18-month treatment window, using pacing strategies, low-dose naltrexone for fatigue, and antihistamines to manage anxiety symptoms, with roughly 30% of patients also using guided Chinese herbal medicine. Pharmacists played an active role in medication management and family education. The single-center, retrospective design limits how broadly the results apply, but the model itself — treating pediatric long COVID as a multisystem condition requiring coordinated care — is one the field is watching.

CONFIDEX Launches Investor Search for AI-Based Neurotherapy

Alternative headline: CONFIDEX Seeks Investors for AI-Powered Neurotherapy Targeting Long COVID Fatigue and Stress Relief.

Summary

CONFIDEX, in partnership with TRS Technische Rationalisierungssysteme GmbH, has launched an investor search for an AI-based neurotherapy platform aimed at addressing long COVID fatigue and neurological stress. The initiative is targeting a minimum raise of €5 million for technology development and clinical validation, positioning itself within a market where an estimated 10% of COVID-19 survivors continue to experience post-viral complications. The pitch leans on the gap in approved therapies and the high prevalence of fatigue and cognitive dysfunction among long COVID patients. Regulatory pathways for AI-integrated medical devices remain complex, and independent clinical validation will be necessary before the approach gains traction in mainstream healthcare settings.

🔗 Quick Links

• Model of care to promote recovery in older people with long COVID: findings from interviews and a co-design workshop

• Rare pediatric multi-system thrombosis post-COVID-19: a three-year follow-up case report and narrative review on rivaroxaban for long-term management

• Predictors of Long COVID-19 Syndrome and Hospital Admissions Among COVID-19-Diagnosed Adult Patients Who Self-Isolated at Home in KwaZulu-Natal Province, South Africa

• ‘I Want Everyone to Have It, and Everyone to Be on It’: A Feasibility Study of the Transforming Long Covid Intervention

• Interpreting hand grip strength in hospital employees with post-COVID syndrome compared to non-infected controls: a case-control study

• Facilitators of and barriers to participation in Long COVID research: A qualitative analysis

• Health benefit or burden? Unpacking the dual effects of religious group membership on long COVID prevalence and severity

Article of the week

This week’s standout is “Underuse of Pharmacologic Therapies for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Before Specialist Evaluation,” published in the Annals of Family Medicine. The finding is blunt: only 23% of ME/CFS patients received appropriate pharmacologic therapy before being referred to a specialist, despite reporting average symptom severity scores of 8.2 out of 10. Primary care physicians are under-prescribing, often skipping evidence-based options in favor of off-label medications or nothing at all — and patients are waiting, symptomatic, in the gap. The study stops short of being prescriptive about which drugs should be used, but the message is clear: the handoff from primary care to specialist is failing patients, and the longer it takes, the longer they suffer.

Research

Underuse of Pharmacologic Therapies for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Before Specialist Evaluation | Annals of Family Medicine

Alternative headline: Study Finds Only 23% of ME/CFS Patients Receive Needed Medications Before Specialist Care.

Definitions

• Pharmacologic Therapy: The use of medications to manage symptoms or underlying conditions, crucial in treating chronic illnesses like ME/CFS.

Summary

1. The study reveals a significant underutilization of pharmacologic therapies for patients with ME/CFS prior to specialist evaluation, highlighting a gap in early intervention strategies.

2. Findings indicate that only 23% of patients received appropriate pharmacologic therapy, despite the prevalence of debilitating symptoms.

3. Analysis of clinical practice patterns shows variations among primary care providers, leading to inconsistent treatment approaches for ME/CFS.

4. Increased access to pharmacologic therapies prior to specialist evaluation could potentially enhance the quality of life for patients suffering from ME/CFS.

Stats/Trends

1. The study reviewed data from 250 patients diagnosed with ME/CFS, with only 57 receiving pharmacologic interventions before seeking specialist care.

2. Patients reported an average symptom severity score of 8.2 out of 10, indicating a high burden of illness.

3. Less than 30% of primary care physicians recommended pharmacotherapy as part of initial treatment plans.

Counterpoints

1. While compelling, the study is limited by its retrospective design and self-reported data, which may introduce bias.

2. It does not account for variations in the severity of ME/CFS symptoms among patients, suggesting a need for comprehensive prospective studies to validate these results.

Retrospective analysis of patients with cardiopulmonary symptoms of long COVID

Alternative headline: Patients with Sleep Apnea and COPD Face Higher Long COVID Risks After Initial Hospitalization.

Definition

• Oxygen Support: The requirement for supplemental oxygen, non-invasive ventilation, or intubation during hospitalization, often indicative of respiratory illness severity.

Summary

1. This study highlights that patients with a history of obstructive sleep apnea (OSA) or chronic obstructive pulmonary disease (COPD), who required oxygen support during their initial COVID-19 hospitalization, are at a significantly higher risk of developing long COVID symptoms.

2. Among the 246 patients analyzed, those with pre-existing OSA presented an odds ratio (OR) of 3.6 for developing cardiopulmonary symptoms post-infection (P = 0.0012), while those with COPD had an even higher OR of 12.19 (P = 0.0015).

3. The median age of the cohort was 52 years, with a predominance of females (65.9%), and the most common presenting symptoms included dyspnea and fatigue, both reported by over 80% of the patients.

4. Approximately 43.1% of patients required hospitalization, with many needing oxygen support ranging from nasal cannula to ventilatory assistance.

Stats/Trends

1. The study identified 246 adult patients from a larger cohort of 390 who presented with long COVID symptoms 8–12 weeks post-infection.

2. Patients requiring oxygen support during initial hospitalization accounted for 36.6% of the cohort.

3. The median length of hospital stay for patients was 15.5 days.

Counterpoints

1. The retrospective nature of the study may introduce selection bias, as patients with pre-existing conditions might have been more likely to seek specialized care.

2. The study did not thoroughly account for potential confounding variables such as healthcare access and socioeconomic factors, necessitating further multi-center research for validation.

Action Items

1. Consider advocating for increased awareness of the long COVID risks associated with pre-existing respiratory conditions.

2. Encourage healthcare providers to incorporate assessment of respiratory health in follow-up care for COVID-19 survivors.

3. Support research initiatives aimed at understanding the long-term effects of COVID-19 in patients with OSA and COPD.

Long-term health outcomes in elderly COPD patients with long COVID: a 2-year prospective cohort study | Respiratory Research

Alternative headline: Elderly COPD Patients with Long COVID Experience Persistent Symptoms and Reduced Lung Function Over Time.

Definitions

• Serum Proteomic Analysis: A technique to analyze protein expressions in serum to identify biomarkers related to disease, aiding in understanding underlying mechanisms.

• EQ-VAS: EuroQol Visual Analog Scale, a tool for assessing a patient’s overall health status from their perspective.

• mMRC: Modified Medical Research Council dyspnea scale, used to evaluate the severity of breathlessness in patients.

Summary

1. The study reveals that elderly COPD patients with long COVID experience a greater symptom burden and frequent adverse events over a two-year follow-up period.

2. At the one-year and one-and-a-half-year follow-ups, patients in the long COVID group showed consistently poorer lung function and diffusion capacity.

3. Serum proteomic analysis indicated significant upregulation of blood coagulation and platelet activation proteins in long COVID patients, possibly elucidating the condition’s underlying mechanisms.

4. Improvements in lung function observed in the non-long COVID patients at the one-and-a-half-year mark were not replicated in those with long COVID.

5. The findings suggest a need for targeted strategies addressing the unique challenges faced by elderly COPD patients recovering from COVID-19.

Stats/Trends

1. The longitudinal cohort study monitored elderly COPD patients at 1, 1.5, and 2 years post-COVID-19, assessing symptom burden and physiological function.

2. Both EQ-VAS and mMRC scores indicated a significantly higher symptom burden in the long COVID group throughout the study period.

3. Long COVID patients demonstrated lower pulmonary ventilation function parameters compared to controls at the one-year (P < 0.05) and one-and-a-half-year follow-ups.

Counterpoints

1. The research may be limited by confounding factors such as variations in comorbidities, treatment adherence, and lifestyle changes influencing long-term health outcomes.

2. The single-center design may restrict the broader applicability of results, necessitating multi-center studies for validation.

Long-term cardiovascular function and cardiopulmonary performance in athletes after COVID-19: results from the COSMO study | Frontiers in Cardiovascular Medicine

Alternative headline: Study Finds Stable Heart Function in Athletes After Mild COVID-19 Infection, Supports Safe Return to Sports.

Definitions

• Cardiovascular Function: The ability of the heart and circulatory system to deliver oxygenated blood to tissues, assessed through metrics such as ejection fraction and strain imaging.

• Cardiopulmonary Performance: The efficiency of the heart and lungs during physical exertion, evaluated through tests like cardiopulmonary exercise testing (CPET).

Summary

1. The COSMO study evaluated 52 athletes over 12 months post-mild COVID-19 infection, revealing stable cardiac function and cardiopulmonary performance.

2. No significant changes in left ventricular ejection fraction, volumes, or global longitudinal strain were observed, indicating preserved cardiac structure.

3. Minor changes in diastolic metrics were recorded, but these were not clinically significant, suggesting maintained diastolic function.

4. Peak exercise performance metrics, including VO₂peak, remained stable, supporting a safe return to sports for asymptomatic athletes recovering from mild COVID-19.

5. The study emphasizes the protective role of regular athletic training on cardiovascular health during recovery from infection.

Stats/Trends

1. The study tracked 52 athletes (27 females; median age 32.5 years) from various sports disciplines.

2. At the 12-month follow-up, the left ventricular ejection fraction remained unchanged at 73.37 ± 1.21%.

3. No significant reduction in VO₂peak was noted, with values averaging 2.69 ± 0.37 at follow-up.

Counterpoints

1. The study’s modest sample size may limit the robustness of its conclusions.

2. It lacks systematic records of training loads and individual recovery trajectories, raising questions about variations in recovery experiences.

Disrupted fluid homeostasis in patients with post-Covid-19 syndrome – a case series | Frontiers in Endocrinology

Alternative headline: Disrupted fluid balance linked to severe long-term symptoms in post-COVID syndrome patients.

Definitions

• Post-COVID Syndrome (PCS): A collection of persistent symptoms continuing for weeks or months after COVID-19 infection, including fatigue, dysautonomia, and cognitive issues.

• Osmolality: A measure of solute concentration in body fluids, crucial for understanding fluid balance.

Summary

1. This case series identifies disrupted fluid homeostasis as a significant clinical feature of post-COVID syndrome (PCS), with abnormalities in serum and urine osmolality.

2. Seven out of ten patients reported polydipsia and/or polyuria, reflecting hydration issues, while all participants exhibited abnormal osmolality measures.

3. The combination of high serum and low urine osmolality was linked to poorer health status, indicating a relationship between osmolality irregularities and symptom severity.

4. Patients in this cohort experienced severe long-term symptoms, including fatigue and dysautonomia, highlighting the debilitating nature of PCS.

5. Disrupted fluid homeostasis could serve as a diagnostic biomarker for PCS and may lead to new therapeutic approaches.

Stats/Trends

1. The study analyzed 10 consecutive patients with PCS, comprising an equal gender distribution (5 males, 5 females) with a mean age of 44 ± 14 years.

2. Serum osmolality was above the normal reference range in 9 out of 10 patients, with a mean value of 298 ± 4 mOsm/kg; urine osmolality was below normal in 7 out of 10 patients, averaging 707 ± 149 mOsm/kg.

3. Quality of life scores averaged 36 on a 0–100 scale, with physical functioning scores at 46 ± 23, indicating significant impairment.

Counterpoints

1. The small sample size limits the ability to generalize findings, and without a control group, determining causative relationships is challenging.

2. The lack of detailed ADH level assessment and controlled comparisons may undermine the robustness of the conclusions drawn.

A retrospective cohort study of viral and sociodemographic determinants of long COVID among Idaho veterans | Frontiers in Public Health

Alternative headline: Study Finds Female Veterans Face Greater Long COVID Challenges and Slower Recovery than Males.

Definition

• Viral Variant: Genetically distinct forms of a virus resulting from mutations that can impact disease severity and long-term effects.

• Social Vulnerability Index (SVI): A tool that identifies communities at higher risk during public health emergencies based on socioeconomic factors, housing, and healthcare access.

Summary

1. The study reveals that female veterans are more likely to experience neuropsychiatric long COVID while showing less recovery than their male counterparts.

2. The Omicron variants are linked to a higher likelihood of multisystem long COVID and poorer recovery compared to pre-Delta variants.

3. Age influences long COVID outcomes, with older adults exhibiting fewer neuropsychiatric symptoms and more cardiopulmonary issues.

4. Rural residents show marginally less recovery from long COVID symptoms compared to urban individuals, although this was not statistically significant.

5. This research combines genetic sequencing to identify viral variants within an underrepresented rural veteran population, adding new insights into long COVID’s epidemiology.

Stats/Trends

1. The cohort consisted of 1,120 veterans with sequenced SARS-CoV-2 samples collected between April 2, 2020, and December 20, 2022.

2. Female participants, making up 13% of the cohort, experienced a higher incidence of neuropsychiatric long COVID symptoms.

3. Patients infected with Omicron variants had a 10.75% lower recovery rate compared to pre-Delta infections (P < 0.05).

Counterpoints

1. The study’s generalizability may be limited due to its focus on a rural veteran population, which may not represent the broader U.S. demographic.

2. The relatively small sample size raises concerns about the robustness of the study’s conclusions.

Media

Park-Pagliuca Fund Donates $10 Million to PolyBio Long COVID Cure Initiative

Alternative headline: Park-Pagliuca Fund Commits $10 Million to Advance Research on Long COVID Treatment and Diagnosis.

Summary

The Park-Pagliuca Fund has pledged $10 million to the Long COVID Cure Initiative (LCCI), a significant private investment aimed at accelerating diagnostics and treatment development for a condition that has left hundreds of millions of people worldwide without clear answers. The LCCI’s core strategy centers on building a national clinical trials network that uses diagnostic results to guide treatment — a model it also intends to extend to conditions like ME/CFS and chronic Lyme disease. The scale of long COVID’s economic impact, estimated in the trillions in the U.S. alone due to workforce disruption, gives the investment urgency beyond the medical. Whether the funding translates into actionable therapies will depend on how well the initiative can bridge patient experience with research infrastructure across disciplines.

Long Covid Service Extended to Cover Wider Range of Conditions – NHS Forth Valley

Alternative headline: NHS Forth Valley Expands Long Covid Service to Address Post-Acute Infection Syndromes.

Summary

NHS Forth Valley has quietly broadened its Long Covid service into a Post-Acute Infection Syndromes (PAIS) service, now covering ME/CFS and post-viral postural tachycardia syndrome (PoTS) alongside long COVID. Open to anyone 16 and older, the service offers initial face-to-face appointments followed by individualized or group-based support, with referrals through local GPs. It’s a meaningful shift in framing — treating long COVID not as an isolated condition but as part of a wider category of post-infectious illness — and reflects the Scottish Government’s commitment to keeping care available for those with lingering infection-related symptoms. The ongoing challenge will be adapting protocols fast enough to match the evolving science.

Unions Meet Taoiseach Regarding Long Covid | RTÉ

Alternative headline: Healthcare Unions Urge Government Action to Support Workers Affected by Long Covid Sick Pay Changes.

Summary

Irish healthcare unions — including the INMO, SIPTU, Forsa, and the IMO — met with Taoiseach Micheál Martin to press for action on sick pay for the roughly 120 healthcare workers still sidelined by long COVID. The issue: a special leave with pay scheme that provided full salary support ended last December, and workers have since been moved to a standard scheme that cuts to half pay after three months and nothing shortly after. With a June deadline approaching, unions are calling for reinstatement of the Critical Illness Protocol to prevent affected workers from losing their income entirely. The meeting was described as positive, with the government committing to further discussions — though the clock is running.

AU Student Uncovers Potential Link in Long Covid Symptoms | FOX 5 DC

Alternative headline: Study Reveals Potential Biological Factors Behind Gender Differences in Long COVID Symptoms.

Summary

An American University student has published research suggesting a biological basis for the gender gap in long COVID symptoms — specifically, that hormonal differences and immune response variations may explain why females tend to report a wider range and greater severity of symptoms. In the study’s sample of over 300 long COVID patients, 75% of female participants reported fatigue and cognitive issues compared to 45% of males, and estrogen levels correlated with symptom severity (r = 0.65, P < 0.01). The findings are preliminary — sample sizes are modest and confounders weren’t fully controlled — but they add biological specificity to a pattern that clinicians have observed anecdotally for years, and point toward the case for gender-informed treatment approaches.

Professional Tennis Player Emma Raducanu Has Post-Viral Syndrome. And Commentators Are Giving Her Terrible Advice. | The Sick Times

Alternative headline: Tennis Star Emma Raducanu Faces Challenges of Post-Viral Syndrome After Illness During Tournament.

Summary

Emma Raducanu has been dealing with post-viral syndrome after contracting a virus at a tournament in Cluj, Romania — and the public commentary around her situation has been about as useful as it usually is when high-profile athletes get sick and don’t immediately bounce back. The Sick Times piece takes aim at figures like Greg Rusedski, whose advice to simply “get healthy” ignores what post-viral conditions actually involve: months or years of unpredictable symptoms, immune dysregulation, and risk of relapse from overexertion. The piece situates Raducanu’s experience within the broader conversation around infection-associated chronic conditions (IACCs) — a category now affecting an estimated 400 million people globally — and argues that the sports world’s push-through culture is one of the least helpful frameworks for understanding what she and athletes like Tanysha Dissanayake are going through.

Article of the week

This week’s article — “Identification of novel reproducible combinatorial genetic risk factors for myalgic encephalomyelitis in the DecodeME patient cohort and commonalities with long COVID,” published in the Journal of Translational Medicine — takes one of the most rigorous looks yet at the genetic architecture of ME/CFS. Using three separate patient cohorts, the study identified 22,411 reproducible disease signatures involving 7,555 unique SNPs consistently linked to higher ME prevalence. More striking is the overlap with long COVID: the genes flagged here touch immune response, neural regulation, and cellular damage — the same terrain long COVID researchers keep circling back to. The practical upshot is real: shared pathways mean existing drugs might be repurposed for both conditions, potentially shortening the road to treatment.

Research

Identification of novel reproducible combinatorial genetic risk factors for myalgic encephalomyelitis in the DecodeME patient cohort and commonalities with long COVID | Journal of Translational Medicine

Alternative headline: Study Reveals Genetic Links Between Myalgic Encephalomyelitis and Long COVID, Offering New Treatment Insights.

Definitions

• Myalgic Encephalomyelitis (ME/CFS): A multi-system disease characterized by extreme fatigue and cognitive impairment, often worsened by exertion.

• SNPs (Single Nucleotide Polymorphisms): Genetic variations that can influence disease development and response to various factors.

• Polygenic Risk Score: A score summarizing the cumulative effect of many genetic variants on disease predisposition.

Summary

1. The study identified 22,411 reproducible genetic disease signatures involving 7,555 unique SNPs consistently associated with an increased prevalence of Myalgic Encephalomyelitis (ME).

2. Multiple disease signatures significantly correlate with a higher risk of developing ME, with patients exhibiting the highest counts having a 1.64-fold increased likelihood compared to those with the lowest.

3. There is a striking genetic overlap between Myalgic Encephalomyelitis and long COVID, suggesting potential pathways for repurposing existing drugs for both conditions.

4. Core genes identified impact immune responses, neural activity regulation, and cellular damage responses, crucial for understanding the heterogeneous nature of ME.

5. These findings highlight the polygenic nature of ME and underscore the importance of personalized treatment approaches.

Stats/Trends

1. Data from the DecodeME patient cohort highlighted genetic factors in three disjoint patient populations.

2. A higher count of disease signatures is significantly associated with increased prevalence of ME (p < 10^-21).

3. Out of the identified SNPs, 259 were classified as core genes significantly contributing to the disease’s biological pathways.

Long COVID: Deep single-cell immunophenotyping and machine learning reveal a general signature for fatigue | Journal of Translational Medicine

Alternative headline: New Study Suggests Long COVID Shares Immune Features with Other Fatigue Conditions in Youth.

Definitions

• CyTOF: Cytometry by Time-of-Flight, a method for detailed profiling of immune cell phenotypes and functions.

• Machine Learning: A subset of artificial intelligence that analyzes complex data to identify patterns and make predictions.

• Polyfunctional Responses: The ability of immune cells to perform multiple functions simultaneously, indicating a robust immune response.

Summary

1. The study indicates that Long COVID shares immune signatures with other fatigue states, particularly in young females aged 12 to 25 years.

2. Higher frequencies of terminal NK cells were found in individuals with Long COVID, suggesting a hyperresponsive immune state that could serve as a marker for fatigue.

3. Elevated levels of activated and exhausted CD4+ T cells were observed among participants with Long COVID, along with a decrease in specific B cell populations.

4. Machine learning analysis identified terminal NK cells as pivotal features associated with fatigue, highlighting their potential utility in diagnostics.

5. No unique immune alterations were detected that could distinguish Long COVID from other forms of fatigue, indicating common underlying mechanisms.

Stats/Trends

1. The study followed 40 female participants aged 12 to 25 over six months, categorizing them into four health status groups: Long COVID (LC), recovered convalescents (RC), fatigued controls (FC), and healthy controls (HC).

2. Increased terminal NK cell frequency was noted in both Long COVID (LC) and fatigued controls (FC), correlating with the severity of fatigue.

3. Levels of activated effector memory T cells expressing PD-1 were elevated in both LC and FC groups (P < 0.05), indicating potential immune dysfunction common to these conditions.

Counterpoints

1. The small sample size and specific demographic (young females) raise questions about the generalizability of the results.

2. The absence of distinct immune alterations specific to Long COVID suggests that more research is needed to explore its nuances across diverse populations and ages.

Endovascular profiles linked to neutrophil activation in children and young adults with long COVID | Pediatric Research

Alternative headline: Study Links Long COVID in Young People to Inflammation, Microclots, and Cardiovascular Symptoms.

Definitions

• Microclots: Small aggregated structures of fibrin or amyloid associated with vascular inflammation and damage, often found in long COVID.

• Neutrophil Extracellular Traps (NETs): Web-like structures released by activated neutrophils that can contribute to tissue damage and inflammation.

• Endothelial Dysfunction: A condition where the endothelium, the thin layer of cells lining blood vessels, fails to function normally, increasing vascular permeability and inflammation.

• Cytokine Panel: Tests measuring levels of various cytokines in the blood, indicating inflammation and immune response.

• LASSO Model: A statistical method for variable selection in regression analysis, useful for identifying key predictors in complex data sets.

Summary

1. The study reveals that children and young adults with long COVID exhibit significant increases in microclot burden and markers of neutrophil activation, indicating a link between inflammation and vascular injury.

2. Cardiovascular symptoms, such as dizziness on standing and palpitations, were prevalent in 77% and 63% of participants with long COVID, respectively.

3. Elevated levels of endovascular cytokines suggest that altered endothelial responses could be driving long COVID pathology.

4. In vitro experiments show that neutrophil activation contributes to endothelial cell injury through mechanisms involving NETosis.

5. A LASSO model identified key predictors of long COVID symptoms, including microclot burden and cell-free DNA, indicating their potential as biomarkers for diagnosis.

Stats/Trends

1. The study involved 84 participants, including 61 children and young adults with long COVID and 23 healthy pediatric controls from the US and Canada.

2. The quantity of microclots was significantly higher in individuals with long COVID (P < 0.0001), suggesting a novel pathway driving disease symptoms.

3. Altered endothelial cytokine responses showed significant elevations in pro-inflammatory cytokines in the long COVID cohort compared to controls (P < 0.001).

4. LASSO analysis determined microclot burden to be a critical factor in predicting long COVID severity, with a coefficient of 3.9.

Counterpoints

1. While the findings provide compelling evidence of endovascular changes in pediatric long COVID patients, the relatively small sample size limits the robustness of the conclusions.

2. The demographic skew towards a higher proportion of female participants raises questions about sex-based differences in long COVID manifestation, warranting further research to validate these outcomes.

The impact of COVID-19 vaccination on long-term risk of new-onset atrial fibrillation/flutter after COVID-19 infection: A retrospective cohort study | PLOS One

Alternative headline: COVID-19 Vaccination Linked to Lower Risk of Atrial Fibrillation After Infection, Study Finds.

Definitions

• New-Onset Atrial Fibrillation/Flutter (NOAF): Diagnosis of atrial fibrillation or flutter occurring after COVID-19 infection, without prior history.

• Hazard Ratio (HR): Measure of the effect of an intervention (like vaccination) on the risk of an event occurring over time.

Summary

1. The study found that COVID-19 vaccination significantly reduced the incidence of new-onset atrial fibrillation/flutter (NOAF) after COVID-19 infection over a 24-month follow-up period.

2. The cumulative NOAF incidence was 1.91% in vaccinated individuals compared to 2.18% in unvaccinated individuals, translating to a hazard ratio of 0.82, indicating an 18% reduction in risk.

3. This protective effect of vaccination against NOAF was consistently observed at 1 month (HR: 0.73), 6 months (HR: 0.71), and 12 months (HR: 0.77) post-infection.

4. Sensitivity analyses confirmed the robustness of findings, even when excluding patients who experienced severe COVID-19 illness.

Stats/Trends

1. A total of 477,500 adult patients were analyzed, divided equally into vaccinated (238,750) and unvaccinated cohorts.

2. Among the vaccinated group, the incidence of NOAF 24 months post-infection was significantly lower than in unvaccinated controls (1.91% vs 2.18%; HR: 0.82, 95% CI: 0.78–0.85).

3. Validation analysis showed that patients with COVID-19 had a 63% higher incidence of NOAF compared to those with acute upper respiratory infections (HR: 1.63).

Counterpoints

1. The study’s retrospective nature raises concerns about data accuracy and potential biases from using electronic medical records.

2. Further research is necessary to validate these results across diverse populations and healthcare systems.

Action Items

1. Consider further studies to explore the long-term cardiovascular effects of COVID-19 vaccination.

2. Advocate for public health campaigns emphasizing the cardiovascular benefits of vaccination.

3. Examine the impact of different vaccine types on the incidence of NOAF.

PTPRN2 hypomethylation and PHB2-associated miR-153-3p maturation define dual epigenetic features linked to symptom variability in Myalgic encephalomyelitis | Journal of Translational Medicine

Alternative headline: New research identifies potential biomarkers linked to cognitive symptoms in Myalgic Encephalomyelitis patients.

Definitions

• PTPRN2: A gene encoding a protein involved in signal transduction related to cellular processes, including insulin signaling.

• miR-153-3p: A microRNA that regulates gene expression and is implicated in neuronal functions.

• DNA Methylation: An epigenetic modification that alters gene expression without changing the DNA sequence.

• Summary

1. The study reveals significant hypomethylation of PTPRN2 and maturation of PHB2-associated miR-153-3p, linking these features to symptom variability in Myalgic Encephalomyelitis patients.

2. Analysis of saliva samples shows that PTPRN2 hypomethylation correlates with the severity of cognitive symptoms, including brain fog and memory issues.

3. The research involved 54 ME patients and 21 sedentary healthy controls, providing a comparative analysis of epigenetic alterations.

4. Findings suggest potential biomarkers for ME, highlighting the role of epigenetic factors in the condition’s pathophysiology and symptoms.

Stats/Trends

1. The investigation analyzed 54 saliva samples from individuals diagnosed with Myalgic Encephalomyelitis compared to 21 control samples.

2. A Bonferroni-corrected analysis revealed significant DNA hypomethylation at the CpG site cg19803194 associated with PTPRN2 (p < 0.001).

3. Patients with PTPRN2 hypomethylation reported higher scores on cognitive symptom questionnaires, with a mean score increase of 15 points out of 100 (P = 0.001).

Understanding quality-of-life patterns in long COVID: How Symptoms and socioeconomic conditions shape patient wellbeing | PLOS One

Alternative headline: Study Uncovers Distinct Symptom Profiles in Long COVID Patients Affecting Quality of Life.

Definitions

• Quality of Life (QoL): An individual’s overall well-being encompassing physical, mental, emotional, and social health.

• Latent Class Analysis (LCA): A statistical method used to identify unobserved subgroups within a population based on multiple observed variables.

Summary

1. The study identified two distinct symptom profiles in Long COVID patients: a low-burden profile primarily characterized by fatigue and cognitive issues, and a high-burden profile indicating multisystem involvement.

2. Quality of life was categorized into three profiles: high, medium, and low QoL, with over half of the participants classified in the low QoL group.

3. Employment status emerged as a significant predictor of QoL; those employed reported lower QoL compared to individuals on sick leave or with permanent incapacity.

4. The study underscored the interaction between clinical symptom burden and social determinants, particularly noting that social support was more frequently reported among participants with low QoL.

5. Findings suggest that tailored, multidisciplinary interventions combining medical care and psychosocial support are essential for improving the quality of life in Long COVID patients.

Stats/Trends

1. A total of 363 patients with Long COVID participated in the study, recruited via an online survey across Spain.

2. Latent class analysis revealed two symptom profiles: low-burden (n=133) and high-burden (n=230).

3. Quality of life profiles indicated that 52.6% of participants were in the low QoL group, 34.2% in the medium QoL group, and 13.2% in the high QoL group.

Counterpoints

1. The study’s reliance on an online survey may lead to selection bias, predominantly attracting individuals with more severe Long COVID symptoms.

2. The cross-sectional design limits the ability to draw causal relationships between symptoms, employment status, and QoL outcomes.

A prospective cohort study for characterization and predictive factors of long-term POST-COVID interstitial changes | Respiratory Research

Alternative headline: Long-term lung changes observed in COVID-19 patients despite significant improvement in function over time.

Definitions

• Post-COVID Interstitial Changes: Chronic pulmonary alterations following severe COVID-19 infection, characterized by persistent lung abnormalities detectable through imaging.

• KL-6: A serum biomarker associated with interstitial lung diseases; elevated levels indicate potential lung damage or fibrosis.

• High-Resolution Computed Tomography (HRCT): An advanced imaging technique providing detailed images of lung structures, useful for diagnosing interstitial lung disease.

Summary

1. The study assesses 290 patients with severe COVID-19 pneumonia, revealing a significant prevalence of long-term interstitial lung changes post-recovery.

2. Baseline Pulmonary Function Tests showed mean FVC values improved from 88.8% to 99.5%, indicating notable recovery in lung capacity over time.

3. Elevated serum levels of MMP-7 and KL-6 may serve as predictive biomarkers for patients at risk for persistent pulmonary abnormalities after severe COVID-19.

4. Over 24 months, significant improvements in pulmonary function were observed, yet a notable subset of patients displayed enduring interstitial lung changes.

Stats/Trends

1. Out of 290 enrolled patients, 247 completed the follow-up after 24 months.

2. Patients recorded a significant increase in mean FVC from 88.8% at baseline to 99.5% at the final assessment (P < 0.001).

3. Persistent interstitial changes were observed in a substantial number of patients, highlighting the need for long-term monitoring.

Counterpoints

1. The study’s multicenter design and relatively small cohort size could limit the breadth of its conclusions.

2. The lack of comprehensive control for confounding variables, such as pre-existing lung disease or differing treatment protocols during the acute phase, may affect the study’s outcomes.

Endothelial and cardiac dysfunction in long COVID with cardiovascular symptoms is associated with imbalance in the ADMA–DDAH–NOx pathway

Alternative headline: Genetic markers linked to persistent COVID-19 symptoms may reveal new treatment targets for long COVID.

Definitions

• ADMA: Asymmetric dimethylarginine, a molecule involved in cardiovascular regulation.

• DDAH: Dimethylarginine dimethylaminohydrolase, an enzyme that degrades ADMA, affecting nitric oxide production.

Summary

1. Marked variability in responses to SARS-CoV-2 infection indicates some individuals may be at greater risk for persistent symptoms.

2. Exploring genetic markers that influence the ADMA–DDAH–NOx pathway may provide insights into this susceptibility.

3. The study highlights alterations in this pathway as potential therapeutic targets for managing long COVID-related cardiovascular issues.

4. Future research should validate findings across diverse populations and explore innovative therapeutic strategies.

Stats/Trends

1. Variability in individual responses to SARS-CoV-2 infection has been observed, suggesting differential susceptibility to persistent symptoms.

2. Research on genetic markers is ongoing to identify those at higher risk for long-term complications.

Trends in long COVID among US adults, 2022–2024

Alternative headline: Long COVID prevalence rises among U.S. adults, with notable impact on vulnerable populations.

Definitions

• Long COVID: A condition characterized by persistent symptoms lasting at least three months post-COVID-19 infection, affecting overall quality of life.

• National Health Interview Survey (NHIS): A comprehensive survey in the US that assesses various health factors and trends, including long COVID.

• Activity Limitation: A decrease in the ability to perform daily tasks due to health conditions, pertinent to long COVID impact.

Summary

1. The prevalence of ever long COVID among US adults increased from 7.0% in 2022 to 8.4% in 2023, before plateauing at 8.3% in 2024.

2. Among adults with prior COVID-19 infection, ever long COVID significantly declined from 17.7% to 13.7% during the same timeframe.

3. Notably, 19.8% of individuals with current long COVID reported significant activity limitation, with higher prevalence in older adults and those with lower income.

4. Long COVID was more prevalent among women, middle-aged adults, and those with lower educational attainment and income levels.

Stats/Trends

1. The study analyzed data from 88,731 adults over three NHIS cycles (2022–2024).

2. The prevalence of ever long COVID rose to 8.4% in 2023, while current long COVID remained stable at around 3.3%.

3. Long COVID was reported by 17.7% of adults with prior infection in 2022, diminishing to 13.7% by 2024 (P < 0.001).

4. 19.8% of individuals with current long COVID reported significant activity limitations across 2023–2024.

Chronic stress and cognitive dysfunction in myalgic encephalomyelitis/chronic fatigue syndrome: HPA axis dysregulation and hippocampal plasticity

Alternative headline: Chronic stress and HPA axis dysfunction linked to cognitive impairments in ME/CFS patients.

Definitions

• HPA Axis: The hypothalamic-pituitary-adrenal axis, crucial to the body’s stress response and immune regulation.

• Neuroinflammation: The inflammation of nervous tissue, impacting neuronal function and health.

• Cognitive Dysfunction: Impairments in memory, attention, and problem-solving reported by chronic condition patients.

Summary

1. The review identifies chronic stress as a key factor contributing to cognitive dysfunction in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), mediated through hypothalamic-pituitary-adrenal (HPA) axis dysregulation.

2. Up to 89% of ME/CFS patients report cognitive impairments, commonly described as “brain fog,” significantly affecting daily functioning.

3. HPA axis dysregulation is linked to alterations in cortisol levels, influencing cognitive abilities and contributing to symptom severity in ME/CFS patients.

4. Neuroinflammatory responses and oxidative stress are important mechanisms that may exacerbate cognitive dysfunction in ME/CFS.

5. Understanding the interplay of chronic stress, HPA axis dysfunction, and hippocampal alterations is essential for developing targeted interventions for cognitive symptoms in ME/CFS.

Stats/Trends

1. Global prevalence of ME/CFS is approximately 1%, affecting 17–24 million people worldwide.

2. Up to 89% of patients report cognitive complaints, with testing showing deficits in attention, memory, and processing speed.

3. Studies reveal significant alterations in cortisol levels and HPA axis function in ME/CFS patients, including a state of hypocortisolism in some cohorts.

Counterpoints

1. The heterogeneity of ME/CFS and variations in study methodologies may limit the applicability of findings.

2. Larger, multi-center studies are needed to validate these findings and explore underlying neurobiological mechanisms.

Media

Cellist Joshua Roman Awarded Grant to Research Effects of Long COVID

Alternative headline: Cellist Joshua Roman Receives Grant to Explore Music’s Role in Long COVID Treatment Research.

Summary

Cellist Joshua Roman has been awarded a $25,000 Renée Fleming Neuroarts Investigator Award to research the effects of long COVID in collaboration with Dr. Elizabeth Bast at the Miami Veterans (VA) Medical Center. The grant is part of a broader initiative distributing funding to teams working at the intersection of arts and clinical medicine — a growing field studying how artistic practices affect brain health and recovery. Roman’s project specifically investigates music as a potential therapeutic tool for long COVID patients, building on his prior health-related musical research. While quantifying the health benefits of arts integration remains a methodological challenge, this award signals growing institutional interest in interdisciplinary approaches to treatment.

LTD Benefits Case Involving Long COVID Survives Summary Judgment

Alternative headline: Federal Judge Denies Summary Judgment in Long COVID Disability Benefits Case, Highlighting Legal Complexities.

Summary

A New York federal judge largely denied cross-motions for summary judgment in a long-term disability (LTD) benefits case tied to long COVID, finding that too many material facts remain in dispute to resolve the claim without a full proceeding. The ruling — made under ERISA, the federal law governing private workplace benefit plans — reflects the ongoing difficulty courts face when evaluating long COVID as a disabling condition. The judge determined that both the claimant’s medical evidence and the plan’s definition of disability raised unresolved questions, meaning the case goes forward. For the long COVID community, the ruling is meaningful: it keeps the door open and signals that courts are taking the condition seriously, even where legal precedent is still thin.

PridCor Therapeutics Secures Global Antiviral Portfolio

Alternative headline: PridCor Therapeutics Aims to Transform Treatment for Long COVID and Chronic Illnesses with New Portfolio.

Summary

PridCor Therapeutics has acquired a global antiviral asset portfolio targeting long COVID and other infection-associated chronic illnesses (IACI), including conditions like fibromyalgia and chronic fatigue syndrome. The portfolio’s lead candidates are IMC-2, a Phase 2b-ready combination therapy designed to address a broad range of long COVID symptoms, and IMC-1, a Phase 3-ready candidate for fibromyalgia — both built around the hypothesis that viral reactivation drives persistent disease. PridCor is partnering with the Icahn School of Medicine at Mount Sinai’s SHIELD study for scientific validation. The move positions the company as a clinical-stage player in a space with significant unmet need, though the effectiveness of these candidates in diverse patient populations still depends on trial outcomes.

🔗 Quick Links

• The “two-hit” storm: a hyper-inflammatory endotype in pediatric long COVID and its role in the severity of secondary bacterial pneumonia — a mechanistic review and clinical implications

• Care Pathways and Patient Experiences Among Patients With Post COVID-19 Condition: Study Protocol for a Mixed-Methods Study in Germany

• Investigating the ME/CFS experience through qualitative analysis of memorial entries

• Prevalence and influencing factors of long COVID brain fog among college students: a cross-sectional study in Taizhou, China

• TACO: TabPFN Augmented Causal Outcomes for early detection of Long COVID

Long COVID research is moving fast right now and this week’s edition covers a lot of ground. We’re looking at what’s happening inside the immune systems of people still sick years after infection, and how AI and proteomics might finally unlock personalized treatment. There’s also a sobering number: up to €115 billion a year in economic costs across OECD countries over the next decade. The science is getting sharper. The stakes are getting clearer.

🗞️ Article of the week

Our article of the week is titled “The Role of Gut Microbiota in Modulating Immune Response during Viral Infections,” published in the Journal of Immunology Research. This article explores the intricate relationships between gut microbiota and the immune system’s response to viral infections, specifically focusing on the implications for COVID-19 outcomes. The study emphasizes the potential role of microbiota in influencing systemic immune responses and highlights therapeutic avenues that could enhance patient outcomes.

A couple of key findings highlighted in the study:

1. “Alterations in the gut microbiome composition during viral infections may drastically influence the activation and regulation of immune responses.”

2. “Targeting gut microbiota through probiotics or dietary interventions could serve as a supplementary strategy to improve antiviral immunity and patient recovery.”

These insights could pave the way for novel therapeutic approaches in managing viral infections, including COVID-19, by harnessing the power of the gut microbiome.

Research

Article: Acute SARS-CoV-2 viral load and systemic inflammation are associated with neuropsychiatric and musculoskeletal symptoms in long COVID | PLOS One

alternative headline: Study Finds Nearly 60% of Mild COVID-19 Patients Experience Long-Term Symptoms After Ten Months

🗞️ Definitions

• Biochemical Markers: Substances in the blood that can indicate health status, including inflammatory markers (e.g., IL-6, ferritin) and micronutrients (e.g., vitamin D, vitamin B12).

🗞️ Summary

• The study revealed that 59% of previously diagnosed mild COVID-19 patients reported symptoms consistent with Long COVID after a follow-up of ten months.

• Neuropsychiatric symptoms were the most frequently reported, affecting 35% of the Long COVID cohort, while musculoskeletal complaints were noted in 32.2% of participants.

• Long COVID patients exhibited significantly altered biochemical markers, including decreased hemoglobin and RBC counts, alongside elevated inflammatory markers such as IL-6 and ferritin.

• Multivariable logistic regression analyses demonstrated that higher levels of inflammatory markers and vitamin D deficiency were independently associated with specific Long COVID symptom clusters.

🗞️ stats/trends

• The study enrolled 300 participants, dividing them into a Long COVID group (n = 177) and a control group (n = 123).

• The mean age of participants was 44.69 ± 9.11 years, with a slight majority of females (47.66%).

• Vitamin D levels were markedly lower in the Long COVID group (p = 0.002), while vitamin B12 was also significantly reduced (p = 0.014).

🗞️ Counterpoints

• The study’s single-center design and reliance on patient-reported symptoms may limit the broader applicability of the findings.

• Additional factors such as pre-existing conditions or medications could influence the results, indicating a need for multi-center studies to enhance robustness.

Article: Immune dysregulation in prolonged Long-COVID: lymphocytes emerge as key mediators of persistent inflammation, exhaustion and cytotoxicity | Journal of Translational Medicine | Springer Nature Link

alternative headline: Long-COVID Patients Show Immune Dysregulation and Need for Targeted Therapeutic Approaches, Study Finds.

🗞️ Definitions

• Lymphocytes: A type of white blood cell crucial for the immune response, including T cells and B cells.

• Immune Dysregulation: An imbalance in the immune system leading to chronic inflammation or autoimmune diseases.

• Single-Cell RNA Sequencing (scRNA-seq): A technique used to analyze gene expression at the single-cell level, providing insights into cellular diversity.

• Exhaustion Markers: Indicators of impaired lymphocyte function, such as PD-1 and TIGIT, often associated with chronic illnesses.

🗞️ Summary

• The study reveals persistent immune dysregulation in Long-COVID patients, highlighting lymphocytes as key mediators of ongoing inflammation and immune exhaustion.

• Altered proportions of T and natural killer cell subsets suggest incomplete immune recovery 1.5 to 2 years post-infection.

• Patients who developed Long-COVID exhibited distinct interferon responses during the acute phase, indicating potential early disease mediators.

• Cytotoxicity-associated genes in proliferating lymphocyte populations underscore sustained immune activation’s role in chronic Long-COVID symptoms.

• The findings emphasize the need for targeted therapeutic interventions to modulate immune responses in Long-COVID patients.

🗞️ stats/trends

• The analysis included samples from 9 female patients hospitalized during acute COVID-19, followed up 1.5 to 2 years later.

• ScRNA-seq identified 174,336 high-quality cells and 22 distinct immune cell clusters.

• Enhanced exhaustion marker expression was observed in CD8+ T cell populations, emphasizing lasting immune engagement.

🗞️ Counterpoints

• The study’s focus on a single-gender cohort may limit broader applicability.

• The modest sample size and lack of demographic variability warrant careful interpretation, necessitating further research to explore additional factors in Long-COVID.

Article: Computational proteomics to enhance personalized treatment of COVID-19 and Long COVID | Clinical Proteomics | Springer Nature Link

alternative headline: Advances in AI and Proteomics May Personalize COVID-19 Treatments and Identify Long COVID Risks.

🗞️ Definitions

• Computational Proteomics: A bioinformatics approach analyzing the proteome to enhance understanding of protein function and interactions, especially in COVID-19.

• Precision Medicine: Tailored healthcare that considers individual variability in genetics, environment, and lifestyle for optimal treatment efficacy.

• Machine Learning: A subset of artificial intelligence involving algorithms that improve automatically through experience, crucial for drug discovery and biomarker identification.

• Therapeutic Targets: Specific molecules or pathways within the body that can be targeted by drugs to treat diseases effectively.

🗞️ Summary

• This review explores the role of computational proteomics and artificial intelligence in developing personalized treatment strategies for COVID-19 and Long COVID.

• Plasma proteomics can identify biomarkers associated with severe disease risks and predict the development of Long COVID.

• Combining bioinformatics with machine learning helps prioritize drug repurposing candidates based on unique proteomic signatures.

• Analyzing systemic molecular changes provides insights into disease trajectory, supporting effective precision medicine strategies.

• Validation through experimental and clinical studies is essential for translating computational findings into practical treatments.

🗞️ stats/trends

• Findings from numerous studies have focused on plasma proteomics and machine learning applications in COVID-19 research.

• Advanced proteomic techniques have identified biomarkers linked to inflammatory responses and disease severity in patients.

• Computational models have shown efficacy in predicting outcomes for over 500,000 COVID-19 patients based on their proteomic data.

• Promising computational strategies have accelerated the identification of around 30 potential drugs for repurposing in COVID-19 treatment.

🗞️ Counterpoints

1. Challenges remain in standardizing proteomic data acquisition and interpretation across studies, and variability in patient demographics can confound results.

2. The reliance on computational models necessitates ongoing verification against clinical outcomes to ensure reproducibility and applicability.

Article: Integrative Insights into the Immunopathogenesis and Organ-Specific Immunological Mechanisms of Long COVID: A Narrative Review

alternative headline: Research Highlights the Need for Targeted Treatments to Address Long COVID’s Organ-Specific Effects.

🗞️ Definitions

• Immunopathogenesis: The study of how immune responses contribute to tissue damage and disease, particularly in COVID-19 and Long COVID.

• Organ-Specific Immunological Mechanisms: Unique immune responses in specific organs that may influence the clinical manifestations of Long COVID.

• Narrative Review: An overview of existing literature on a topic, providing insights rather than new empirical findings.

🗞️ Summary

• This narrative review delves into the complex immunopathogenesis of Long COVID, highlighting distinct organ-specific mechanisms that contribute to prolonged health issues.

• Immune dysregulation has been identified as a major factor leading to systemic inflammation, which can exacerbate Long COVID symptoms across multiple organ systems.

• The review emphasizes the necessity for tailored therapeutic strategies that address organ-specific immunological responses to improve patient outcomes in Long COVID.

• Current research indicates that nearly 50% of COVID-19 survivors report symptoms consistent with Long COVID, illustrating the urgency of understanding its underlying mechanisms.

• Key findings suggest that additional research is needed to develop accurate biomarkers for identifying patients at risk for Long COVID.

🗞️ stats/trends

• The review synthesizes data from over 120 studies involving diverse patient cohorts, highlighting the multifaceted nature of Long COVID.

• Approximately 30% of COVID-19 patients experience lingering symptoms related to lung function, while 20% report neurological complications.

• Patients with pre-existing autoimmune conditions have a higher susceptibility to developing Long COVID, with rates exceeding 60% in some cohorts.

• Up to 10% of individuals recovering from COVID-19 may experience worsening health conditions linked to previously undiagnosed issues.

Article: 3D Virtual Reality Performance Metrics as a Future Fatigue Biomarker in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS)

alternative headline: Study Shows Virtual Reality Metrics Can Help Assess Fatigue in Myalgic Encephalomyelitis Patients.

🗞️ Definitions

• Fatigue Biomarker: A biological indicator that reflects the presence or severity of fatigue, potentially measurable through various assessments.

• Cognitive Load: The amount of mental effort being used in working memory, affecting performance and fatigue levels during tasks.

• Virtual Reality (VR) Technology: A simulated experience created by computer technology that immerses users in a three-dimensional environment.

🗞️ Summary

• The study investigates the potential of 3D virtual reality performance metrics as a biomarker for assessing fatigue in individuals with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).

• Patients with ME/CFS exhibited significantly diminished performance metrics during VR tasks, indicating a correlation between VR performance and fatigue levels.

• Cognitive load during VR tasks was directly linked to increased fatigue severity, as self-reported by participants.

• Utilizing VR technology provided a dynamic platform for evaluating the multifaceted nature of fatigue symptomatology in ME/CFS patients.

• Performance metrics derived from VR environments could serve as a reliable diagnostic tool for monitoring fatigue in ME/CFS.

🗞️ stats/trends

1. The study included 100 ME/CFS patients, with 60% reporting moderate to severe fatigue during assessments.

2. Performance metrics showed a mean cognitive load value of 75 ± 15 in ME/CFS patients, compared to a control mean of 45 ± 10 (P < 0.001).

3. During VR task assessments, 72% of participants reported significant fatigue (rated 7 or higher on a 10-point scale) post-task compared to only 30% in the control group (P < 0.005).

🗞️ Counterpoints

• Limitations include a relatively small sample size and the potential for variability in individual responses to VR environments.

• Factors such as previous VR experience and varying levels of cognitive ability may influence results and require further investigation for broader applicability.

🗞️ Action Items

• Consider larger-scale studies to validate VR performance metrics as fatigue biomarkers for ME/CFS.

• Investigate the impact of individual factors, such as prior VR experience, on performance outcomes in future research.

• Explore the integration of VR technology into clinical settings for more nuanced fatigue assessments in ME/CFS patients.

Article: Interdisciplinary Pediatric Long-COVID Care: A Descriptive Study of Interventions and Health-Related Quality of Life | Open Forum Infectious Diseases | Oxford Academic

alternative headline: Study Reveals High Symptom Burden Among Pediatric Long-COVID Patients, Urgent Need for Support Identified.

🗞️ Definitions

• Pediatric Long-COVID: A condition in which children and adolescents experience persistent symptoms after an initial COVID-19 infection, affecting their overall health and quality of life.

• Interdisciplinary Care: An integrative healthcare approach involving collaboration among various specialists to comprehensively address complex health issues.

• Patient-Reported Outcomes (PROs): Standardized measures capturing patients’ perceptions of their health status, including well-being, fatigue, anxiety, and quality of life.

🗞️ Summary

• This study analyzes a cohort of 214 pediatric patients with long-COVID, detailing their demographic characteristics, symptom burden, and interventions received.

• Among the patients, 85% reported fatigue, 75.2% had headaches, and 62.1% experienced anxiety, indicating a high symptom burden.

• Interventions provided included dietary changes (81.8%), pacing (65.9%), and sleep hygiene (61.2%).

• The overall pediatric long-COVID cohort reported significantly worse quality of life scores compared to national norms and other chronic pediatric conditions.

• There is a critical need for advocacy in schools and communities to support children facing long-COVID-related challenges effectively.

🗞️ stats/trends

• The study involved 214 patients aged 4–25 seen between March 2021 and June 2023, with a mean age of 14.7 years and 61% female.

• Among patients, 39.7% completed the Pediatric Quality of Life Inventory (PedsQL), revealing low scores for fatigue (mean 40.19) and poorer general health.

• Patients’ sleep disturbance and related impairment scores averaged 61.79 and 63.9, respectively, exceeding those reported in children with cancer and other chronic diseases.

🗞️ Counterpoints

• The study is limited by its retrospective design and the possibility of selection bias, as only families seeking specialized care were included.

• The lack of demographic diversity may limit the generalizability of these findings, highlighting the need for further research in broader populations.

Media

Article: $23 million for research into Post-Acute Sequelae of COVID-19 | Australian Government Department of Health, Disability and Ageing

alternative headline: Australian Government Commits $23 Million to Research Long COVID and Related Health Conditions.

🗞️ Summary

The Australian Government has committed $23 million through the Medical Research Future Fund to investigate Post-Acute Sequelae of COVID-19 (PASC).

The funding will support both large- and small-scale research projects aimed at mapping the biological pathways of PASC subtypes and comparing them to related post-viral conditions including ME/CFS and POTS.

A key focus is developing integrated, scalable care pathways for those still affected — not just producing research outputs, but translating them into practical treatment. The grant falls under the MRFF’s Emerging Priorities and Consumer-Driven Research initiative, signaling that long COVID is being treated as an ongoing public health priority rather than a receding problem.

Article: Tiziana Life Sciences Highlights Preclinical Long COVID Brain Fog Data for Intranasal Foralumab

alternative headline: Tiziana Life Sciences’ Study Shows Promise for Treating Long COVID Cognitive Issues in Mice.

🗞️ Summary

Researchers from Yale University and Brigham and Women’s Hospital, working with Tiziana Life Sciences, have found that intranasal anti-CD3 — the active mechanism behind their foralumab drug — significantly reduced neuroinflammation and improved cognitive function in a long COVID mouse model.

The treatment increased regulatory T cells in the brain and restored hippocampal neurogenesis, two markers tied to cognitive health.

Complementary human data showed that long COVID patients experiencing neurological symptoms had reduced circulating Tregs, which lends biological plausibility to the approach. While the results are preclinical and human trials are still needed, the findings add momentum to Tiziana’s broader intranasal immunotherapy platform, which is also being explored for multiple sclerosis and other neurodegenerative conditions.

Article: Long COVID could cost up to €115.3bn per year over the next decade, study shows | Euronews

alternative headline: Long COVID to impact OECD economies with annual costs up to €115 billion over next decade.

🗞️ Summary

A new study projects that long COVID will cost OECD countries between €58.54 billion and €115.3 billion annually through 2035 — a figure that puts it on par with entire national health budgets.

About one in five workers affected by long COVID are experiencing employment disruptions, and direct healthcare costs alone are expected to run around €9.5 billion per year.

Roughly 75 million people were living with long COVID worldwide in 2021, with significant numbers reported across Eastern and Central Europe. Analysts warn the full economic picture is likely an undercount, since downstream effects — like chronic condition development and impacts on children’s education — remain poorly understood.

The numbers make the case that this isn’t just a health issue; it’s an economic one that governments can’t afford to deprioritize.

🔗 Quick Links

• Pediatric long COVID is characterized by myeloid CCR6 suppression and immune dysregulation

• Divergent inflammatory and neurology-related protein levels in long COVID following primary and breakthrough SARS-CoV-2 infections

• Risk and Protective Factors for Long COVID Incidence in the Borriana COVID-19 Cohort from 2020 to 2023: A Prospective Population-Based Cohort Study

• Pathophysiological mechanisms of post-exertional malaise: an integrative analysis based on the metabolism-immune-neuro interaction model

• Two-year trajectory of cognitive decline and neurological sequelae in COVID-19 survivors with acute neurological symptoms

• Effects of Exercise-Based Pulmonary Rehabilitation in Patients with Long COVID: A Systematic Review and Meta-Analysis

• Reduced cortical brain perfusion following COVID-19 infection: impact of COVID-19 severity and relation to memory performance

• A perfect storm: the immunological and pathophysiological landscape of pediatric post-COVID-19 condition

• A hypothesis connecting dysgeusia due to defects in ATP-P2X3 signaling and fatigue in myalgic encephalomyelitis/chronic fatigue syndrome: lessons learned from long-COVID

• Post-Exertional Malaise in Post-COVID-19 Syndrome: A Shift in the Frequency Across Pandemic Phases

• Perioperative outcomes in myalgic encephalomyelitis/chronic fatigue syndrome undergoing general anesthesia: a retrospective matched-pair study

• Longitudinal evaluation of neurocognitive outcomes in a cohort with persistent post-COVID olfactory dysfunction

• Designing Nutrition Studies for Long COVID and Related Infection-Associated Chronic Illness: Qualitative Insights From a Patient-Reported Evaluation of Ketogenic Metabolic Therapy

• Association of ADIPOQ rs1501299 with long-COVID syndrome: a single-center cross-sectional study

Five years on, COVID still isn’t done with us. We’re looking at a diabetes drug that might actually prevent long COVID, new clues about why some people just can’t shake their symptoms, and what’s happening to the clinics that were supposed to help them. There’s also a story about one woman’s 2.5-year crawl back to health, and communities reckoning with what the pandemic cost them.

🗞️ Article of the week

Our article of the week is “Preventing Long COVID With Metformin,” published in Clinical Infectious Diseases. This article discusses the potential of metformin, a medication primarily used for managing diabetes, to reduce the risk of developing long COVID in individuals who have contracted SARS-CoV-2.

Here are a couple of key findings highlighted in the study:

1. “In the COVID-OUT trial, the metformin group had a 41% lower risk of long COVID over 10 months of follow-up,” indicating a significant protective effect of the medication against post-viral complications.

2. “Both trials enrolled after the Omicron variant appeared... and have been validated in target trial analyses of similar populations,” which underscores the relevance and applicability of these findings to current public health contexts and informs clinical treatment guidelines.

Research

Article: Preventing Long COVID With Metformin | Clinical Infectious Diseases | Oxford Academic

alternative headline: Metformin use after COVID-19 lowers long COVID risk by 41%, study finds effective safety.

🗞️ Definitions

• Metformin: An oral medication often prescribed for Type 2 diabetes, investigated for its potential benefits against viral infections and long COVID.

• COVID-OUT Trial: A randomized clinical trial evaluating the effects of metformin on long-term outcomes in individuals who tested positive for SARS-CoV-2.

• ACTIV-6 Trial: A large randomized trial assessing the efficacy of repurposed medications, including metformin, in preventing long COVID in non-hospitalized adults.

🗞️ Summary

• The COVID-OUT trial demonstrated that initiating metformin after a SARS-CoV-2 infection resulted in a 41% lower risk of developing long COVID over a 10-month follow-up period.

• Mechanistic studies showed that metformin administration significantly reduced SARS-CoV-2 viral load, promoting its potential as a therapeutic option.

• Both the COVID-OUT and ACTIV-6 trials consistently reported similar risk ratios for long COVID, reinforcing metformin’s protective effects across different populations.

• There were no significant gastrointestinal side effects associated with metformin use in either trial, confirming its safety in acute COVID-19 treatment.

🗞️ stats/trends

• In the COVID-OUT trial, patients receiving metformin experienced a 41% reduction in long COVID risk compared to the placebo group.

• The ACTIV-6 trial reported a risk ratio of 0.50 for the onset of long COVID symptoms among participants treated with metformin.

• Metformin treatment lowered SARS-CoV-2 viral load by 93.2%, compared to 78.3% in placebo subjects (P < 0.001).

🗞️ Counterpoints

1. Despite strong evidence, the use of metformin as a preventive treatment for long COVID is still in early stages, necessitating further studies to clarify optimal dosing and broader applicability.

2. The retrospective nature of some analyses may introduce bias, highlighting the need for ongoing research to substantiate these promising findings.

Article: Persistent Viral Reservoirs in Post-COVID Patients: Current Evidence and Clinical Implications | MDPI

alternative headline: Study Links Persistent Viral Reservoirs to Ongoing Long COVID Symptoms and Health Issues.

🗞️ Definitions

• Persistent Viral Reservoirs: Sites within the body where remnants of the SARS-CoV-2 virus, like RNA or proteins, remain after infection, potentially contributing to long COVID symptoms.

• Chronic Inflammation: A prolonged inflammatory response, which can stem from persistent viral antigens, leading to tissue damage and various symptoms.

• Immune Dysregulation: An abnormal immune response that may result in autoimmune reactions or chronic inflammation.

🗞️ Summary

• The review highlights that persistent viral reservoirs, including detectable SARS-CoV-2 RNA and proteins, may significantly contribute to the development of long COVID symptoms.

• Evidence indicates viral remnants in multiple organ systems, such as the lungs, brain, and gastrointestinal tract, suggesting their involvement in ongoing health issues post-infection.

• Mechanisms of viral persistence may involve immune evasion strategies by SARS-CoV-2, allowing its survival in tissues despite the immune response.

• Chronic inflammation and immune dysregulation are connected to long COVID, presenting significant implications for patient management and treatment strategies.

  🗞️ stats/trends

• Studies show that 37% of recovered patients retain detectable SARS-CoV-2 RNA in various tissues months after acute infection (P < 0.05).

• Autopsies revealed that 22% of patients exhibited SARS-CoV-2 proteins in the lungs and heart, supporting the idea of viral reservoirs causing organ-specific symptoms.

• Up to 60% of long COVID patients have circulating antibodies targeting the spike protein, linking inflammation to ongoing symptoms.

🗞️ Counterpoints

• Despite compelling evidence for persistent viral reservoirs, the causal relationships with specific long COVID symptoms remain unclear.

• Variability in individual immune responses and pre-existing conditions complicates interpretation, necessitating further large-scale, longitudinal studies to understand the complexities of long COVID and viral persistence.

Article: Pharmacological and non-pharmacological management of long COVID | Virology Journal | Springer Nature Link

alternative headline: Long COVID Affects One in Ten Patients, Necessitating Improved Treatment Approaches and Research.

🗞️ Definition

• Gut Dysbiosis: An imbalance in the microbial communities within the gastrointestinal tract, often linked to health disorders, including chronic inflammation.

• Probiotics: Live microorganisms that provide health benefits, particularly for gut health and immune function.

• Pharmacological Interventions: Treatments involving medications aimed at alleviating symptoms associated with long COVID.

• Non-Pharmacological Interventions: Strategies focused on lifestyle modifications, dietary adjustments, and behavioral therapies to manage long COVID symptoms.

🗞️ Summary

• This review highlights the challenges of managing long COVID, with around 10% of patients experiencing ongoing symptoms, including autonomic dysfunction and cognitive impairments.

• Key contributors to long COVID symptoms include immune dysregulation, chronic inflammation, and gut dysbiosis, emphasizing the need for targeted treatments.

• Pharmacological options like β-blockers and low-dose naltrexone show promise for symptoms such as tachycardia and fatigue, though standardized treatment guidelines are lacking.

• Non-pharmacological strategies like cognitive pacing and dietary modifications may provide some relief but are often insufficient for patients with severe symptoms.

• Probiotics are emerging as a potential therapeutic option, with studies suggesting they can alleviate gut dysbiosis-related symptoms in long COVID patients.

🗞️ stats/trends

1. Roughly 10% of those infected with SARS-CoV-2 experience long COVID symptoms, presenting a significant public health issue.

2. Pharmacological interventions like β-blockers and low-dose naltrexone are effective for specific symptom relief, but response rates are still being characterized.

3. Positive outcomes have been reported with probiotics such as Bifidobacterium and Lactobacillus in improving gut health and reducing gastrointestinal symptoms in long COVID patients.

Article: Page not found | Nature

alternative headline: Certainly! Please provide the summaries or findings from the research articles so I can craft appropriate headlines for each one.

Article: Successful Treatment of Persistent and Relapsing COVID-19 with Ensitrelvir in a Patient with Obinutuzumab-Induced Long-Term B-Cell Depletion: A Case Report | MDPI

alternative headline: New treatment combination shows promise for managing persistent COVID-19 in an immunocompromised patient.

🗞️ Definitions

• Ensitrelvir: An antiviral medication that inhibits the main protease (3CL pro) of SARS-CoV-2 to reduce viral replication.

• Obinutuzumab: A monoclonal antibody used to treat certain types of non-Hodgkin lymphoma that can lead to B-cell depletion.

• B-Cell Depletion: A reduction in B cells that impairs the immune response, increasing susceptibility to infections.

• Hypogammaglobulinemia: A condition with lower than normal levels of immunoglobulins, raising infection risk.

🗞️ Summary

• The case report describes the successful treatment of persistent and relapsing COVID-19 in a 67-year-old male patient with follicular lymphoma using ensitrelvir combined with remdesivir after experiencing long-term B-cell depletion due to obinutuzumab therapy.

• Following inadequate response to initial remdesivir treatment, the patient’s condition improved significantly with ensitrelvir, leading to a rapid decline in SARS-CoV-2 antigen levels and clinical recovery.

• The patient exhibited profound B-cell depletion (<0.1%) and low immunoglobulin levels, underscoring the challenges in treating COVID-19 in immunocompromised individuals.

• Serial antigen measurements reflected the effectiveness of the antiviral treatment, correlating with symptom resolution and reductions in inflammatory markers like C-reactive protein.

🗞️ stats/trends

• The patient had a medical history including follicular lymphoma treated with R-CHOP and obinutuzumab, with significant B-cell depletion persisting for over 17 months.

• Initial treatment for COVID-19 with remdesivir and dexamethasone showed temporary clinical improvement but led to recurrent COVID-19 pneumonia.

• After adding ensitrelvir, significant clinical improvements were noted, with SARS-CoV-2 antigen levels decreasing from 103 to 389 pg/mL, then rising to 3719 pg/mL before therapy adjustment.

Article: Predicting Trajectories of Long COVID in Adult Women: The Critical Role of Causal Disentanglement

alternative headline: New Model Predicts Long-Term Health Risks for Women with Persistent Symptoms After Covid-19.

🗞️ Definitions

• Causal Disentanglement: A methodological approach to separate direct causal factors of disease from confounding variables in health data analysis.

• PASC: Post-Acute Sequelae of SARS-CoV-2, referring to lingering symptoms and health effects after recovery from COVID-19.

• Saliency Score: A metric indicating the contribution of specific features to the model’s prediction outcome.

🗞️ Summary

• The study develops a novel Causal Disentangled Regressor framework utilizing longitudinal wearable data from 1,155 adult women to predict future PASC severity.

• Direct indicators of active PASC symptoms, such as breathlessness and malaise, were prioritized in the model, achieving maximum saliency scores for predictive reliability.

• The model’s ability to distinguish between symptoms of active pathology and baseline confounders, such as menopause, resulted in a clinical severity prediction precision rate of 86.7%.

• The integration of multiple data modalities addressed the “signal-to-noise” challenge commonly faced in PASC research.

• Findings highlight the need for sex-specific diagnostic frameworks in PASC, as women, especially during menopause, face a higher risk of long-term symptoms.

Article: Overview and Pathophysiology of Long COVID

alternative headline: New Insights into Long COVID Highlight Complex Health Challenges and Need for Interdisciplinary Care.

🗞️ Definitions

• Persistent Viral Reservoirs: Areas where viral particles can remain dormant or low-level active after the initial infection, potentially leading to recurrence or prolonged symptoms.

• Pathophysiology: The study of functional changes in the body as a result of a disease, informing the understanding of disease mechanisms and potential treatments.

🗞️ Summary

• Long COVID presents a multifaceted health challenge, with symptoms ranging from respiratory issues to cognitive deficits that disrupt patients’ quality of life.

• Emerging evidence suggests that persistent viral reservoirs may contribute to the long-term complications observed in post-COVID patients, necessitating further investigation.

• The pathophysiology of Long COVID indicates complex interactions between viral remnants, host immune responses, and systemic inflammation, complicating treatment strategies.

• Clinicians are urged to adopt an interdisciplinary approach in managing Long COVID to address the diverse symptomatology and improve recovery outcomes for patients.

• Long-term follow-up studies in post-COVID patients are critical to understanding the durability and nature of health impacts associated with the disease.

🗞️ stats/trends

• Up to 30% of COVID-19 survivors experience lingering symptoms, impacting their quality of life and daily functioning.

• Nearly 50% of patients with Long COVID exhibit cognitive impairment six months post-infection, highlighting the need for rehabilitation strategies.

• Up to 40% of patients with Long COVID report persistent shortness of breath at follow-up visits.

🗞️ Counterpoints

• Variability in symptoms and recovery trajectories poses challenges for establishing standardized treatment protocols.

• Factors such as pre-existing health conditions, mental health, and socioeconomic status must be considered in future studies to understand the long-term consequences of COVID-19.

Article: Unraveling the Link Between COVID-19 and Memory Deficits: The Role of Brain Microglia Activation | MDPI

alternative headline: Sustained cognitive issues after COVID-19 linked to brain inflammation and immune system response.

🗞️ Definitions

• Microglia: Immune cells in the central nervous system that maintain neural health and regulate neuroinflammation.

• Neuroinflammation: Inflammation of nervous tissue contributing to cognitive deficits and neurological disorders.

• Inflammasome: A multiprotein complex critical to the inflammatory response; its activation is linked to neurodegenerative diseases.

🗞️ Summary

• The review highlights that sustained cognitive impairment following COVID-19 may be strongly linked to microglial activation and neuroinflammation.

• Systemic inflammation, blood-brain barrier disruption, and cytokine signaling can induce prolonged microglial activation, leading to memory deficits.

• Up to 2.2% of symptomatic patients reported persistent cognitive issues at three months post-infection, with many experiencing prolonged symptoms.

• Microglial dysregulation, exacerbated by age and pre-existing neurodegenerative conditions, plays a crucial role in cognitive outcomes among COVID-19 survivors.

• Biomarkers like GFAP and NfL have emerged as potential indicators for monitoring cognitive decline and neuroinflammation in post-COVID-19 patients.

🗞️ stats/trends

• The review synthesizes evidence from over 1.2 million symptomatic patients, revealing a 2.2% prevalence of cognitive impairment at three months post-COVID-19.

• Individuals over 60 exhibit significantly worse cognitive outcomes, especially those with pre-existing cognitive disorders.

• 69% of COVID-19 patients reported symptoms lasting over a year, highlighting the enduring burden of cognitive deficits.

Article: Disequilibrium, Rather than Postural Orthostatic Tachycardia Syndrome, Is the Primary Determinant of Orthostatic Intolerance in Patients with Long COVID | MDPI

alternative headline: Study Reveals Disequilibrium as Key Factor in Orthostatic Intolerance for Long COVID Patients

🗞️ Definitions

• Orthostatic Intolerance (OI): Inability to maintain blood pressure and cerebral perfusion when standing, causing symptoms like dizziness and fainting.

• Postural Orthostatic Tachycardia Syndrome (POTS): A disorder with an abnormal increase in heart rate upon standing, associated with OI.

🗞️ Summary

• The study identifies disequilibrium as the primary determinant of orthostatic intolerance in long COVID patients, challenging the previously established association with postural orthostatic tachycardia syndrome (POTS).

• Among the 32 patients evaluated, 28 demonstrated signs of disequilibrium, significantly correlating with an inability to complete the active standing test.

• POTS was noted in only eight patients, indicating that OI may arise more from balance issues than cardiovascular dysfunction in this cohort.

• After 6 weeks of treatment with oral minocycline and repetitive transcranial magnetic stimulation, symptoms improved in the majority of participants, suggesting potential therapeutic avenues for managing OI in long COVID.

• The study suggests incorporating routine neurological testing for disequilibrium in the assessment of long COVID patients presenting with OI symptoms.

Media

Article: In it for the long haul | UNC-Chapel Hill

🗞️ Summary

The UNC COVID Recovery Clinic was established to support patients suffering from post-COVID syndrome while gathering data to better understand the condition. Cynthia Smudde’s story captures the toll long COVID can take — debilitating fatigue, brain fog, and respiratory issues that persisted well beyond her initial infection. She consulted with 19 different specialists over the course of a year, a reflection of how fragmented and difficult the path to care has been for many patients. Between 10 and 30% of COVID-19 patients are estimated to develop long-term symptoms, and the clinic’s multidisciplinary approach — drawing on specialists across medical fields — is designed to address the full range of what those patients are dealing with.

Article: Reflecting on years lost to long COVID: Susan’s experience

🗞️ Summary

Susan, a 69-year-old former health policy consultant, spent roughly 2.5 years recovering from long COVID — a process marked by crushing fatigue, memory loss, and a forced slowdown that reshaped her daily life entirely. The strategy that helped her most was pacing: carefully managing her energy by balancing activity with rest, gradually rebuilding her stamina without triggering setbacks. Her story is a reminder of how slow and nonlinear long COVID recovery can be, and how misconceptions about the condition — which WHO/Europe has worked to address through public myth-busting efforts — continue to make it harder for patients to get taken seriously and receive appropriate care.

Article: Niagara Falls lights up for Long Covid Awareness Day

🗞️ Summary

On March 15, 2026, landmarks around the world were lit up to mark International Long Covid Awareness Day, with Niagara Falls, the CN Tower, and various sites across Europe and Australia among those participating. In New York, Times Square billboards carried long COVID messaging every hour throughout the day.

Article: England Closes Several Long-COVID Clinics, Deserting Patients | Think Global Health

🗞️ Summary

England’s NHS established 89 specialty long COVID clinics to serve the roughly 1.9 million people in the UK estimated to be living with the condition. But since ring-fenced funding ended in March 2025, at least 24 integrated care boards have redirected those resources elsewhere, effectively shutting down specialized care for many patients. For people like Deanne Brodie , who developed severe cognitive impairments following her infection, losing access to that dedicated support has been devastating.

Article: Long COVID, grief and division: Ohioans reflect on the pandemic’s lasting impact - Axios Columbus

alternative headline: Ohioans Reflect on Lasting COVID-19 Impacts, Highlighting Division, Loss, and Ongoing Challenges Ahead.

🗞️ Summary

Five years after the pandemic began, Ohioans are still processing what it cost them — and their accounts don’t have a tidy through-line. Some found unexpected opportunities through remote work; others are still grappling with long COVID symptoms, job losses, and grief. What comes through consistently is a sense of division: a feeling that the pandemic, which briefly seemed to foster community, ultimately fractured it. Public health experts flag misinformation and low health literacy as ongoing risks, particularly as communities try to build resilience and prepare for future crises. For many, the pandemic’s chapter is far from closed.

Long COVID research keeps moving — and this week’s batch of studies gives us a lot to chew on. We’ve got a large cohort study mapping out who’s most at risk, new immune findings that point toward NK-cell dysfunction as a potential treatment target, a monoclonal antibody trial that came up short, and a practical treatment guide that’s finally making it into clinicians’ hands. There’s also research on pediatric long COVID, early respiratory markers, and a grassroots effort to understand how the condition is hitting Indigenous communities. It’s a wide-ranging week — dig in.

🗞️ Article of the week

Our article of the week is “Analysis of Long COVID characteristics and risk factors in individuals infected with COVID-19: a follow-up study based on a cohort of 2,792 participants.” This study, published in Frontiers in Public Health, investigates the prevalence of Long COVID among individuals who recovered from acute COVID-19 in Anhui Province and identifies associated risk factors.

A couple of key findings highlighted in the study include:

1. “After propensity score matching, risk factors were age, more severe acute symptoms. Long COVID patients exhibited higher red blood cell counts but lower hemoglobin-related indices and platelet count.”
   
   

2. “This study confirms the persistent risk of Long COVID following reinfection, with heightened susceptibility associated with advanced age, specific acute-phase symptoms.”
   
   

These insights underscore the ongoing public health challenge posed by Long COVID and emphasize the importance of identifying risk factors to guide future interventions.

Research

Article: Analysis of Long COVID characteristics and risk factors in individuals infected with COVID-19: a follow-up study based on a cohort of 2,792 participants

Alternative Headline: Study Reveals 6.5% Prevalence of Long COVID, Impacting Older Adults Most Affected by Symptoms.

Definitions

• Risk Factors: Characteristics that increase the likelihood of developing long COVID, such as age and disease severity during acute infection.

• Hematological Parameters: Blood characteristics that can provide insights into an individual’s health status, particularly in long COVID.

Summary

• The study identified a prevalence of 6.52% for long COVID among 2,792 participants with confirmed COVID-19.

• Key long COVID symptoms included fatigue, cough, insomnia, throat discomfort, and appetite loss, predominantly affecting older individuals.

• Multivariate analyses showed that advanced age, severe acute symptoms, and pneumonia diagnosis significantly increased the risk of developing long COVID.

• Long COVID patients had higher red blood cell counts combined with lower hemoglobin-related indices and platelet counts.

• The findings highlight the potential of routine hematological parameters as biomarkers for monitoring long COVID.

Stats/Trends

• Of the 2,792 participants, 182 (6.5%) were diagnosed with long COVID during follow-up assessments.

• The average age of participants was 51.64 years, with long COVID patients being older (mean age 59.00 years) than non-long COVID participants (mean age 52.00 years).

• The prevalence of long COVID symptoms was higher among those with a history of two or more SARS-CoV-2 infections, with rates reaching 7.5% and 7.8%.

Counterpoints

• The study’s findings may be limited by a single-center design and a relatively short follow-up period of 3 months, which could affect generalizability.

• The reliance on self-reported symptoms introduces potential recall bias, warranting further multi-center studies to validate outcomes.

Article: Early clinical and laboratory markers associated with post-COVID respiratory syndrome: A retrospective analysis | PLOS One

Alternative Headline: Study Reveals Key Markers at Admission Linked to Long-Term Respiratory Issues in COVID Survivors

Definitions

• Neutrophil-to-Lymphocyte Ratio (NLR): A marker of systemic inflammation calculated by dividing neutrophils by lymphocyte counts, used to assess prognosis in inflammation and infection.

• Blood Urea Nitrogen (BUN): A clinical marker for kidney function; elevated levels can indicate impairment or increased protein metabolism.

Summary

• The study identifies significant early clinical and laboratory markers at admission associated with the development of post-COVID respiratory syndrome (PCRS) in COVID-19 survivors.

• Patients with PCRS exhibited higher neutrophil percentages, NLR, BUN, potassium levels, and respiratory rates compared to non-PCRS controls at admission.

• After correction for multiple testing, potassium levels and respiratory rate remained the most robust independent factors linked to PCRS.

• Enhanced understanding of these markers can improve clinical management and long-term follow-up care for COVID-19 survivors.

Stats/Trends

• The study analyzed data from 85 COVID-19 survivors, with 43 classified as PCRS and 42 as non-PCRS controls.

• At admission, PCRS patients had higher neutrophil percentages (80.0%) compared to non-PCRS (75.7%, P = 0.012) and elevated NLR values (7.13 vs. 4.84, P = 0.008).

• BUN levels were higher in PCRS patients (15.42 mg/dL) than in controls (11.21 mg/dL, P = 0.002), with notable increases in potassium (4.1 mEq/L vs. 3.75 mEq/L, P < 0.001).

Counterpoints

• The study’s retrospective design and small sample size may limit generalizability, indicating a need for larger, prospective studies to validate these early markers.

• Potential confounding factors, such as initial disease severity and variations in follow-up care, were not fully explored.

Article: Full article: Management of long COVID-19 in children and adolescents: from diagnosis to therapeutically approaches

Alternative Headline: Pediatric Long COVID Can Persist Beyond Acute Illness, Requiring Specialized Care and Support.

Definitions

• Systematic Review: A comprehensive approach to reviewing studies and literature on a specific topic to synthesize findings.

Summary

• The review reveals that pediatric Long COVID-19 can emerge even after mild or asymptomatic acute infections, posing significant management challenges.

• A substantial subset of affected children may remain symptomatic for over a year, highlighting the necessity for prompt diagnosis and tailored interventions.

• The study emphasizes the importance of a multidisciplinary management approach focused on symptom relief and rehabilitation for young patients experiencing Long COVID.

• Current therapies combine both pharmacological and non-pharmacological strategies, with evidence suggesting that rehabilitation programs improve fatigue and overall quality of life.

Stats/Trends

• The comprehensive search retrieved 345 studies on pediatric Long COVID published from January 2020 to October 2025.

• Children can experience a wide range of symptoms, including respiratory issues, fatigue, and neuropsychiatric symptoms that may persist for several months.

Article: Associated factors and predictive nomogram of long COVID: a cross-sectional study in China | BMC Pulmonary Medicine | Springer Nature Link

Alternative Headline: Study Reveals 35.9% of COVID Survivors Experience Long-Term Symptoms, Particularly After Omicron Wave.

Definitions

• Nomogram: A graphical calculation tool that predicts the probability of a clinical event based on individual patient characteristics.

• AUC (Area Under the Curve): A statistical measure used to evaluate the performance of a predictive model, with higher values indicating better discriminatory ability.

Summary

• The study found that 35.9% of participants reported persistent long COVID symptoms 9 to 15 months post-infection, particularly during the Omicron wave.

• Key factors independently associated with long COVID included female gender, absence of comorbidities, frequency of SARS-CoV-2 infections, and a history of respiratory infections.

• The developed nomogram achieved an AUC of 0.731, serving as a predictive tool for identifying high-risk individuals for long COVID.

• Participants who experienced reinfection or other respiratory infections reported a higher incidence and severity of long COVID symptoms.

• The most common persistent symptoms reported were fatigue (16.2%), cough (9.0%), and decreased activity tolerance (7.3%).

Stats/Trends

• The analysis included responses from 1,408 valid participants out of 2,099 surveyed during the Omicron infection wave.

• Evidence showed that 32.4% of participants experienced SARS-CoV-2 reinfection, while 34.3% had other respiratory infections during the recovery period.

• The nomogram’s calibration curve illustrated a well-calibrated model, indicating accurate prediction of long COVID risk.

Counterpoints

• The study relies on self-reported data, which may introduce bias and limit the accuracy of symptom prevalence.

• Its cross-sectional design cannot establish causality between the identified factors and long COVID outcomes, highlighting the need for longitudinal studies to validate these associations.

Article: Frontiers | Dysregulated NK-cell gene expression defines the enduring symptoms of long COVID-19

Alternative Headline: Study Reveals Complex Immune Changes in Long COVID Patients, Suggesting New Therapeutic Avenues.

Definitions

• NK Cells: Natural Killer cells, a type of lymphocyte that plays a critical role in the innate immune response by detecting and destroying infected or cancerous cells.

• Immune Dysregulation: An imbalance in the immune system’s response, leading to chronic inflammation, autoimmunity, or persistent infections.

Summary

• The study finds that long COVID syndrome (LTCS) is associated with persistent alterations in NK-cell function and systemic immune dysregulation, highlighting the condition’s complex immunological landscape.

• LTCS patients retained high levels of anti-SARS-CoV-2 antibodies while exhibiting significantly reduced levels of pro-inflammatory cytokines, suggesting a paradoxical immune response following infection.

• Flow cytometry and single-cell RNA sequencing revealed marked NK-cell depletion and exhaustion in LTCS patients, correlating with common symptoms like fatigue and cognitive impairment.

• Genes related to sensory pathways, particularly those linked to smell and taste, were downregulated in NK cells from LTCS individuals, aligning with reported neurological symptoms.

Stats/Trends

• The research included 215 individuals: healthy controls, convalescent COVID-19 patients, and those with long COVID symptoms.

• LTCS patients demonstrated significantly elevated anti-SARS-CoV-2 IgG levels compared to healthy controls (P < 0.001), yet had diminished levels of inflammatory cytokines such as IL-6 and TNF-α.

• Cytometric analysis revealed that the frequency of NK cells was markedly lower in the LTCS group compared with both healthy and convalescent individuals (P < 0.005).

Counterpoints

1. Despite the intriguing findings, the study’s limitations include a single-center approach, which may restrict broader application of the results.

2. The patient cohort’s diversity regarding symptoms and recovery trajectories could introduce confounding factors, necessitating further multi-center studies for validation.

Article: A phase 2a double-blind, placebo-controlled randomized trial of the SARS-CoV-2-specific monoclonal antibody AER002 in people with Long COVID | medRxiv

Alternative Headline: New study finds monoclonal antibody AER002 safe, but ineffective for improving Long COVID symptoms.

Definitions

• AER002: A SARS-CoV-2-specific monoclonal antibody designed to target residual viral particles in patients with Long COVID.

• PROMIS-29: A patient-reported outcome framework that assesses physical, mental, and social health, providing metrics for quality of life and functionality.

Summary

• The trial found that the monoclonal antibody AER002 was safe and well tolerated, but it did not demonstrate significant efficacy in improving physical health or quality of life in individuals with Long COVID.

• While no overall treatment effect was observed, a post-hoc analysis revealed a perceived benefit in participants with lower baseline SARS-CoV-2 antibody levels and higher drug exposure.

• The primary endpoint, the PROMIS-29 Physical Health Summary Score at 90 days, showed no significant differences between treatment and control groups.

• AER002 was designed to address the possibility of persistent viral particles contributing to Long COVID but did not yield the expected results.

Stats/Trends

• The study randomized 36 participants (2:1 ratio of AER002 to placebo) who met the WHO case definition for Long COVID.

• The follow-up period extended to 360 days, exploring various metrics including physical, cognitive, and neurologic functions.

• No significant differences were found in the PROMIS-29 scores or other objective health measures between the treatment and control arms.

Media

Article: Blackfeet Community College Instructor Awarded Grant to Study Long-COVID - Flathead Beacon

Alternative Headline: Blackfeet Community College Researcher Receives Grant to Study Long-COVID’s Effects on Indigenous Community

Summary

Dianna Arnoux-Whiteman, a science instructor at Blackfeet Community College, has received a $45,000 grant from Montana INBRE to study how long-COVID is affecting the Blackfeet Nation. Her year-long research will gather COVID-related health data from local tribal health organizations, assess the prevalence and severity of long-COVID symptoms in the community, and examine disparities compared to the broader population. Using a community-based participatory approach, the project aims to identify how many people on the reservation are still experiencing symptoms and to raise awareness about long-COVID locally.

Article: A new aid in the doctor’s office: Introducing the Long COVID Treatment Guide - The Sick Times

Alternative Headline: New Guide Offers Clinicians and Patients Varied Strategies for Managing Long COVID Symptoms

Summary

A new Long COVID Treatment Guide developed with input from both patients and clinicians is aiming to fill a critical gap in medical education and bedside practice. With no FDA-approved therapies for long COVID yet available, the guide lays out 24 options spanning off-label prescription medications, procedures, supplements, and lifestyle modifications — each accompanied by a prompt to consult a healthcare provider before starting anything new. The options are grounded in clinical evidence available through November 2025 and were shaped significantly by real-world patient and clinician feedback. Roughly one in five prescriptions are already written off-label in general practice, making the guide’s pragmatic approach timely.

Article: Federal vaccine advisory panel meeting: How to submit comments on Covid vaccine injuries, Long Covid - Healthbeat

Alternative Headline: Advisory Committee on Immunization Practices Faces Scrutiny Ahead of Meetings on Vaccine Issues.

Summary

The Advisory Committee on Immunization Practices (ACIP) is set to meet March 18–19 to take up COVID-19 vaccine injuries and long COVID, and the public can weigh in — either via written comments online or oral remarks before any scheduled votes. The meetings come at a turbulent moment for the committee: all of its members have been replaced amid governance controversies, and a lawsuit from the American Academy of Pediatrics and allied medical groups is seeking to halt proceedings over concerns about potential funding cuts affecting low-income families and uninsured children. ACIP meets three times a year to evaluate vaccination protocols, but critics say the current lack of agenda transparency and ongoing legal uncertainty are undermining public trust. Advocates are urging participation in the comment process while pushing for a more inclusive and accountable approach going forward.

Our pick this week looks at one of the biggest unanswered questions in long COVID: how many people recover, and who is still being left behind. Using national survey data from 2022 through 2024, the study offers a broad snapshot of how long COVID prevalence and recovery have shifted over time in the U.S. The topline is encouraging in one sense → more people are reporting recovery than a few years ago → but the burden remains substantial, especially for older adults and lower-income groups. It’s a useful reminder that while the acute phase of the pandemic has faded, long COVID is still shaping millions of lives.

A couple of key findings highlighted in the study:

1. In 2024, 8.3% of U.S. adults → an estimated 21.3 million people → reported ever having long COVID, and nearly 6 in 10 of those individuals said they had recovered.

2. With no long COVID treatment yet showing clear efficacy, the authors argue that more investment in understanding the biology of persistent symptoms could help uncover better targets for treatment.

Research

Article: Long COVID and Recovery Among US Adults

alternative headline: Study Shows Long COVID Affects 8.3% of U.S. Adults, But Recovery Rates Are Improving

Definitions

• NHIS: National Health Interview Survey, an annual cross-sectional survey designed to gather health-related data from a representative sample of the US noninstitutionalized civilian population.

Summary

• Approximately 8.3% of U.S. adults — an estimated 21.3 million people — reported ever experiencing long COVID, a figure that has declined from earlier in the pandemic.

• Among those with long COVID, recovery rates rose from 51.2% in 2022 to 59.7% in 2024, though older adults were still less likely to recover. The study also found that female sex, ages 35–64, and lower household income were consistently associated with greater odds of long COVID, while prevalence among previously infected individuals fell from 19.7% in 2022 to 13.7% in 2024.

stats/trends

• Data was analyzed from 39,067 adults surveyed over three years, with 9,022 in 2022, 15,354 in 2023, and 18,691 in 2024.

• The proportion of adults reporting prior COVID-19 infection increased from 39.6% in 2022 to 60.4% in 2024.

• The prevalence of long COVID among infected individuals dropped from 19.7% (95% CI, 18.7%-20.7%) to 13.7% (95% CI, 13.1%-14.4%) over the study period.

Counterpoints

• The reliance on self-reported data may introduce classification biases, as individuals with intermittent symptoms might be misclassified as recovered.

• The narrow definition of long COVID in the study may affect the accuracy of prevalence estimates, and crucial variables such as vaccination status were not included due to data limitations.

Action Items

• Continue advocating for more research into the biological mechanisms of long COVID to inform better interventions.

• Increase awareness of long COVID symptoms and the importance of reporting them accurately.

• Encourage healthcare stakeholders to consider broader definitions and variables in future research studies on long COVID.

Article: Full article: Long COVID: mechanisms of disease, multisystem sequelae, and prospects for treatment

alternative headline: Long COVID Affects Many, with Research Exploring Causes and Promising New Treatment Opportunities

Definitions

• Long COVID: A chronic health condition that manifests after an initial SARS-CoV-2 infection, leading to persistent symptoms that affect multiple organ systems and quality of life.

• Symptomatic Management: Approaches aimed at alleviating symptoms rather than curing the underlying condition, central to treating Long COVID due to the absence of specific therapies.

Summary

• Long COVID has emerged as a major global health issue affecting people across the spectrum of initial disease severity.

• Researchers point to several possible drivers, including incomplete viral clearance, immune dysregulation, microbiome changes, and mitochondrial dysfunction, all of which may contribute to chronic inflammation and multisystem symptoms.

• Fatigue, cognitive dysfunction, and cardiovascular complications remain among the most disruptive features, while vaccination appears to reduce risk and newer strategies such as antivirals and microbiome-focused therapies are being actively explored.

stats/trends

• The reported prevalence of Long COVID ranges from under 10% to 60% across various populations.

• Approximately 40% of Long COVID patients experience symptoms like dyspnea lasting over six months.

Article: Assessment and Incidence Determination of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Following a SARS-CoV-2 Infection in a Prospective Cohort of Hospital Employees

alternative headline: Study Finds High Rates of ME/CFS Symptoms Among Hospital Workers Three Months After COVID-19

Definitions

• Prospective Cohort Study: A longitudinal research design tracking a group over time to assess outcomes related to a specific event, like SARS-CoV-2 infection.

Summary

• The study found a substantial incidence of ME/CFS-like symptoms among hospital employees after SARS-CoV-2 infection, underscoring the potential long-term burden on healthcare workers.

• Among 150 participants, 35% met criteria for ME/CFS symptoms three months after infection. Persistent fatigue, cognitive dysfunction, and unrefreshing sleep were especially common, and six-month follow-up suggested these individuals had notably greater functional impairment than those who recovered more fully.

stats/trends

• The study involved 150 hospital employees who contracted SARS-CoV-2, with assessments conducted at three and six months after infection.

• At three months, 52 participants (35%) met the case definition for ME/CFS, with an additional 25 individuals reporting moderate to severe fatigue.

• Functional assessments revealed that 65% of ME/CFS patients scored in the moderate to severe range on the Short Form Health Survey (SF-36) compared to 25% of recovered individuals (P < 0.01).

Article: Singing Voice Symptomatology Following Presumed SARS-CoV-2 Infection | Journal of Voice

Alternative headline: Singers with Long COVID report significant difficulties performing

Definitions

• Phonatory: The articulation of sounds by causing the vibration of the vocal cords.

• Dysphonia: Loss of the normal timbre of the voice.

Summary

• This cross-sectional survey found that those who responded to the questionnaire reported more phonatory (42.2%) than pulmonary (34%) concerns.

• Severe infections were over five times more likely to experience a change in singing voice as compared with those who had a mild infection.

• There were no significant interactions between demographic variables such as age and sex on the prediction of a change in singing voice.

• Of the 34 signs and symptoms presented, lingering cough, shortness of breath, and chronic fatigue were significantly correlated with a change in singing voice.

• This study has added to our understanding of this growing population’s unique vocal needs, and may inform strategies for singing voice habilitation in COVID-19 survivors.

stats/trends

• Of those who responded, 60.3% reported lingering symptoms lasting 4 weeks or more following their initial infection.

• The three most commonly reported recurring symptoms were fatigue (62.8%), shortness of breath (40.8%), and brain fog (32.8%).

• The most common phonatory (dysphonia) concern was vocal fatigue (24.3%), while the most common pulmonary (dyspnea) concern was changes to breath support or control (40.8%).

• One singer reported, “Shortness of breath and difficulty with breathing support, all the right sensations were there but I got very tired, dizzy and the effort was too much with little result.”

Counterpoints

• 60.3% is an unusually high percentage of respondents with Long COVID. Authors surmise that this may represent a sampling bias, as those who took the time to complete the survey may have been motivated by their own lingering signs and symptoms.

Article: Assessment of physical status and analysis of lipidomic and metabolomic alterations in patients with Post-COVID-19 condition | PLOS One

alternative headline: Post-COVID-19 Condition Linked to Decreased Muscle Strength and Abnormal Metabolite Levels in Patients

Definitions

• Lipidomic Analysis: A technique for characterizing the lipid profile of biological samples to evaluate changes in health and disease.

• Metabolomic Analysis: The comprehensive study of small molecule metabolites to assess metabolic changes and disease mechanisms.

Summary

• Patients with post-COVID-19 condition showed meaningful reductions in muscle strength and exercise tolerance, alongside metabolomic changes that may point to ongoing mitochondrial dysfunction and inflammation.

• Researchers observed lower HDL-cholesterol, elevated lactate, altered amino acid levels, and persistent changes in lipoprotein profiles.

• Taken together, the findings suggest that lingering physical limitations in PCC may be tied to measurable metabolic disruption, not just subjective symptom reports.

stats/trends

• The study evaluated 46 patients with Post-COVID-19 Condition alongside 26 controls, incorporating assessments to quantify physical health and metabolic alterations.

• On average, PCC patients achieved a mean distance of 437.04 meters in the 6-minute walk test, with 34.78% falling below the clinically acceptable threshold of 400 meters.

• Blood samples from 39 participants showed a significant difference in HDL-cholesterol levels: 42.2 mg/dL for PCC versus 68.7 mg/dL for healthy controls (P < 0.001).

• Lactate levels were significantly elevated in PCC patients (1007 µM) compared to healthy controls (237 µM), indicating metabolic disturbances (P < 0.001).

Counterpoints

• The findings provide valuable insights into the lingering effects of COVID-19, but the limited sample size and observational design may restrict applicability.

• Factors such as pre-existing health conditions and lifestyle habits necessitate larger, multi-center studies for validation and broader understanding.

Action Items

• Advocate for larger studies to validate the findings and enhance understanding of Post-COVID-19 Condition.

• Encourage multidisciplinary approaches for patient management, integrating rehabilitation and metabolic assessments.

• Promote awareness of ongoing metabolic disturbances in PCC patients to support tailored interventions.

Article: Microbiota-derived extracellular vesicles link intestinal dysbiosis to neuroimmune activation in long COVID | bioRxiv

alternative headline: Study Links Microbiota-Derived Vesicles to Ongoing Neurological Issues in Long COVID Patients

Definitions

• Microbiota-derived extracellular vesicles (GMEVs): Small membrane-bound particles released by gut microbiota that influence host physiology, particularly regarding inflammation and immune responses.

• Gut dysbiosis: An imbalance in the gut microbial communities that can contribute to health issues, including neuroinflammation in long COVID.

Summary

• This preprint points to microbiota-derived extracellular vesicles as a possible bridge between gut dysbiosis and neuroimmune activation in long COVID.

• Patients with long COVID showed a persistent gut microbial signature associated with neurological symptoms, and transplant experiments in germ-free mice suggested these microbial changes may contribute to intestinal barrier disruption and neuroinflammatory effects.

• The study adds to growing evidence that the gut-brain-immune axis could be an important piece of the long COVID puzzle.

stats/trends

• The longitudinal study involved individuals diagnosed with long COVID, showcasing their specific microbiota profiles over time.

• Transplantation experiments demonstrated that 70% of germ-free mice exhibited intestinal barrier disruption following the introduction of long COVID-associated microbiota.

• Long COVID patients showed a 40% higher prevalence of certain dysbiotic bacterial genera compared to healthy controls.

Article: ACHTSAM study protocol: outreach diagnostics and assessment of tolerability in severe ME/CFS—a pilot study

alternative headline: Study Explores Feasibility of Home Assessments for Patients with Severe ME/CFS Symptoms

Definitions

• Bell Score: A scale to classify the severity of ME/CFS, ranging from 0 (very severe) to 100 (normal).

• Home-based Diagnostics: Remote assessments used to evaluate health parameters, reducing barriers for patients with severe healthcare needs.

Summary

• The ACHTSAM pilot study is testing whether home-based assessments for patients with severe and very severe ME/CFS can be carried out without triggering post-exertional malaise or forcing early termination due to fatigue.

• The protocol uses remote screening followed by home visits and is designed around the practical reality that the sickest patients are often excluded from research because travel itself is too burdensome.

• If successful, the study could help make severe ME/CFS research more accessible and more representative.

stats/trends

• The study intends to recruit 25 participants with severe to very severe ME/CFS, evaluated over a three-month period starting from September 2025.

• Assessments will evaluate various parameters, including autonomic nervous system function and cognitive performance, tailored to patients’ limited capacities.

• Completion rates are expected to vary significantly, with high-burden tests anticipated at less than 50% and low-burden assessments exceeding 80%.

Article: Psychomotor and neurofunctional sequelae after COVID-19

alternative headline: Long-Term COVID-19 Effects Include Lasting Neurofunctional Impairments Across Different Age Groups

Definitions

• Psychomotor sequelae: Changes in coordination, balance, reaction time, or fine motor performance after illness.

• Neurofunctional impairments: Ongoing changes in cognitive/neurological function (e.g., memory, attention, processing speed).

• Rh factor (Rh-negative): Blood type classification based on presence/absence of the Rh antigen.

Summary

• This study suggests that COVID-19 can leave behind measurable psychomotor and neurofunctional impairments for at least 24 weeks after infection.

• The impacts were not evenly distributed: adults aged 31–45 showed more pronounced psychomotor deficits, while memory-related issues were more evident in younger adults aged 18–30.

• The authors flagged symptoms such as body pain, coryza, and sore throat as potential indicators associated with later impairment.

• They also noted a possible association between Rh-negative blood type and worse psychomotor outcomes.

• While limited by sample size, the paper reinforces concerns that even non-severe infections may carry lingering neurological consequences.

stats/trends

• Small case-control style design (post-COVID participants compared with healthy controls), evaluated with psychomotor/cognitive testing across a ~24-week post-infection window.

• Group differences were reported across multiple measures, with some tests showing statistically significant separation between post-COVID and control participants.

• Findings suggested age-stratified “profiles” (motor vs memory) rather than uniform impairment.

Article: The Impact of Acute COVID-19 Infection and Long COVID in Patients with Congenital Heart Disease: A Longitudinal Study by the German National Register for Congenital Heart Disease

alternative headline: Study Reveals 35% of Congenital Heart Disease Patients Experience Long COVID Symptoms After Infection

Definitions

• Congenital heart disease (CHD): Structural heart differences present from birth, spanning simple to complex conditions.

• Longitudinal study: Tracks outcomes in the same participants over time after an exposure/event.

• Quality of life (QoL): Patient-reported well-being across physical, emotional, and social functioning.

Summary

• This longitudinal study found that roughly 35% of patients with congenital heart disease reported persistent long COVID symptoms six months after infection, commonly fatigue and dyspnea.

• Patients with more complex CHD experienced worse quality-of-life outcomes compared to those with simple CHD.

• Cardiac function appeared stable for most participants, yet symptom burden persisted, suggesting ongoing impact beyond standard cardiac metrics.

• The findings support tailored follow-up for CHD patients post-COVID, especially when symptoms continue beyond the acute phase.

• Overall, the paper highlights that medically vulnerable populations may face distinct recovery trajectories.

Article: Clinical characteristics and long-term treatment outcomes of patients with new-onset epileptic seizures associated with COVID-19 infection

alternative headline: Study Reveals Distinct Outcomes for COVID-Related Seizures in Patients with Encephalopathy Versus Without

Definitions

• New-onset epileptic seizures: First seizures occurring in someone without a prior epilepsy diagnosis.

• Encephalopathy: Acute brain dysfunction (e.g., confusion, altered consciousness) during illness.

• Status epilepticus (SE): Prolonged seizure activity or repeated seizures without recovery—medical emergency.

• Seizure freedom: No seizures during a defined follow-up window.

Summary

• This study examines patients with new-onset epileptic seizures associated with COVID-19, splitting outcomes by presence vs absence of acute encephalopathy.

• Those with encephalopathy were older, developed seizures sooner, and had a much higher incidence of status epilepticus.

• Despite a more severe acute course in the encephalopathy group, long-term outcomes were relatively reassuring.

• After a median follow-up of about two years, roughly three-quarters of patients achieved seizure freedom, with no major differences between groups.

• The work emphasizes that acute presentation can differ sharply even when longer-term seizure control ends up similar.

stats/trends

• Small cohort design with follow-up reported around 25 months (median).

• Status epilepticus occurred far more often in the encephalopathy group than the non-encephalopathy group.

• Overall seizure freedom was ~75% by follow-up.

Article: A paper-based immunoassay with signal amplification for the sensitive detection of nucleocapsid protein toward the diagnosis of long COVID

alternative headline: New paper-based test detects COVID-19 protein in long COVID patients, pointing to potential biomarkers

Definitions

• Nucleocapsid protein (N): A SARS-CoV-2 structural protein; detection in blood may indicate persistent antigen presence.

• Immunoassay: Antibody-based test to detect specific molecules in a sample (e.g., plasma).

• Signal amplification: Methods that boost readout so lower concentrations can be detected.

• Biomarker: A measurable biological signal associated with disease presence or subtype.

Summary

• Researchers developed a paper-based immunoassay with signal amplification to detect SARS-CoV-2 nucleocapsid protein in plasma.

• In this early study, long COVID samples showed higher signal intensity than healthy controls, suggesting possible detection of persistent viral protein in at least a subset of patients.

• The platform is attractive because it aims to be sensitive, relatively simple, and potentially scalable.

• However, the evidence is preliminary and based on a very small sample, so clinical utility is not established.

• If validated, this approach could contribute to efforts to identify measurable biomarkers and stratify long COVID subtypes.

stats/trends

• Small validation study (tens of samples) comparing long COVID vs healthy controls.

• The assay demonstrated strong analytical sensitivity (low limit of detection) under controlled conditions.

• Long COVID samples showed materially higher signal than controls, but real-world diagnostic performance remains unknown.

Long COVID continues to blur the line between “recovered” and “still sick.” This week we zoom in on what’s happening inside the immune system and how those discoveries connect to real-world costs, inequities, and policy decisions. From single-cell maps of exhausted T cells to county-level patterns of who gets long COVID, these pieces help explain why some people struggle for years while others seem to bounce back.

🗞️ Article of the week

This week, we spotlight the article titled “Single-cell analysis reveals immune remodeling of monocytes, NK cells, T cell exhaustion, and Galectin-9–associated depletion of gamma delta and mucosal-associated invariant T cells in Long COVID with ME/CFS.” Published in Frontiers in Immunology, this research provides critical insights into the immunological landscape of Long COVID patients who also meet criteria for myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS).

Key findings from the study include:

• A significant reduction in naive T cells among Long COVID patients: “our analysis also revealed reduced frequencies and altered transcriptional profiles of NK (natural killer) cells in LC patients.” This suggests ongoing immune activation and potential pathways for intervention.

• The authors emphasize that “these signatures were most prominent in monocytes and LDNs (low-density neutrophils), highlighting a central role for innate immune dysregulation,” which is crucial for understanding the chronic symptoms associated with Long COVID.

These results underscore the complexity of immune responses in Long COVID and mark a step toward developing targeted therapeutic measures for affected patients.

Research

Article: Frontiers | Single-cell analysis reveals immune remodeling of monocytes, NK cells, T cell exhaustion, and Galectin-9–associated depletion of gamma delta and mucosal-associated invariant T cells in Long COVID with ME/CFS

Alternative headline: Long COVID Linked to Immune Changes in Patients with Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome

🗞️ Definitions

• ME/CFS: Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, a disorder defined by extreme fatigue that does not improve with rest.

• Single-cell RNA sequencing (scRNA-seq): A technology enabling the examination of gene expression at the single-cell level.

• Galectin-9 (Gal-9): A carbohydrate-binding protein that regulates immune responses, particularly in apoptosis and immune cell regulation.

🗞️ Summary

• The study demonstrates that Long COVID in patients with ME/CFS is marked by significant immune remodeling, particularly characterized by T cell exhaustion.

• Patients with Long COVID show a significant reduction in naive CD4+ T cells and an increased presence of effector T cell subsets.

• Single-cell RNA sequencing revealed extensive alterations in immune cell transcriptional profiles, highlighting immune dysregulation.

• The study identified Galectin-9 as a key factor contributing to the depletion of γδ and mucosal-associated invariant T cells in Long COVID patients.

• Comparative analysis revealed notable differences in immune landscapes between Long COVID patients and idiopathic ME/CFS.

🗞️ stats/trends

• The study involved 20 participants: 10 with Long COVID associated with ME/CFS and 10 recovered individuals.

• scRNA-seq analysis identified a reduction in naive T cells by approximately 50% in Long COVID patients compared to the recovered group.

• Gene set enrichment analysis indicated significant activation of the TNF-α signaling pathway in immune cell clusters from Long COVID patients (P < 0.01).

• Galectin-9 levels were elevated in the plasma of Long COVID patients, correlating with the depletion of MAIT (mucosal associated invariant T cells) and γδ (gamma delta) T cells (P = 0.005).

🗞️ Counterpoints

• The study’s small sample size may limit the broader applicability of the findings.

• The reliance on single-center data necessitates further replication in larger, multi-center studies to understand the generalizability and potential confounding factors.

Article: Distinguishing post-COVID from long-COVID in adults: Development and validation of a biomarker signature using targeted proteomics and machine learning in a cross-sectional observational study | PLOS One

Alternative headline: Distinct Profiles of Long-COVID and Post-Severe COVID Patients Highlight Need for Targeted Treatments

🗞️ Definitions

• Proteomics: The large-scale study of proteins to identify biomarkers in clinical research.

• Random Forest Classifier: A machine learning algorithm that improves classification accuracy by creating and merging multiple decision trees.

🗞️ Summary

• The study revealed that long-COVID patients exhibited distinct clinical profiles characterized by fatigue and neurocognitive symptoms, while post-severe COVID patients primarily presented with pulmonary impairments.

• Targeted proteomics and machine learning analysis identified a biomarker panel that distinguished between long-COVID and post-severe COVID patients with 89% accuracy.

• The median age of long-COVID patients was significantly younger than that of post-severe COVID patients.

• Elevated levels of interleukin 6 (IL-6) and D-dimers in post-severe COVID patients suggest persisting systemic inflammation and potential coagulation issues.

• The findings emphasize the potential of machine learning to refine diagnostic classifications and inform therapeutic strategies in post-COVID recovery.

🗞️ stats/trends

• The study included 76 participants: 40 with post-severe COVID, 24 with long-COVID, and 12 mild COVID control participants.

• The mean age for long-COVID participants was significantly lower at 52 years compared to 58 years in post-severe COVID (P = 0.006).

• The oxygen partial pressure was significantly lower in the post-severe COVID group (63.0 mmHg) than in the long-COVID group (71.0 mmHg, P = 0.008).

Article: Long COVID: mechanisms of disease, multisystem sequelae, and prospects for treatment | Immunological Medicine

Alternative headline: Long COVID Presents Diverse Challenges, Affecting Many Organ Systems and Requiring Personalized Treatments

🗞️ Definitions

• Pathophysiology: The study of the functional changes resulting from disease, especially the mechanisms underlying Long COVID.

• Microbiome Dysbiosis: An imbalance in microbial communities, particularly in the gut, which may contribute to Long COVID symptoms.

• Endothelial Dysfunction: A condition where the inner lining of blood vessels fails to function normally, often linked to inflammation and cardiovascular issues in Long COVID.

🗞️ Summary

• Fatigue affects around 30% of patients three months post-infection, alongside cognitive difficulties and respiratory challenges.

• Proposed mechanisms for Long COVID include incomplete viral clearance, immune dysregulation, and microbiome dysbiosis.

• Emerging therapies under investigation include antiviral treatments, immunomodulators, microbiota interventions, and mitochondria-targeted therapies.

• The clinical presentation of Long COVID varies significantly, highlighting the need for personalized treatment approaches.

🗞️ stats/trends

• Prevalence rates of Long COVID symptoms range from under 10% to as high as 60%, depending on definitions and populations studied.

• Approximately 40% of patients report persistent dyspnea six months after initial infection.

Article: Progressively Widening Healthcare Costs in Long COVID Over Five Years | MedRxiv

Alternative headline: Long COVID Patients Face Rising Healthcare Costs Over Five Years, Research Finds Significant Burden

🗞️ Definitions

• Cumulative Costs: The total healthcare expenditures attributed to Long COVID patients over a defined period.

• Charlson Comorbidity Index: A method of classifying comorbidity in studies, scoring conditions based on their impact on mortality risk.

🗞️ Summary

• The study finds that healthcare costs associated with Long COVID increased progressively over five years, with excess quarterly costs rising from $79 to $236.

• Long COVID is linked to 20% higher odds of any healthcare utilization and 30% higher costs when accessing care compared to controls.

• The divergence in healthcare visit frequency reached 44% higher for Long COVID patients by the 19th quarter.

• Cumulative expected healthcare costs for Long COVID patients were about $16,663 over five years, $7,124 higher than non-Long COVID peers.

🗞️ stats/trends

• A total of 143,544 adults were analyzed, with 27,986 diagnosed with Long COVID and 115,558 serving as controls.

• The adjusted excess quarterly healthcare costs for Long COVID patients expanded from $79 at baseline to $236 by quarter 19 (P < 0.001).

• Healthcare utilization was consistently higher among Long COVID patients, averaging 0.73 visits by quarter 19 compared to 0.51 for controls (P < 0.001).

Article: Genome-wide DNA methylation profiling in COVID-19 positive patients reveals alterations in pathways linked to neurological dysfunction | Clinical Epigenetics | Springer Nature Link

Alternative headline: Study Finds DNA Methylation Changes in COVID-19 Patients Linked to Neurological Issues and Severity

🗞️ Definitions

• Genome-wide DNA Methylation Profiling: A technique that analyzes DNA methylation patterns to identify epigenetic modifications linked to diseases.

• Epigenetic Mechanisms: Biological processes involving changes in gene expression without altering the underlying DNA sequence, often involving DNA methylation.

• Post-Acute Sequelae: Persistent symptoms and complications following the acute phase of disease, commonly referred to as long COVID in the case of SARS-CoV-2 infection.

🗞️ Summary

• The study reveals significant alterations in DNA methylation pathways linked to neurological dysfunction in COVID-19 positive patients, suggesting potential epigenetic repercussions of SARS-CoV-2 infection.

• Patients with more severe symptoms exhibited distinct methylation patterns, indicating a correlation between symptom severity and neurogenic epigenetic modifications.

• Whole-genome methylation sequencing identified differentially methylated genes associated with neuropsychiatric disorders, which may contribute to cognitive and psychiatric sequelae in COVID-19 patients.

🗞️ stats/trends

• The study analyzed whole-genome methylation sequencing data from 150 COVID-19 positive patients, ranging from asymptomatic to severe cases.

• Over 1,000 differentially methylated genes were identified, with specific pathways associated with neurological and immunological functions impacted in severe COVID-19 cases (P < 0.01).

• Changes in DNA methylation correlated with symptom severity scores, indicating significant relationships to epigenetic variants associated with cognitive decline (R² = 0.67).

🗞️ Counterpoints

• While the findings provide crucial insights into DNA methylation’s role in COVID-19’s neurological impact, the limited sample size and lack of longitudinal design restrict definitive causative conclusions.

• Confounding factors such as pre-existing conditions and environmental influences require further investigation, underscoring the need for larger, multi-center studies to validate these results.

Article: Intrauterine SARS-CoV-2 Exposure and Infant Neurodevelopment through 18 Months of Age: Findings from the Researching COVID to Enhance Recovery (RECOVER) Pregnancy Study | The Journal of Pediatrics

Alternate headline: No developmental delays seen in early childhood after exposure to COVID-19 during pregnancy - a RECOVER trial

🗞️ Definitions

• ASQ-3 (Ages and Stages Questionnaire, 3rd Edition): A validated screening tool for developmental delays in the first 5 years of life.

• M-CHAT-R (Modified Checklist for Autism in Toddlers, Revised): A validated screening tool to assess risk for autism spectrum disorder (ASD) for toddlers between 16 and 30 months of age.

🗞️ Summary

• In this multicenter cohort exposed to SARS-CoV-2 since Omicron and in the second or third trimester of pregnancy, exposure was not associated with differences in neurodevelopmental screening outcomes through 18 months of age.

• Similar proportions of groups (exposed vs. unexposed) met the screening threshold for referral for professional assessment. Findings were similar when stratified by SARS-CoV-2 variant or by trimester of pregnancy.

🗞️ stats/trends

• 1179 participants were enrolled in the study. 1008 (85.5%) had exposure, with 806 (80.0%) exposed during Omicron predominance.

• Of those with known timing, 349 (41.4%) and 295 (35.0%) were exposed in the second and third trimesters of pregnancy, respectively.

• Exposure was not associated with differences in the ASQ-3 (adjusted difference −0.61, 95% CI −10.03 to 8.81) or ASQ-3 subdomains at 12 months, ASQ-SE at 18 months (adjusted difference 0.19, 95% CI −4.02 to 4.41), or M-CHAT-R scores.

🗞️ Counterpoints

• Authors of the study cautioned that they were unable to exclude a clinically meaningful association due to wide confidence intervals (CIs) and that the predictive validity of neurodevelopmental screening is low prior to 2 years of age.

Article: The age paradox in post-infectious sequelae: physiological reserve outweighs chronological age in Long COVID susceptibility | MedRxiv

Alternative Headline: Aging and chronic disease significantly influence the risk of post-acute sequelae of COVID-19

🗞️ Definitions

• Causal Mediation Analysis: A statistical method that assesses whether the relationship between an independent variable (such as age) and a dependent variable (such as PASC) is mediated by another variable.

🗞️ Summary

• The study reveals that, post-adjustment for comorbidity burden, each decade of age is associated with a 6% lower odds of experiencing PASC (odds ratio 0.94).

• Causal mediation analysis indicates that accumulated comorbidity accounts for 145% of the total effect of age on PASC risk, suggesting that age’s protective benefits are obscured by chronic disease.

• A fundamental shift occurs past age 65, where the direct protective effect of age disappears, making comorbidity the sole influence on PASC risk.

• Specification Curve Analysis confirms a non-linear relationship between age and PASC, challenging common assumptions about age as an independent risk factor.

🗞️ stats/trends

• The study analyzed data from 133,792 COVID-19 patients, with 24,833 developing PASC within 12 months of infection.

• Patients under 65 years exhibited a direct protective effect from aging, while those 65 and older showed diminished protective benefits.

• The mean Charlson Comorbidity Index was 2.21 overall, increasing to 2.87 in the PASC group.

Article: Exploratory analyses of Immunologic Features in a Randomized, Placebo-Controlled Trial of Nirmatrelvir/Ritonavir for Long COVID | MedRxiv

Alternative Headline: Study Finds No Significant Immune Changes in Long COVID Patients Treated with Nirmatrelvir/Ritonavir

🗞️ Definitions

• Nirmatrelvir/Ritonavir (NMV/r): An antiviral combination where nirmatrelvir is a protease inhibitor targeting SARS-CoV-2, and ritonavir enhances its pharmacokinetics.

• Placebo-Controlled Trial: A clinical study comparing treatment effects against a placebo.

🗞️ Summary

• The PAX LC trial explored immunologic features in individuals with Long COVID treated with nirmatrelvir/ritonavir (NMV/r) versus a placebo, revealing no substantial immune changes post-treatment.

• Participants showed no significant differences in major immune cell populations or SARS-CoV-2 specific antibody levels after NMV/r treatment compared to placebo.

• Baseline assessments indicated comparable demographic and immunological profiles among participants across both treatment arms.

• Notable hematologic changes were observed in the NMV/r group, including reductions in red blood cell numbers and hemoglobin levels, although these values remained within normal limits.

• The decrease in circulating RANTES levels correlated with self-reported symptom improvement, suggesting this could be a potential biomarker for recovery.

🗞️ stats/trends

• The study included 82 participants (45 receiving placebo and 37 receiving NMV/r) across 28 states in the U.S.

• There were no significant differences in immune cell populations or SARS-CoV-2 specific antibody levels between treatment arms at baseline or post-treatment.

• The median age of participants was 42 years, with uniform vaccination history and symptom duration across groups.

• A significant decrease in RANTES levels was associated with reported symptom improvement (p = 0.0319) across treatment arms.

Article: Post-COVID-19 Cardiovascular Complications: An Updated Systematic Review | Journal of Respiration

Alternative Headline: Study Finds High Rate of Cardiovascular Complications in Patients Recovering from COVID-19.

🗞️ Definitions

• Cardiovascular Complications: Health issues related to the heart and blood vessels that may arise after recovery from COVID-19.

• Myocarditis: Inflammation of the heart muscle, which can affect the heart’s ability to pump and cause arrhythmias, often linked to viral infections.

• Thrombosis: The formation of a blood clot inside a blood vessel, which can obstruct blood flow and is a known complication post-COVID-19 infection.

🗞️ Summary

• The systematic review reveals a significant incidence of cardiovascular complications in post-COVID-19 patients, with myocarditis and thrombosis being the most frequently reported conditions.

• Approximately 25% of recovered COVID-19 patients experienced cardiovascular issues, underscoring the need for ongoing monitoring.

• Patients with Long COVID exhibited a 15% incidence of arrhythmias, highlighting their elevated risk for cardiovascular problems.

• Chronic inflammation post-COVID-19 may contribute to the development of cardiovascular complications.

• Early intervention and tailored cardiovascular care may mitigate risks for patients experiencing post-COVID complications.

🗞️ stats/trends

• The review analyzed data from 50 studies involving over 12,000 patients who had recovered from COVID-19.

• Myocarditis was reported in 11% of patients, and venous thromboembolism occurred in 10% of cases.

• The incidence of arrhythmias increased to 15% in patients with Long COVID symptoms compared to 2–5% in the general population.

Article: Association of SARS-CoV-2 infection with long-lasting increase in circulating IL-32 levels | Frontiers

Alternative Headline: Study links elevated IL-32 levels to severe COVID-19, suggesting a potential biomarker for inflammation

🗞️ Definitions

• IL-32: A pro-inflammatory cytokine implicated in the immune response to viral infections, particularly associated with inflammation and long COVID sequelae.

• Neutrophil-to-Lymphocyte Ratio (NLR): A clinical marker calculated from the number of neutrophils to lymphocytes in the blood, often used to assess inflammation and predict COVID-19 severity.

🗞️ Summary

• The study demonstrates a significant association between SARS-CoV-2 infection and elevated circulating IL-32 levels, persisting for up to one year post-discharge in COVID-19 patients.

• Patients hospitalized during the first wave exhibited notably higher IL-32 levels compared to both pre-pandemic blood donors and those hospitalized in subsequent waves, suggesting an acute inflammatory response.

• A strong correlation was observed between IL-32 levels and corticosteroid treatment, indicating its potential as a biomarker for hyper-inflammation in severe COVID-19 cases.

🗞️ stats/trends

• The study analyzed samples from 949 healthy blood donors (pre-pandemic and pandemic era) and 212 hospitalized COVID-19 patients during the first five infection waves.

• IL-32 levels in pandemic-era blood donors were significantly elevated, showing an increase of +0.78 ± 0.09 log compared to pre-pandemic levels (p < 0.001).

• One-year follow-up revealed stable IL-32 levels in patients, with a mean increase of +0.03 ± 0.12 log compared to hospitalization values.

Article: Mapping spatial and social inequities of long COVID across the United States: a retrospective cohort study | The Lancet Regional Health

Alternative Headline: Long COVID Cases Rise Significantly Across U.S. Following Emergence of Omicron Variant, Study Finds

🗞️ Definitions

• Social Vulnerability Index (SVI): A tool used to identify communities that may be vulnerable to adverse health effects due to socioeconomic status and other factors.

• Bayesian Spatial Random Effect Models: A statistical approach that accounts for spatial dependence and improves effect estimation while considering data uncertainty.

🗞️ Summary

• The study delineates significant spatiotemporal disparities in long COVID incidence across the U.S., revealing variation before and after the emergence of the Omicron variant.

• Long COVID incidence increased from 204 cases per 10,000 COVID-19 cases prior to Omicron to 248 cases per 10,000 after its emergence (P < 0.001).

• An increase in significant spatial correlation was noted, with 48.8% of counties exhibiting this trend following the Omicron variant’s rise, compared to 43.5% before.

• Key sociodemographic factors, such as economic vulnerability and limited healthcare access, significantly correlated with higher long COVID incidence across the studied regions.

🗞️ stats/trends

• The analysis included 5,652,474 COVID-19 cases and 41,694 long COVID cases across 1,063 U.S. counties from 2021 to 2024

• Quarterly long COVID incidence fluctuated between 0.015% to 14.29% over the study period.

• A spatial clustering analysis revealed 328 of 673 counties had significant spatial correlations following the Omicron emergence (P < 0.05).

Media

Article: CDC vaccine advisors to consider COVID-19 vaccine injuries, long COVID | Reuters

🗞️ Summary

• The CDC’s vaccine advisory committee will review COVID-19 vaccine injuries and long COVID at its March 18–19 meeting, a discussion that could influence insurance coverage, state policies, and clinical guidance.

• The committee was reconstituted after all prior members were dismissed by Health Secretary Robert F. Kennedy Jr., raising concerns about political influence over scientific decision-making. Major U.S. medical organizations have filed a lawsuit challenging proposed policy changes, underscoring how contentious vaccine and long COVID policy has become as the pandemic response shifts into a new phase.

Article: Chairman Garbarino Applauds Disbursements for Long-Delayed FEMA COVID-19 Disaster Funds Following Oversight | Representative Andrew Garbarino

🗞️ Summary

• Following congressional oversight, FEMA has approved more than $2 billion in long-delayed COVID-19 disaster reimbursement funds for New York State. Representative Andrew Garbarino framed the disbursements as a major step toward strengthening health and emergency infrastructure after years of stalled claims.

• He credited recent pressure on the Department of Homeland Security and FEMA leadership for accelerating reviews, while signaling that continued monitoring is needed to ensure remaining claims are processed and funds reach affected communities.

Article: Los Angeles recognizes Long COVID Awareness Day - The Sick Times

🗞️ Summary

• The Los Angeles City Council has officially designated March 15 as Long COVID Awareness Day, following more than two years of advocacy from local organizers and health groups.

• Advocates estimate that about 268,000 adults in the city are living with long COVID, and see the resolution as a first step toward accountability and concrete support. Councilmember Hugo Soto-Martínez and organizers from groups like Clean Air LA describe the day as an opportunity to center patients’ experiences, push for better indoor air policies, and keep long COVID on the city’s policy agenda through rallies and public events at Gloria Molina Grand Park and City Hall.

Article: Solve M.E. Funds GLP-1 and Immune Target Studies to Accelerate ME/CFS and Long Covid Breakthroughs

🗞️ Summary

• Solve M.E. has announced new Catalyst Award–funded projects focused on GLP-1–based therapies and immune targets in ME/CFS and Long COVID.

• The grants will support studies testing whether drugs like semaglutide can alleviate symptoms, as well as work to identify antigens driving dysfunctional T-cell responses. President and CEO Emily Taylor emphasized that patient perspectives are central to shaping these projects, which aim to move the field toward concrete diagnostics and treatments in conditions that currently lack FDA-approved options.

• The initiative is framed as both a scientific and advocacy effort to draw more funding and attention to chronic post-viral illness.

🗞️ Article of the week
Our article of the week is titled “Pediatric Long COVID Is Characterized by Myeloid CCR6 Suppression and Immune Dysregulation,” and it provides vital insights into the immunological underpinnings of long COVID in children and young people. The research highlights significant differences in immune profiles between pediatric patients with long COVID and healthy controls, revealing potential avenues for targeted interventions.

Key findings include:

1. “Pediatric LC was associated with decreased expression of both CCR7 and CCR6 in DCs and monocyte populations,” indicating a disruption in the migration and function of immune cells pivotal for inflammation and immune response.

2. “The RF (Random Forest Analysis) model achieved an overall accuracy of 79.3% in differentiating LC cases from controls,” demonstrating the potential of specific immunophenotypic features, including CCR6 expression on myeloid cells, to serve as biomarkers for long COVID.

These findings not only advance our understanding of pediatric long COVID but also underscore the differing immune responses in this population compared to adults, highlighting the need for age-specific research and treatment strategies.

Research

Article: Pediatric long COVID is characterized by myeloid CCR6 suppression and immune dysregulation

Alternative headline: Study finds pediatric long COVID linked to immune system dysregulation and impaired antibody response

🗞️ Definitions

• Pediatric Long COVID: A condition characterized by persistent symptoms following acute SARS-CoV-2 infection in children and young adults, often leading to significant fatigue, cognitive impairments, and immune dysregulation.

• CCR6: A chemokine receptor implicated in the migration of immune cells to sites of inflammation and infection, important for understanding immune responses.

• Random Forest Analysis: A machine learning technique that identifies significant variables contributing to a particular outcome.

🗞️ Summary

• The study reveals pediatric long COVID is characterized by immune dysregulation, highlighting altered innate immunity and overactivated T-, B-, and NK-cell responses.

• Children and young people (CYP) with long COVID showed significant impairments in the humoral immune response to SARS-CoV-2, indicated by dysregulated B-cell compartments and reduced antibody levels.

• Random forest analysis identified CCR6 expression on myeloid cells as a key biomarker, achieving 79% classification accuracy in distinguishing long COVID patients from controls.

• Pediatric long COVID participants exhibited lower levels of anti-RBD IgG and IgA antibodies compared to controls, correlating with diminished neutralizing capacity against SARS-CoV-2

• Impaired innate immunity may limit adaptive immune responses in CYP, contributing to persistent symptoms associated with long COVID.

🗞️ stats/trends

• The study analyzed 99 pediatric patients diagnosed with long COVID and 18 controls without long COVID or inflammatory conditions.

• Fatigue was found in 98.0% and dyspnea in 63.6% of the pediatric long COVID cohort.

• PBMC (peripheral blood mononuclear cells) analysis revealed significant alterations in immune cell frequencies between groups, with 15% myeloid cells, 12% NK cells, 65% T cells, and 8% B cells.

🗞️ Counterpoints

• The small sample size of the control group raises questions about the robustness and generalizability of the results.

• The cross-sectional design limits understanding of the longitudinal effects of immune dysregulation over time, and potential confounding factors may influence antibody response interpretations.

Article: Complement System Dysregulation in the Immunopathogenesis of Long COVID: Systematic Evidence Synthesis | MDPI-Biomedicines

Alternative headline: Study finds link between complement system dysregulation and persistent symptoms in long COVID patients

🗞️ Definitions

• Complement System: A crucial part of the innate immune system that helps clear pathogens and damaged cells, promoting inflammation and tissue healing.

• Complement Activation: The process by which proteins in the complement system are triggered to initiate an immune response.

🗞️ Summary

• This systematic review synthesizes evidence indicating that dysregulation of the complement system is implicated in the immunopathogenesis of long COVID.

• Elevated levels of markers indicative of complement activation were consistently observed in long COVID patients compared to controls, suggesting a persistent inflammatory state.

• The activation of the classical complement pathway showed significant variability, with markers such as C2 and C5 elevated in patients with long COVID.

• Patients exhibiting symptoms like fatigue demonstrated increased levels of complement components, indicating a potential link between symptomatology and immune dysregulation.

• Major limitations of the reviewed studies include small sample sizes and a lack of consistent adjustment for confounding variables such as age, sex, and comorbidities.

🗞️ stats/trends

• A total of 1435 individuals with long COVID and 1124 control subjects were included in the systematic review.

• Nine studies evaluated the classical pathway, while three each assessed the lectin and alternative pathways, revealing diverse activation patterns.

• Specific markers such as C2 and C5 were elevated in long COVID patients, highlighting potential immunological targets for therapeutic intervention.

Article: SARS-CoV-2 spike protein expression drives post-acute coagulopathy | Journal of Virology

Alternative headline: Study links Delta variant spike protein to severe inflammation and long COVID symptoms in mice

🗞️ Definitions

• Post-Acute Coagulopathy (PAC): A condition characterized by clotting abnormalities following the acute phase of COVID-19, often accompanied by symptoms such as inflammation and microthrombosis.

• Cytokine Array: An experimental technique used to detect the concentration of multiple cytokines in a sample, aiding in understanding inflammation and immune response.

🗞️ Summary

• The study highlights the role of SARS-CoV-2 spike protein expression in driving post-acute coagulopathy, showcasing distinct pathological features linked to the Delta variant.

• Transient expression of the Delta variant’s spike protein in K18-hACE2 mice resulted in significant pulmonary inflammation, neutrophil activation, and microthrombosis, with approximately 40% mortality observed within 8 to 16 days.

• Elevated serum levels of the biomarkers IGFBP-1 and CXCL13 were noted in affected mice, correlating with clinical manifestations reminiscent of long COVID symptoms in human patients.

• Treatment with the antiplatelet agent aspirin led to a substantial reduction in both mortality and severe weight loss among mice expressing the Delta spike protein.

🗞️ stats/trends

• Approximately 40% mortality was reported in mice infected with the Delta variant spike protein, significantly higher than previous findings related to other variants.

• Serum samples from long COVID patients showed notably high IGFBP-1 levels, with median concentrations reaching 25.7 ng/mL in those with moderate to critical symptoms (P < 0.001).

• Cytokine assays indicated increased CXCL13 levels in patients with severe long COVID, suggesting a direct correlation with symptom severity and systemic inflammation.

Article: Myalgic encephalomyelitis/chronic fatigue syndrome and fibromyalgia - overlap, differences, and emerging insights | Journal of Translational Medicine | Springer Nature Link

Alternative headline: Study examines overlapping symptoms of ME/CFS and fibromyalgia, highlighting key differences and management strategies

🗞️ Definitions

• Post-Exertional Malaise (PEM): A significant worsening of symptoms after physical or mental exertion that can last for days or weeks.

• Immune Dysregulation: An imbalance in the immune system, often seen as altered cytokine levels, contributing to disease symptoms.

🗞️ Summary

• The review explores the overlapping symptoms of ME/CFS and FM, focusing on shared features like fatigue, pain, and cognitive impairment.

• While both conditions frequently co-occur, ME/CFS is characterized by post-exertional malaise (PEM) and multi-system involvement, while FM emphasizes chronic widespread pain and symptom variability.

• Distinct differences in immune function are highlighted, with ME/CFS showing immune exhaustion and fluctuating cytokine levels, while FM exhibits chronic inflammation related to pain amplification.

• Emerging evidence suggests that both disorders share microbial alterations, although ME/CFS patients exhibit reduced microbial diversity compared to those with FM.

• Digital health tools and early intervention strategies are recommended to better manage symptoms and improve quality of life for individuals with ME/CFS and FM.

🗞️ stats/trends

• A total of 239 articles were reviewed, consolidating insights into the diagnostic overlap, immune profiles, and treatment impacts.

• Post-exertional malaise was documented in 70% of patients with ME/CFS, highlighting its significance in symptomatology.

• Approximately 40% of ME/CFS patients had alterations in cytokine profiles, directly correlating with symptom severity.

• The prevalence of co-morbid FM in ME/CFS patients ranges from 25% to over 50%, indicating substantial overlap in the patient populations.

Article: Peak alpha frequency is associated with pain severity in Long COVID patients with new-onset chronic pain | MedRxiv

Alternative headline: Study links lower alpha frequency to increased chronic pain severity in long COVID patients

🗞️ Definitions

• Peak Alpha Frequency (PAF): The frequency of peak oscillatory activity in the alpha band (8–13 Hz) measured through electroencephalography (EEG), indicative of brain function related to cognitive processes and pain perception.

• Aperiodic-Adjusted PAF: A method of estimating PAF that accounts for aperiodic EEG activity, providing a more accurate representation of oscillatory phenomena.

• C19-Yorkshire Rehabilitation Scale (C19-YRS): A validated tool for assessing and monitoring symptoms related to Long COVID, covering various dimensions of health.

• Chronic Pain: A persistent pain condition lasting over three months, often linked with various health issues, including post-COVID syndromes.

🗞️ Summary

• The study establishes a significant association between lower peak alpha frequency (PAF) and increased severity of chronic pain in Long COVID patients.

• Lower PAF is correlated with higher pain severity scores over the posterior scalp region, suggesting its relevance in pain perception for this population.

• No significant differences in alpha band power were observed between Long COVID patients and healthy controls, indicating that power alone may not indicate pain severity.

• Patients with moderate pain demonstrate significantly higher PAF than severe pain patients and healthy controls, suggesting a potential protective factor in those with milder symptoms.

• The findings propose that PAF could serve as a potential biomarker for assessing chronic pain in Long COVID, informing future therapeutic strategies.

🗞️ stats/trends

• The study included 31 Long COVID patients with new-onset chronic pain and 31 age- and sex-matched healthy controls for comparative EEG data analysis.

• Peak alpha frequency measurements revealed significant associations with pain severity, with standardized β coefficients of –0.602 and –0.581, significant at p = 0.001 and p = 0.002, respectively.

• The median pain severity score separating moderate and severe subgroups was found to be 7, providing a critical cutoff for further brain activity analysis.

Article: Risk of new-onset obstructive sleep apnea up to 4.5 years after COVID-19 in the urban population | MedRxiv

Alternative headline: Study links SARS-CoV-2 infection to increased risk of obstructive sleep apnea in patients

🗞️ Definitions

• Obstructive Sleep Apnea (OSA): A sleep disorder characterized by repeated airway blockage during sleep, leading to disrupted sleep and oxygen deprivation.

• Cox Proportional Hazards Model: A statistical technique used to analyze survival data and time-to-event results in relation to various risk factors.

• Kaplan-Meier Survival Curve: A method for estimating time until an event occurs, providing a visual representation of survival rates across different groups.

🗞️ Summary

• The study reveals that SARS-CoV-2 infection significantly increases the risk of developing new-onset obstructive sleep apnea (OSA) among both hospitalized and non-hospitalized patients.

• Hospitalized COVID+ patients showed a higher adjusted risk of new-onset OSA with a hazard ratio (HR) of 1.41, while non-hospitalized COVID+ patients had an HR of 1.33 compared to COVID− controls.

• Risk of heart failure and pulmonary hypertension was notably increased post-OSA diagnosis in hospitalized COVID+ patients, underscoring the long-term cardiovascular implications.

• Elevated risk profiles were particularly pronounced in younger individuals and demographic groups traditionally facing higher health disparities.

🗞️ stats/trends

• The cohort included 910,393 eligible patients, with 65,009 testing positive for COVID-19.

• Hazard ratios revealed that hospitalized COVID+ patients faced an increased risk of new-onset OSA (HR 1.41) compared to their COVID− counterparts.

• Among hospitalized COVID+ patients, 8.42% developed heart failure post-OSA diagnosis.

Article: Patient-Made Knowledge Networks: Long COVID Discourse, Epistemic Injustice, and Online Community Formation | aRxiv - Cornell University

Alternative headline: Long COVID patients leverage social media to share experiences and seek recognition of their condition

🗞️ Definitions

• Epistemic Injustice: The systemic devaluation or dismissal of knowledge claims made by individuals or groups, especially in medical contexts.

• Mixed-Methods Approach: A research methodology that combines quantitative and qualitative techniques to enrich understanding of complex phenomena.

• Exponential Random Graph Models (ERGM): A statistical model used in network analysis to understand how different attributes influence the formation of ties between nodes.

🗞️ Summary

• This study analyzes 2.8 million tweets using the hashtag #LongCOVID, identifying seven key themes that reveal how patients construct knowledge networks and challenge epistemic injustice surrounding their condition.

• Long COVID patients engage in collective symptom documentation, validating individual experiences and countering medical dismissal while promoting legitimacy in their illness narratives.

• The emergence of long COVID and its rapid recognition by the WHO contrasts sharply with the historical struggles faced by patients with ME/CFS, who have fought for decades for recognition and care.

• Network ties within the long COVID community primarily form around epistemic practices focused on resource sharing and community building, emphasizing the role of shared experiential knowledge.

🗞️ stats/trends

• The dataset comprised 2,818,709 tweets from 409,272 unique users discussing Long COVID, with the initial tweets starting in May 2020.

• Analysis revealed seven thematic clusters in the discourse, including framing, epistemic injustice experiences, resource sharing, and advocacy.

Article: Correction: Characterization of Post-Viral Infection Behaviors Among Patients With Long COVID: Prospective, Observational, Longitudinal Cohort Analyses of Fitbit Data and Patient-Reported Outcomes | JMIR Formative Research

Alternative headline: Study finds MVPA participation may affect recovery and sleep in long COVID patients over time

🗞️ Definitions

• MVPA: Moderate-to-Vigorous Physical Activity, which has beneficial effects on health outcomes.

• T-score: A standard score indicating how many standard deviations an individual’s score is from the mean, used in assessing health-related quality of life.

• Patient-Reported Outcomes (PROs): Subjective assessments provided directly by patients regarding their health status or quality of life.

🗞️ Summary

• The study proposes that MVPA-active patients with long COVID experienced statistically less improvement in social role participation and increased intensity of sleep symptoms over a three-month period.

• Longitudinal analysis reveals a significant estimated group difference in social role participation T-scores between MVPA-active and MVPA-inactive patients, supporting a nuanced understanding of post-viral recovery behaviors.

• The correction in the abstract emphasizes the need for precise terminology in representing the health trajectories of long COVID patients, as earlier wording may have misrepresented the data implications.

• By analyzing wearable technology alongside patient-reported outcomes, the researchers highlight the multifaceted challenges faced by long COVID patients in achieving recovery.

🗞️ stats/trends

• The study includes longitudinal data from a cohort of patients diagnosed with long COVID, monitored over three months.

• MVPA-inactive patients showed a statistically significant decrease in ability to participate in social roles, with a group difference of –4.21 T-score points (95% CI –6.64 to –1.78, P<.001).

• The intensity of sleep symptoms in MVPA-active patients increased, with a notable group difference of 2.06 severity score points (95% CI 0.40 to 3.71, P=.02).

Article: Increased phosphorylated tau (pTau-181) is associated with neurological post-acute sequelae of coronavirus disease in essential workers: a prospective cohort study before and after COVID-19 onset | The Lancet

Alternate title: Alzheimer’s Disease biomarker is elevated in those with neurological Long Covid

Definitions

• N-PASC (neurological post-acute sequelae of COVID-19): A subtype of PASC, symptoms include neurocognitive changes such as brain fog, forgetfulness, or diminished executive functioning.

• pTau-181: A neurological serum biomarker that correlates well with cerebral amyloid, pTau, and neurodegeneration.

• Prospective study: A research design that follows a group of individuals (a cohort) forward in time, starting from the present and moving into the future, to observe outcomes and analyze the relationship between risk factors and disease development.

Summary

• N-PASC with symptoms consistent with central damage were associated with increased pTau-181 levels in essential workers.

• Increases in pTau-181 were associated with increased risk of changes to amyloid biomarkers consistent with Alzheimer’s disease in participants with N-PASC and could inform prognosis for N-PASC.

• Symptoms of N-PASC that persisted for more than 1.5 years were at increased risk of developing higher than normal circulating levels of pTau-181: this could predict worsened cognitive functioning as individuals age.

Stats/trends

• Study participants with N-PASC had evidence of a 59.3% increase in pTau-181 levels from pre-COVID-19 levels that was not evident in other essential workers; the increase was the worst among those whose N-PASC had persisted for more than 1.5 years.

• Among participants with N-PASC who exhibited pTau-181 increases ≥20% relative to pre-COVID levels, 45.1% expressed pTau-181 levels above an established cutoff to identify Alzheimer’s Disease or a Related Dementia (ADRD).

Strengths/Limitations

• One study strength: this was a moderately-sized prospective study, which is the gold standard for research and provides more reliable and sensitive results.

• A study limitation: it examined only a serum biomarker (ptau-181) for tauopathy in the brain, but not whether tau was associated with actual cerebral tau burden. Changes in blood may not reflect changes in the brain. Follow-up research is needed that examines the implications of this work to cerebral tauopathy in N-PASC.

Media

Article: Former employee sues McKinsey for pulling Long COVID accommodation | Human Resources Director

🗞️ Summary

• Karin Drucker has filed a lawsuit against McKinsey alleging wrongful termination and disability discrimination after the firm rescinded her long COVID accommodation.

• She had worked part-time for five months with positive performance feedback before being told the arrangement would not continue and being given a deadline to find another internal role.

• Drucker claims at least three non-disabled colleagues in the same role were allowed to remain part-time, raising questions about inconsistent application of policies.

• After being placed on unpaid leave and ultimately let go in September 2024, she was cleared by her doctor to return to full-time work four months later; the suit seeks back pay and punitive damages and could shape how firms handle long COVID accommodations.

Article: Office of the Lieutenant Governor Releases 2026 Annual Report on Long COVID - by Jan Wondra - Ark Valley Voice

🗞️ Summary

• Colorado’s 2026 long COVID report highlights higher symptom rates among women, people with chronic illnesses, and individuals of diverse sexual orientations, underscoring significant health disparities.

• Among adults with long COVID, about one in five reported taking time off work and a notable share reduced hours or left jobs entirely, pointing to real economic consequences.

• State officials emphasize strengthening surveillance systems and partnerships to better track long COVID and design supports, while acknowledging challenges like self-report bias and the need for cross-sector coordination.

Article: Champions League winner Jari Litmanen reveals long Covid hell: What are the symptoms? | FootballTransfers.com

🗞️ Summary

• Jari Litmanen describes how long COVID kept him away from football for roughly four years, with lingering symptoms that affected his daily life and fitness.

• His appearance in a 2024 legends match marked an emotional milestone and illustrates how gradual recovery can restore both physical capacity and a sense of identity.

• The piece situates his story within broader WHO estimates of long COVID burden, reminding readers that experiences range from mild and short-lived to severe and prolonged and that tailored care is essential.